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A B S T R A C T
Background
Observational evidence suggests a potential benefit with several anti-adhesion therapies in women undergoing operative hysteroscopy
(e.g. insertion of an intrauterine device or balloon, hormonal treatment, barrier gels or human amniotic membrane grafting) for
decreasing intrauterine adhesions (IUAs).
Objectives
To assess the effectiveness of anti-adhesion therapies versus placebo, no treatment or any other anti-adhesion therapy, following operative
hysteroscopy for treatment of female subfertility.
Search methods
We searched the following databases from inception to June 2017: the Cochrane Gynaecology and Fertility Group Specialised Register;
the Cochrane Central Register of Studies (CRSO); MEDLINE; Embase; CINAHL and other electronic sources of trials, including
trial registers, sources of unpublished literature and reference lists. We handsearched the Journal of Minimally Invasive Gynecology, and
we contacted experts in the field. We also searched reference lists of appropriate papers.
Selection criteria
Randomised controlled trials (RCTs) of anti-adhesion therapies versus placebo, no treatment or any other anti-adhesion therapy
following operative hysteroscopy in subfertile women. The primary outcomewas live birth. Secondary outcomeswere clinical pregnancy,
miscarriage and IUAs present at second-look hysteroscopy, along with mean adhesion scores and severity of IUAs.
Data collection and analysis
Two review authors independently selected studies, assessed risk of bias, extracted data and evaluated quality of evidence using the
GRADE method.
1Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
The overall quality of the evidence was low to very low. The main limitations were serious risk of bias related to blinding of participants
and personnel, indirectness and imprecision. We identified 16 RCTs comparing a device versus no treatment (two studies; 90 women),
hormonal treatment versus no treatment or placebo (two studies; 136 women), device combined with hormonal treatment versus no
treatment (one study; 20 women), barrier gel versus no treatment (five studies; 464 women), device with graft versus device without
graft (three studies; 190 women), one type of device versus another device (one study; 201 women), gel combined with hormonal
treatment and antibiotics versus hormonal treatment with antibiotics (one study; 52 women) and device combined with gel versus
device (one study; 120 women). The total number of participants was 1273, but data on 1133 women were available for analysis. Only
two of 16 studies included 100% infertile women; in all other studies, the proportion was variable or unknown.
No study reported live birth, but some (five studies) reported outcomes that were used as surrogate outcomes for live birth (term
delivery or ongoing pregnancy).
Anti-adhesion therapy versus placebo or no treatment following operative hysteroscopy.
There was insufficient evidence to determine whether there was a difference between the use of a device or hormonal treatment compared
to no treatment or placebo with respect to term delivery or ongoing pregnancy rates (odds ratio (OR) 0.94, 95% confidence interval
(CI) 0.42 to 2.12; 107 women; 2 studies; I² = 0%; very-low-quality evidence).
There were fewer IUAs at second-look hysteroscopy using a device with or without hormonal treatment or hormonal treatment or
barrier gels compared with no treatment or placebo (OR 0.35, 95% CI 0.21 to 0.60; 560 women; 8 studies; I² = 0%; low-quality
evidence). The number needed to treat for an additional beneficial outcome (NNTB) was 9 (95% CI 5 to 17).
Comparisons of different anti-adhesion therapies following operative hysteroscopy
It was unclear whether there was a difference between the use of a device combined with graft versus device only for the outcome of
ongoing pregnancy (OR 1.48, 95% CI 0.57 to 3.83; 180 women; 3 studies; I² = 0%; low-quality evidence). There were fewer IUAs at
second-look hysteroscopy using a device with or without graft/gel or gel combined with hormonal treatment and antibiotics compared
with using a device only or hormonal treatment combined with antibiotics, but the findings of this meta-analysis were affected by
evidence quality (OR 0.55, 95% CI 0.36 to 0.83; 451 women; 5 studies; I² = 0%; low-quality evidence).
Authors’ conclusions
Implications for clinical practice
The quality of the evidence ranged from very low to low. The effectiveness of anti-adhesion treatment for improving key reproductive
outcomes or for decreasing IUAs following operative hysteroscopy in subfertile women remains uncertain.
Implications for research
More research is needed to assess the comparative safety and (cost-)effectiveness of different anti-adhesion treatments compared to no
treatment or other interventions for improving key reproductive outcomes in subfertile women.
P L A I N L A N G U A G E S U M M A R Y
Anti-adhesion treatment after hysteroscopy for women having difficulty becoming pregnant
Review question
To assess the effects of treatments for prevention of scar tissue (called adhesions) anti-adhesion treatment) inside the womb after surgical
treatment in women having difficulty becoming pregnant.
Background
Abdominal adhesions are web-like structures where two normally separate surfaces in the tummy (abdomen) stick together due to
damage to the lining of the abdomen. They commonly form after surgery to the abdomen. They can cause multiple conditions such
as chronic pelvic pain and infertility. The present practice is based on tradition or observational studies.
Study characteristics
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We searched for studies that randomly compared any treatment versus no treatment, placebo (pretend treatment) or any other inter-
vention. Outcomes were live birth, clinical pregnancy, miscarriage and presence or severity of scar tissue at the second-look procedure.
Key results
We found 16 studies. Treatments included using a device versus no treatment (two studies; 90 women), hormonal treatment versus
no treatment or placebo (two studies; 136 women), device combined with hormonal treatment versus no treatment (one study; 20
women), barrier gel versus no treatment (five studies; 464 women), device with the use of membranes of the afterbirth of newborn
babies versus device without membranes (three studies; 190 women), one type of device versus another device (one study; 201 women),
gel combined with hormonal treatment and antibiotics versus hormonal treatment with antibiotics (one study; 52 women) or device
combined with gel versus device (one study; 120 women). From 1273 randomly assigned women, data on 1133 women were available
for analysis.
In only two studies, all women had difficulty becoming pregnant. Most studies (14/16) were at high risk of bias for at least one reason.
As no study reported live births, we also included data on term delivery or ongoing pregnancy, which five studies reported.
It was unclear whether there was a difference between anti-adhesion treatment compared to no treatment (two studies; 107 women) or
to other treatment (three studies; 180 women) for increasing the chance of a liveborn baby, a term delivery or an ongoing pregnancy.
The use of some anti-adhesion therapies (device with or without hormonal treatment or hormonal treatment or gels) (eight studies; 560
women) may diminish the risk of scar tissue formation compared to no treatment. We would expect that out of 1000 women treated
by surgery, between 153 and 365 women would develop scar tissue after using gels, compared with 545 women when no treatment
was used. The evidence was current to 6 June 2017.
Quality of the evidence
The overall quality of the study evidence ranged from very low to low. There were limitations to the studies, for example, a serious risk
of bias related to participants and investigators knowing what treatment was given.
More research is needed before anti-adhesion treatment can be offered in everyday clinical practice after surgery of the womb in women
having difficulty becoming pregnant.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any anti- adhesion therapy versus placebo or no treatment following operative hysteroscopy
Patient or population: women treated by operat ive hysteroscopy for uterine pathology associated with subfert ility or adverse pregnancy outcome
Settings: single centre, Hysteroscopy Unit or Department of Obstetrics and Gynaecology of a university or non-university tert iary care hospital
Intervention: any ant i-adhesion therapy
Comparison: no treatment or placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No treatment or
placebo
Anti- adhesion therapy
Live birth a No treatment or
placebo
Device or hormonal
treatment
OR 0.94
(0.42 to 2.12)
107
(2 RCTs)
⊕©©©
Very low c,d,e
-
Mean- risk populationb
407 per 1000 399 per 1000
(261 to 603)
Presence of intrauter-
ine adhesions at sec-
ond- look hysteroscopy
(second-
look hysteroscopy at 4-
12 weeks af ter opera-
t ive hysteroscopy)
No treatment or
placebo
Device ± hormonal
treatment or hormonal
treatment or barrier gel
OR 0.35 g (0.21 to 0.60) 560
(8 RCTs)
⊕⊕©©
Low h,i
-
Low- risk populationf
0 per 1000 0 per 1000
Medium- risk population f
545 per 1000 234 per 1000
(153 to 365)
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High- risk population f
875 per 1000 376 per 1000
(245 to 586)
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on assumed risk in the comparison group and the
relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a The two included studies reported term delivery (Abu Rafea 2013) or ongoing pregnancy (Roy 2014), which we used as a
surrogate outcome for live birth.
b The assumed risk for the mean-risk populat ion was the pooled risk of all live births in control groups of the two included
studies.
c Downgraded one level for serious risk of bias: one study was at high risk of bias in several domains, including allocat ion
concealment.
d Downgraded one level for serious imprecision; only 43 events in total.
e Downgraded one level for serious indirectness, because only 30% (35/ 118) of all randomised women in this analysis were
subfert ile.
f The assumed risk for low-, medium- and high-risk populat ion based on presence of intrauterine adhesions following
hysteroscopic removal of endometrial polyps/ following removal of submucous f ibroids and intrauterine adhesions (mean of
both)/ removal of uterine septum, respect ively, based on f indings of a prospect ive cohort study (Yang 2013).
G Two studies reported no events (Lin 2015a; Vercellini 1989).
h Downgraded one level for serious risk of bias: all eight studies had several lim itat ions but none was at high risk for select ion
bias related to random sequence generat ion or allocat ion concealment.
i Downgraded one level for serious indirectness, because in four of eight studies less than 50%of part icipants were subfert ile
and in four of eight studies it was unclear whether subfert ile women were included.
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B A C K G R O U N D
Description of the condition
Intrauterine adhesions (IUAs) are fibrous strings at opposing walls
of the uterus. The spectrum of severity of IUAs ranges from min-
imal to complete obliteration of the uterine cavity. Any trauma
to the endometrium (the inner layer of the uterus) can lead to
formation of IUAs; in daily clinical practice, nearly 90% of all
IUAs are associated with postpartum or postabortion dilatation
and curettage (Nappi 2007). The aetiological role of infection in
the formation of IUAs is controversial, with the exception of gen-
ital tuberculosis (Deans 2010). IUA formation is the major long-
term complication of hysteroscopic surgery in women of repro-
ductive age.
Several intrauterine anomalies have been linked with female sub-
fertility (Bosteels 2015a). Endometrial polyps are benign, endome-
trial, stalk-like masses protruding into the uterine cavity. Fibroids
are excessive growths originating from the muscular portion of the
uterine cavity. A septate uterus is a congenital malformation in
which the longitudinal band separating left and right Müllerian
ducts, which form the uterus in the human female foetus, has
not been entirely resorbed. Hysteroscopy allows direct visualisa-
tion of the uterine cavity through a rigid, semi-rigid or flexible
endoscope. The hysteroscope consists of a rigid telescope with a
proximal eyepiece and a distal objective lens that may be angled
at 0 degrees to allow direct viewing, or offset at various angles
to provide a fore-oblique view. Operative hysteroscopy requires
adequate visualisation through continuous fluid circulation us-
ing inflow and outflow channels. The sheath system of the op-
erative hysteroscope contains one or two 1.6- to 2.0-mm work-
ing channels for insertion of a small grasping or biopsy forceps,
scissors, myoma fixation instruments, retraction loops, morcella-
tor (surgical instruments used to divide and remove tissue during
endoscopic surgery) and aspiration cannulae or unipolar or bipo-
lar electrodiathermy instruments. Operative hysteroscopic proce-
dures require a complex instrumentation setup, special training
of the surgeon, and appropriate knowledge and management of
complications. Removal of endometrial polyps by an endoscope
is called hysteroscopic polypectomy. Hysteroscopic myomectomy
is the procedure by which a fibroid is removed by hysteroscopy.
Removal of a uterine septum is termed hysteroscopic septoplasty
or septum resection. Removal of IUAs is called hysteroscopic ad-
hesiolysis. A diagnostic or operative hysteroscopy following an op-
erative hysteroscopy is termed a second-look hysteroscopy.
One randomised controlled trial (RCT) reported the following
numbers for the incidence of postsurgical IUAs at second-lookhys-
teroscopy: 3.6% after polypectomy, 6.7% after resection of uterine
septa, 31.3% after removal of a solitarymyoma and 45.5%after re-
section of multiple myomas (Taskin 2000). Mechanisms of tissue
repair in the human endometrium are poorly understood (Revaux
2008) despite several hypotheses on the origin of cells for endome-
trial regeneration (Okulicz 2002). Endometrial stem or progenitor
cells, present in women and rodents, may have an important func-
tion for endometrial regeneration in normal menstrual cycles and
after delivery; this holds promise for new treatments for subfertil-
ity associated with IUAs or Asherman’s syndrome (Deane 2013).
The duration of endometrial wound healing depends on the type
of pathology present, according to one prospective cohort study
of 163 women undergoing operative hysteroscopy (Yang 2013);
these investigators reported that the time needed for complete re-
covery of the endometrium ranges from one month following hys-
teroscopic removal of endometrial polyps to three months for the
hysteroscopic treatment of submucous fibroids.
IUAs are associated with poor reproductive outcomes. This is
due in part to infertility, with a prevalence as high as 43% (922/
2151 women) according to one large review of observational stud-
ies (Schenker 1982). Poor outcomes also result from the clinical
problem of recurrent miscarriage, ranging from 5% to 39% in
women with IUAs, according to one review of observational stud-
ies (Kodaman 2007), and from major, and at times devastating,
obstetrical complications, for example, placenta accreta or increta,
as well as higher risks for preterm delivery, uterine rupture and
peripartum hysterectomy as the endpoint of a successful hystero-
scopic treatment for severe IUAs (Deans 2010).
Description of the intervention
Several observational studies have suggested different anti-ad-
hesion strategies for preventing IUAs following operative hys-
teroscopy.
Intrauterine device
An intrauterine device (IUD) may provide a physical barrier be-
tween the uterine walls, separating the endometrial layers after ly-
sis of IUAs. At least 13 observational studies have recommended
insertion of an IUD as an adjunct therapy for the prevention of
IUAs (Deans 2010). Eight observational studies reported the use
of a Foley catheter balloon as an alternative for similar purposes (
Deans 2010).
Hormonal therapy
In 1964, Wood and Pena suggested use of oestrogen therapy to
stimulate regeneration of the endometrium after surgical treat-
ment for IUAs (Wood 1964).
Barrier gels
Hyaluronic acid (HA) or hyaluronan is a water-soluble polysac-
charide that consists of multiple disaccharide units of glucuronic
acid andN-acetylglucosamine bound together by a β1-3-type glu-
coside bond. Solutions ofHAhave viscoelastic properties that have
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led to interest in developing applications of HA in surgical pro-
cedures, for example, during eye surgery, and for prevention of
postsurgical adhesions. However, HA may not be the ideal sub-
stance for all procedures because of its limited residence time when
applied to a surgical site. It quickly enters the systemic circula-
tion, then is cleared rapidly by catabolic pathways. Attempts to
use HA for prevention of postsurgical adhesions have therefore re-
sulted in variable success. Chemically modified derivatives of HA
have been developed to circumvent the disadvantages of HA. One
such derivative is auto-cross-linked polysaccharide (ACP), which
is formed by cross-linking of HA via direct formation of cova-
lent ester bonds between hydroxyl and carboxyl groups of the HA
molecule. ACP can be prepared through various degrees of cross-
linking: this allows tailoring of the viscosity properties of ACP gels
(Renier 2005). Carboxymethylcellulose (CMC) is a high-molec-
ular-weight polysaccharide that has greater viscosity than dextran
70. CMC can be used for adhesion prevention as a membrane
barrier, or as a gel attained bymixing chemically derivative sodium
hyaluronate and carboxymethylcellulose gel (HA-CMC) (Leach
1998).
Human amniotic membrane grafting
Since the late 1990s, the surgical community has become more
aware of the increasing potential of human amniotic membrane
(HAM) as an adjunctive anti-adhesion intervention. Human
whole foetal membranes or amnion alone has been used in surgery
to aid the repair of surface epithelial defects in the skin, eye, ab-
dominal wall and peritoneum. HAM grafting has not been very
popular in the field of obstetrics and gynaecology; its clinical use
is limited as a graft in forming an artificial vagina, as a barrier
in preventing postoperative intra-abdominal adhesion formation
and, finally, as a biological dressing following radical vulvectomy
or groin dissection (Amer 2006).
How the intervention might work
Hypothetical underlying mechanisms of subfertility associated
with IUAs include obstruction of sperm transport into the cervix,
impaired embryo migration within the uterine cavity and failure
of embryo implantation due to endometrial insufficiency (Deans
2010). Ideal anti-adhesion adjunctive therapy following operative
hysteroscopy would include application of a biologically active
mechanical separator that achieves suppression of IUA formation
and promotes healing of the endometrium. The bulk of evidence
on how different interventions might work has been derived from
observational or animal studies, largely in rodents and regrettably
not in animal models validated for the study of human reproduc-
tion, such as primates (D’Hooghe 2009).
Intrauterine device
Use of an IUD (13 observational studies) or a Foley catheter bal-
loon (eight observational studies) is often recommended following
hysteroscopic treatment of IUAs or septoplasty, to act as a physi-
cal barrier separating opposing walls of the uterine cavity (Deans
2010). The type of IUD selected may be important; copper-con-
taining IUDs provoke an inflammatory reaction, probably with
detrimental effects, whereas T-shaped IUDs might provide too
small a surface area to be truly effective in providing an efficient
physical barrier. The loop IUD (e.g. the Lippes loop) is generally
considered the IUD of choice for treatment of IUAs; however, it
is no longer available in many countries (Kodaman 2007). One
clinical controlled trial (CCT) compared use of a Foley catheter
balloon for 10 days (59 women) versus insertion of an IUD for a
three-month period (51 women); fertility rates were poor in both
the IUD group (20/59 women, or 34%) and the Foley catheter
balloon group (14/51 women, or 28%) (Orhue 2003).
Hormonal therapy
Many studies recommend use of a cyclical oestrogen and pro-
gestogen treatment regimen following hysteroscopic treatment of
IUAs to promote regeneration of the endometrium (Deans 2010).
Various regimens consisting of oestrogen (e.g. conjugated equine
oestrogen 2.5 mg twice daily for 30 days) with or without a pro-
gestogen (e.g. medroxyprogesterone acetate 10 mg for 10 days)
have been proposed (Kodaman 2007). There are no comparative
studies that examine dosage, administration or combinations of
hormones (Deans 2010). In one RCT, 60 women undergoing di-
latation and curettage during the first trimester of pregnancy were
allocated to receive oestrogen combined with progestogen or no
treatment (Farhi 1993). Women in the intervention group had a
significantly thicker endometrium compared with women in the
control group (8.4 with intervention vs 6.7 mm with no treat-
ment; P = 0.02). Study authors concluded that postoperative hor-
monal treatment may be beneficial for IUA prevention following
surgical trauma to the uterine cavity. Nevertheless, they provided
no data on pregnancy outcomes or IUA recurrence (Farhi 1993).
One systematic review of 26 observational studies concluded that
hormonal therapy, particularly oestrogen treatment, may be ben-
eficial for women with IUAs, but as adjunctive therapy combined
with other anti-adhesion strategies (Johary 2014).
Barrier gels
Use of biodegradable gel surgical barriers is based on the principle
of keeping adjacent wound surfaces mechanically separate (Renier
2005). Several preclinical studies in various animalmodels demon-
strated the effectiveness of ACP (Belluco 2001; Binda 2007; Binda
2009; Binda 2010; De Iaco 1998; Koçak 1999; Shamiyeh 2007;
Wallwiener 2006), and HA-CMC gels (Leach 1998; Schonman
2008), or of HA-CMC membranes (Kelekci 2004; Rajab 2010),
for preventing postsurgical adhesions. Other preclinical studies in
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animal models suggest that HA gel remains in situ longer than
five to six days (Laurent 1992; Nimrod 1992). Similarly, animal
studies demonstrated the persistence of HA-CMC for about seven
days after its application (Diamond 1988). The exact mechanisms
by which ACP and HA-CMC are able to reduce adhesion refor-
mation are not well known but may be related to ’hydroflotation’
or ’siliconising’ effects. One French CCT (54 women) compared
application of ACP gel (30 women) versus no gel (24 women) at
the end of an operative hysteroscopic procedure performed to treat
myomas, polyps, uterine septa or IUAs; investigators reported no
statistically significant differences between comparison groups in
the rate of adhesion formation, or in mean adhesion scores and
severity of adhesions (Ducarme 2006). They provided no data on
reproductive outcomes.
Human amniotic membrane grafting
Preclinical data on the effectiveness of HAM grafting in differ-
ent animal models presented conflicting results. One trial demon-
strated a beneficial effect in preventing de novo (new) adhesions
(Szabo 2002), whereas two other animal studies reported that
HAMgrafting failed to prevent IUAs (Arora 1994; Badawy 1989).
One observational study provided data on use of a fresh amniotic
graft over an inflated Foley catheter balloon to prevent recurrence
of IUAs after hysteroscopic lysis in 25 women with moderate-to-
severe Asherman’s syndrome. There was minimal adhesion refor-
mation in 48% of study participants with severe adhesions. Study
authors concluded that HAM grafting might be promising as ad-
junctive therapy following hysteroscopic adhesiolysis; it acts as a
biologically active mechanical barrier to suppress adhesion forma-
tion while promoting endometrial healing (Amer 2006). A fresh
HAM graft preserves its viability for 21 days following applica-
tion in the pelvic cavity (Trelford Sauder 1977). In addition to
serving as an anatomical barrier, HAMmay promote the regener-
ation of epithelium by acting as a basement membrane substrate;
HAM may also facilitate migration of epithelial cells, reinforce
adhesion of the basal epithelium, promote epithelial cell differen-
tiation (Meller 1999), and prevent cellular apoptosis (Hori 2006).
Human amniotic epithelial cells produce factors or create a mi-
croenvironment for effective tissue repair and endometrial regen-
eration, possibly by stimulating endogenous stem cells (Padykula
1991).
Why it is important to do this review
At present, whether anti-adhesion therapies after operative hys-
teroscopy might be beneficial for the outcome of pregnancy or live
birth is unknown, and there are no relevant clinical guidelines.
Providing a summary and critical appraisal of existing evidence on
the effectiveness of different anti-adhesion treatments in subfer-
tile women after operative hysteroscopy is the main objective of
this Cochrane Review. Moreover, little is known about the relative
contributions of different anti-adhesion strategies towards increas-
ing reproductive benefit in women wishing to conceive following
operative hysteroscopy; performing this head-to-head comparison
of alternative anti-adhesion interventions is a secondary objective
of the present review.
Adhesions may cause infertility, abdominal pain or bowel obstruc-
tion. The healthcare burden associated with these three clinical
problems is substantial (DeCherney 1997; diZerega 1994; Renier
2005). The total cost of adhesion-related morbidity for the US
health care system exceedsUSD1billion annually (Baakdah 2005).
One trial in the domain of gynaecological oncology evaluated
the cost-effectiveness of an HA-CMC anti-adhesion barrier ver-
sus routine care, during which no adhesion prevention measures
were taken, by applying a decision analysis model in the setting of
womenundergoing radical hysterectomy and pelvic lymphadenec-
tomy for stage IB cervical cancer (Bristow 2007). Study authors
concluded that given a conservative set of clinical and economic
assumptions, an adhesion prevention strategy utilising an HA-
CMC barrier in women undergoing radical hysterectomy for stage
IB cervical cancer might be cost-effective from the perspective of
society and from the view of a third-party payer. To the best of our
knowledge, no cost-effectiveness studies have explored adhesion
prevention after operative hysteroscopy in an infertile population;
evidence retrieved through the present research could serve as the
basis for economical studies of different anti-adhesion treatments.
This is another secondary objective of the present review.
Infertility, defined as the inability to conceive after a defined pe-
riod of unprotected intercourse, is an often neglected aspect of re-
productive health worldwide. Official ways of providing assistance
for reproductive health care and family planning are few world-
wide, despite an increasing absolute number of couples affected
by infertility from 42.0 million in 1990 to 48.5 million in 2010
(Mascarenhas 2012). Reproductive health has long been recog-
nised by the World Health Organization (WHO) as a priority
global health topic (WHO: Reproductive Health).
O B J E C T I V E S
To assess the effectiveness of anti-adhesion therapies versus
placebo, no treatment or any other anti-adhesion therapy follow-
ing operative hysteroscopy for treatment of female subfertility.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Published and unpublished parallel-group RCTs were eligible for
inclusion. We excluded non-randomised studies (e.g. studies with
evidence of inadequate sequence generation such as alternate days,
participant numbers), as they are associated with high risk of bias.
We planned to include cross-over trials if individually randomly
assigned women were the unit of analysis; we aimed to include
data from the first phase only in the meta-analyses, as the cross-
over trial is not a valid study design in the context of subfertility.
Types of participants
Women of reproductive age undergoing operative hysteroscopy
for subfertility associated with suspected or unsuspected intrauter-
ine pathology before spontaneous conception or any subfertility
treatment. Studies in which at least a proportion of women were
undergoing operative hysteroscopy for subfertility were eligible.
Studies excluding women wishing to conceive were not eligible.
Types of interventions
We included the following randomly assigned comparisons.
• Anti-adhesion therapy versus placebo or no treatment
following operative hysteroscopy.
• Anti-adhesion therapy A versus anti-adhesion therapy B
following operative hysteroscopy.
Types of outcome measures
Primary outcomes
• Live birth.
◦ Live birth was defined as the delivery of at least one
live foetus after 20 weeks of gestation that resulted in at least one
live baby; we counted the delivery of singleton, twin or multiple
pregnancies as one live birth.
In studies that failed to report live birth, we used the following
measures as primary effectiveness outcomes:
◦ Ongoing pregnancy, defined as pregnancy surpassing
the first trimester or 12 weeks of pregnancy and was used as a
surrogate outcome for live birth.
◦ Term delivery, defined as birth at any time between
three weeks before and two weeks after the expected date of
delivery (37 to 42 weeks of gestation) was also used as a surrogate
outcome for live birth.
Secondary outcomes
• Clinical pregnancy, defined as pregnancy diagnosed by
ultrasonographic visualisation of one or more gestational sacs or
definitive clinical signs of pregnancy; this included ectopic
pregnancy. We counted multiple gestational sacs as one clinical
pregnancy.
• Miscarriage, defined as spontaneous loss of a clinical
pregnancy that occurred before 20 completed weeks of gestation
(18 weeks’ postfertilisation) or, if gestational age was unknown,
loss of an embryo or foetus of bodyweight less than 400 g.
• Presence of IUAs at second-look hysteroscopy.
• Mean adhesion scores at second-look hysteroscopy.
• Severity of adhesions at second-look hysteroscopy.
We did not exclude studies on the basis of their reported outcome
measures. We reviewed all potentially eligible studies that could
have measured the outcomes of interest; we aimed to report any
lack of data for the key outcomes in the final review.
We adhered as much as possible to terminology of the Interna-
tional Committee forMonitoring Assisted Reproductive Technol-
ogy (ICMART) (ICMART) for key reproductive outcomes (live
birth, pregnancy and miscarriage) (Zegers-Hochschild 2009); we
contacted primary study authors for clarification in cases of un-
clear definitions. We reported discrepancies or uncertainties in the
final review.
At present, seven classification systems are reported for scoring the
extent or severity of IUAs. None of these systems has been vali-
dated or universally accepted (Deans 2010). Therefore, we avoided
pooling data from studies using different scoring systems, and we
asked for clarification from primary study authors, when there was
any uncertainty on the classification system used in the primary
research.
According to a prospective cohort study, the duration of endome-
trial wound healing may differ according to the type of pathol-
ogy; study authors concluded that recovery of the endometrium
may vary from one month (after hysteroscopic removal of polyps)
to three months (following hysteroscopic myomectomy) (Yang
2013). We planned to pool studies when assessment of IUAs by
second-look hysteroscopy was done between four and 12 weeks
after operative hysteroscopy.
Search methods for identification of studies
We searched for all published and unpublished RCTs of anti-
adhesion therapies following operative hysteroscopy in subfertile
women, with no language restrictions and in consultation with the
Information Specialist of the Cochrane Gynaecology and Fertility
Group (CGFG).
Electronic searches
We searched the following electronic databases, trial registers and
websites using the search strategies provided in the appropriate ap-
pendices: theCGFGSpecialisedRegister (6 June 2017) (Appendix
1), the Cochrane Central Register of Studies Online (CENTRAL)
(2017, Issue 6) (Appendix 2),MEDLINE using PubMed (1950 to
6 June 2017) (Appendix 3) and Embase using Embase.com (1974
to 6 June 2017) (Appendix 4).
The search strategy combined both index and free-text terms.
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Our MEDLINE search included the Cochrane highly sensitive
search strategy for identifying randomised trials as it appears in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).
Our Embase search included the trial filter developed by the Scot-
tish Intercollegiate Guidelines Network (SIGN).
Electronic sources of trials included the following.
• CENTRAL.
• Cochrane Database of Systematic Reviews (CDSR) (2017,
Issue 6).
• Database of Abstracts of Reviews of Effectiveness (DARE)
and the Health Technology Assessment Database (HTA
Database) through the Centre for Reviews and Dissemination (
www.crd.york.ac.uk) (from inception to 6 June 2017).
• National Guideline Clearinghouse (www.guideline.gov/)
for evidence-based guidelines (from inception to 6 June 2017).
• Citations, conference abstracts and proceedings in the
Institute for Scientific Information (ISI) Web of Science (WOS)
core collection, Biosis Previews and Biosis Citation Index
through WOS (
wcs.webofknowledge.com.kuleuven.ezproxy.kuleuven.be) (from
inception to 6 June 2017) (Appendix 5) and the Cumulative
Index to Nursing and Allied Health Literature (CINAHL) (
web.b.ebscohost.com.kuleuven.ezproxy.kuleuven.be) (from
inception to 6 June 2017) (Appendix 6) through EBSCOhost,
available at the Biomedical Library Gasthuisberg of the Catholic
University of Leuven.
• Trial registers for ongoing and registered trials: ISRCTN
Registry (www.isrctn.com/) and WHO International Clinical
Trials Registry Platform search portal (apps.who.int/trialsearch/)
(from inception to 6 June 2017).
• Latin American Caribbean Health Sciences Literature
(LILACS) database, which is a source of trials from the Spanish
and Portuguese speaking countries (lilacs.bvsalud.org/en/) (from
inception to 6 June 2017).
• European grey literature through the Open Grey database (
www.opengrey.eu/) (from inception to 6 June 2017).
• General search engines Turning Research Into Practice
(TRIP) database (www.tripdatabase.com/), Google Scholar (
scholar.google.com/) and Scopus, available at the Biomedical
Library Gasthuisberg of the KU Leuven- University of Leuven,
Leuven, Belgium (www-scopus-
com.kuleuven.ezproxy.kuleuven.be) (from inception to 6 June
2017).
Searching other resources
Two review authors (JB and SJC) examined reference lists of ar-
ticles retrieved by the search and contacted experts in the field to
request additional data. We contacted the first or corresponding
authors of included studies to ascertain whether theywere aware of
any ongoing or unpublished trials.We handsearched the Journal of
Minimally Invasive Gynecology (from inception to 6 June 2017) to
look for conference abstracts that were not covered in the CGFG
Specialised Register, in liaison with the Information Specialist of
the CGFG. We also searched reference lists of appropriate papers.
We documented the search process in a PRISMA flow diagram in
the final review.
Data collection and analysis
Selection of studies
After an initial screen of titles and abstracts retrieved by the search,
we retrieved the full texts of all potentially eligible studies. Two
review authors (JB and SJC) independently examined these full-
text articles for compliance with the inclusion criteria and selected
studies eligible for inclusion in the review. We corresponded with
study investigators, as required, to clarify study eligibility. We re-
solved disagreements as to study eligibility by discussion or by
consultation with a third review author (BWM). We classified the
study as ’awaiting classification’ if disagreements between review
authors were not resolved, and we reported disagreements in the
final review.
Data extraction and management
At least two review authors (JB for all included studies and HT/
SW/SJC each for some studies) independently extracted data from
all eligible studies using a data extraction form designed and pilot-
tested by the review authors. We resolved disagreements by dis-
cussion or by consultation with a third review author (BWM).
Extracted data included study characteristics and outcome data
(Appendix 7). When studies had multiple publications, we col-
lated multiple reports on the same study, so that each study, rather
than each report, was the unit of interest in the review, and we
assigned such studies a single study identity with multiple refer-
ences. We used the main trial report as the reference and derived
additional details from secondary papers. We corresponded with
study investigators to request further data on methods and results,
as required. We included studies irrespective of whether outcomes
were reported in a ’usable’ way. In multiarm studies, we excluded
data from arms that did not meet the eligibility criteria.
Assessment of risk of bias in included studies
At least two review authors (JB for all included studies and HT/
SW/SJC each for some studies) independently assessed included
studies for risk of bias using the Cochrane ’Risk of bias’ tool
(Higgins 2011). We assessed the following seven items: random
sequence generation, allocation concealment, blinding of partic-
ipants and personnel, blinding of outcome assessors, incomplete
outcome data, selective outcome reporting and other potential
sources of bias.We resolved disagreements by discussion or by con-
sultation with a third review author (BWM). We fully described
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all judgements and presented our conclusions in the ’Risk of bias’
table, which we incorporated into our interpretation of review
findings by conducting sensitivity analyses.
Selective reporting is a type of reporting bias that affects the inter-
nal validity of an individual study (see Table 10.1A in theCochrane
Handbook for Systematic Reviews of Interventions; Higgins 2011).
This term refers to selective reporting of some outcomes (e.g. pos-
itive outcomes) and failure to report others (e.g. adverse events).
We took care to search for within-trial selective reporting, such as
trials failing to report obvious outcomes, or failing to report them
in insufficient detail to allow inclusion. We looked for published
protocols and compared outcomes between the protocol and the
final published study. When identified studies did not report the
primary outcome of live birth but did report interim outcomes
such as pregnancy, we planned to undertake informal assessment
as to whether the interim values (e.g. pregnancy rates) were similar
to those reported in studies that also reported live births.
If any outcomes were defined in the protocol or the study report,
and datawere insufficient to allow inclusion, we sought tomention
this lack of data along with the suggestion that additional clinical
trials need to be conducted to clarify these knowledge gaps.
Measures of treatment effect
For dichotomous data (e.g. live births, clinical pregnancy rates),
we used the numbers of events in control and intervention groups
of each study to calculate Mantel-Haenszel odds ratios (ORs). We
treated ordinal data (e.g. adhesion scores) as continuous data. For
continuous data, if all studies reported exactly the same outcomes,
we calculated mean differences (MDs) between treatment groups.
If similar outcomes were reported on different scoring scales, we
did not calculate standardised mean differences (SMDs) because
the seven different adhesion score classifications had not been val-
idated. We aimed to reverse the direction of effect of individual
studies, if required, to ensure consistency across trials. We pre-
sented 95% confidence intervals (CIs) for all outcomes and con-
tacted corresponding or first authors of all included trials that re-
ported data in a form that was not suitable for meta-analysis. We
reported data from reports that did not present additional data
that could be analysed under ’other data.’ When data were not
available for calculating ORs or MDs, we planned to utilise the
most detailed numerical data provided thatmight facilitate similar
analyses of included studies (e.g. test statistics, P values). We com-
pared the magnitude and direction of effect reported by studies
with how they were presented in the review, while taking account
of legitimate differences.
Unit of analysis issues
Weperformed the primary analysis perwoman randomly assigned;
however, we included per-pregnancy data for one secondary out-
come (miscarriage). If studies had reported only per-cycle data,
we would have contacted primary study authors to request per-
woman data. If these had been available, we would have briefly
summarised per-cycle data in an additional table without perform-
ing a meta-analysis. We would have counted multiple live births
(e.g. twins, triplets) as one live birth event only.We would have in-
cluded only first-phase data from cross-over trials if relevant cross-
over trials had been found eligible.
Dealing with missing data
We analysed data on an intention-to-treat (ITT) basis; if data had
been available, we would have attempted to obtain all missing data
from the original researchers. If this had been impossible, wewould
have undertaken imputation of individual values for the beneficial
primary outcome only (live birth); we would have assumed that
live births did not occur in women without a reported outcome.
For all other outcomes, we would have analysed only available
data. We would have subjected any imputation undertaken for
missing data for the primary outcome to sensitivity analysis. (See
Sensitivity analysis.) If studies had reported sufficient detail to
calculate MDs but had not information on associated standard
deviations (SDs), we would have assumed that the outcome had
an SD equal to the highest SD from other studies within the same
analysis.
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. We assessed
statistical heterogeneity by measuring the I² statistic. We took an
I² statistic greater than 50% to indicate substantial heterogeneity
(Higgins 2003).
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, we minimised their potential im-
pact by ensuring a comprehensive search for eligible studies and by
being alert for duplication of data. If we had included 10 or more
studies in an analysis, we would have used a funnel plot to explore
the possibility of small-study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies).
Data synthesis
One review author (JB) entered the data and carried out all sta-
tistical analyses of the data in Review Manager 5 (RevMan 2014).
When studies were sufficiently similar and substantial statistical
heterogeneity could be confidently ruled out, we combined data
derived fromprimary studies in ameta-analysis usingReviewMan-
ager 5 (RevMan 2014). We have used summary Mantel-Haenszel
ORs and a fixed-effect model for the following comparisons.
• Anti-adhesion therapy versus placebo or no treatment
following operative hysteroscopy.
11Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Anti-adhesion therapy A versus anti-adhesion therapy B
following operative hysteroscopy.
We considered outcomes of ’live birth’ and ’clinical pregnancy’ as
positive outcomes of effectiveness and, as a consequence, higher
numbers of these two outcomes as a benefit. We considered ’mis-
carriage,’ ’presence of IUAs,’ ’mean adhesion scores’ or ’severity
of adhesions’ at second-look hysteroscopy as negative outcomes
of safety and interpreted higher numbers as harmful. An increase
in the odds of a particular outcome that was beneficial (e.g. live
birth) or detrimental (e.g. IUAs) was displayed graphically in the
meta-analyses to the right of the centre line, and a decrease in the
odds of an outcome to the left of the centre line.
We defined analyses that were comprehensive and mutually exclu-
sive, so that all eligible study results could be slotted into one stra-
tum for each comparison, and that trials within the same stratum
could be sensibly pooled. Stratification was not a requirement, but
it allowed consideration of effects within each stratum as well as,
or instead of, an overall estimate for the comparison. If we had re-
trieved no RCTs for some comparisons, we would have indicated
their absence in the review to reveal knowledge gaps for which
further research is needed. We would have presented a narrative
overview if meta-analysis had not been appropriate.
Subgroup analysis and investigation of heterogeneity
Where data were available, we conducted subgroup analyses to
identify separate evidence within the following subgroup:
• studies with HA gel versus studies with another type of gel
for the primary outcome and the presence of IUAs at second-
look hysteroscopy.
We interpreted the findings of subgroup analyses cautiously, even
when sufficient data were available; subgroup analysis is by itself
observational in nature and the interpretation of formal statistical
tests to detect differences between subgroups is problematic.
If we detected substantial heterogeneity, we explored possible ex-
planations in the subgroup analyses (e.g. differing populations) or
sensitivity analyses (e.g. differing risk of bias), or both. We took
any statistical heterogeneity into account when interpreting the
results.
Sensitivity analysis
We conducted sensitivity analyses for the primary outcome to
determine whether conclusions were robust to arbitrary decisions
made regarding eligibility and analysis of studies. These analyses
included consideration of whether review conclusions would have
differed if:
• only studies were included reporting the primary outcome
(live birth) versus all studies reporting live birth or a surrogate
outcome;
• eligibility had been restricted to studies without high risk of
bias;
• study used only a random-effects model;
• alternative imputation strategies had been implemented;
• summary effect measure had been risk ratio (RR) rather
than OR.
Overall quality of the body of evidence: ’Summary of
findings’ table
We prepared two ’Summary of findings’ tables using GRADEpro
GDT and Cochrane methods (Higgins 2011). These ’Summary
of findings’ tables evaluated the overall quality of the body of evi-
dence for the two most important review outcomes (live birth as
the primary outcome of effectiveness and presence of IUAs at sec-
ond-look hysteroscopy as the primary outcome of safety) for the
two main review comparisons (i.e. anti-adhesion therapy versus
placebo or no treatment following operative hysteroscopy; anti-
adhesion therapy following operative hysteroscopy versus another
anti-adhesion therapy).We restricted the content of the ’Summary
of findings’ tables to these two main review outcomes in the inter-
est of readability of the review. We presented the evidence for all
other secondary outcomes in the text of the review. We assessed
the quality of the evidence using GRADE criteria, including risk
of bias, consistency of effect, imprecision, indirectness and publi-
cation bias. Two review authors independently made judgements
about evidence quality (high, moderate, low or very low), with
disagreements resolved by discussion. Judgements were justified,
documented and incorporated into reporting of results for each
outcome.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification; and
Characteristics of ongoing studies tables.
Results of the search
Our original search retrieved 11 studies whichwere included in the
original published version of this review in 2015. In the updated
search in 2017, we identified 342 records by searching the fol-
lowing databases: CGFG Specialised Register (11 records), CEN-
TRAL (14), MEDLINE (21), Embase (32), WoS (11), CINAHL
(1), CRD (26), National Guideline Clearinghouse (3), ISRCTN
Register of Controlled Trials (13), WHO ICTRP (22), LILACS
(75), Open Grey (107) and Scopus (6). We retrieved 629 addi-
tional records through other sources: handsearch of the Journal of
Minimally Invasive Gynecology (8) and handsearch of related arti-
cles on included studies (621).
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After combining342 records identified through electronic searches
with 629 additional records obtained by searching other sources,
we screened 971 records for duplicates using specialised soft-
ware (www.myendnoteweb.com).We removed899duplicates.We
screened 72 records for titles and abstracts: we excluded 50 records
for being obviously irrelevant and six records for being duplicates.
We assessed 16 full-text articles for eligibility: we excluded 11 full-
text articles for various reasons. We identified five potentially el-
igible studies for the updated search. We included 16 studies in
the present Cochrane Review for quantitative synthesis and crit-
ical appraisal (Characteristics of included studies table); two tri-
als are ongoing (Characteristics of ongoing studies table) and one
trial is awaiting classification (Characteristics of studies awaiting
classification table).
See the PRISMA flow chart for a summary of studies retrieved by
our search, including both our original search (from inception to
1 March 2015) and an updated search (from 1 March 2015 until
1 June 2017) (Figure 1).
13Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram: summary of searches since 2015. PICO: population, intervention,
comparator, outcome; RCT: randomised controlled trial.
14Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Study design and setting
We included16parallel-designRCTs: 15 studies used two compar-
ison groups (Abu Rafea 2013; Acunzo 2003; Dabir-Ashrafi 1996;
De Iaco 2003; Di Spiezio Sardo 2011; Do 2005; Fuchs 2014; Gan
2017; Guida 2004; Lin 2015a; Lin 2015b; Roy 2014; Vercellini
1989; Wang 2016; Xiao 2015), and one study used three compar-
ison groups (Amer 2010). All but one (Xiao 2015) were single-
centre studies: six from Italy (Acunzo 2003; De Iaco 2003; Guida
2004; Di Spiezio Sardo 2011; Guida 2004; Vercellini 1989), four
from China (Gan 2017; Lin 2015b; Wang 2016; Xiao 2015),
one from Egypt (Amer 2010), one from Saudi Arabia (Abu Rafea
2013), one from Iran (Dabir-Ashrafi 1996), one from India (Roy
2014), one from Taiwan (Lin 2015a), and one from South Korea
(Do 2005).
Funding sources
See Characteristics of included studies table.
In six of 16 studies, primary authors stated that they had obtained
no external funding (Amer 2010; De Iaco 2003; Di Spiezio Sardo
2011; Fuchs 2014; Guida 2004; Roy 2014). In seven of 16 stud-
ies, reporting of external funding was unclear; we failed to ob-
tain clarification from corresponding authors of the primary study
report despite several queries (Abu Rafea 2013; Acunzo 2003;
Dabir-Ashrafi 1996; Do 2005; Lin 2015a; Vercellini 1989; Xiao
2015). Three studies reported external funding by the Chinese
Government (Gan 2017; Lin 2015b; Wang 2016).
Potential conflicts of interest
In nine of 16 studies, primary authors declared no potential con-
flicts of interest (Amer 2010;De Iaco2003;Di Spiezio Sardo2011;
Fuchs 2014; Gan 2017; Guida 2004; Lin 2015b; Roy 2014;Wang
2016). In seven of 16 studies, reporting of potential conflicts of
interest was unclear despite several queries to the corresponding
authors (Abu Rafea 2013; Acunzo 2003; Dabir-Ashrafi 1996; Do
2005; Lin 2015a; Vercellini 1989; Xiao 2015).
Participants
See Characteristics of included studies table for a detailed descrip-
tion of the main participant characteristics.
Abu Rafea 2013 randomly assigned 28 women diagnosed with
an intrauterine septum with from infertility or adverse pregnancy
outcomes, or both.
Acunzo 2003 included 92 women with irregular menses and IUAs
treated by hysteroscopy.
Amer 2010 included 45 women with severe IUAs, all with sub-
fertility, bound to undergo operative hysteroscopy.
Dabir-Ashrafi 1996 randomly assigned 46 participants with sub-
fertility and recurrentmiscarriage with a fundal defect on hysteros-
alpingography (HSG).
De Iaco 2003 included 60 women bound to undergo endome-
trial ablation or hysteroscopic removal of submucosal fibroids, en-
dometrial polyps, septate uterus or intrauterine synechiae.
Di Spiezio Sardo 2011 included 110 women diagnosed at clinic
diagnostic hysteroscopy with single or multiple lesions suitable for
surgical treatment or with resistant dysfunctional uterine bleeding
requiring endometrial ablation.
Do 2005 included64womenwhounderwent intrauterine surgery.
Fuchs 2014 included 52 women of confirmed fertility who under-
went hysteroscopic surgery because of suspected retained products
of conception.
Gan 2017 included 88 women with infertility or at least one spon-
taneous miscarriage and severe IUAs following hysteroscopic ad-
hesiolysis.
Guida 2004 included 138 women with surgically treatable single
lesions (fibroids, polyps and uterine septa, subgroups I to III) at
diagnostic hysteroscopy.
Lin 2015a included 62 women undergoing hysteroscopy.
Lin 2015b included 201 women with moderate-to-severe IUAs
(no prioritisation of the outcomes reported. or greater) after hys-
teroscopic adhesiolysis.
Roy 2014 included 90 women with septate uterus with a history
of miscarriage or subfertility.
Vercellini 1989 included 20womenwith two ormore unexplained
spontaneous miscarriages with a uterine septum.
Wang 2016 included 57 women following hysteroscopic adhesi-
olysis for severe IUAs.
Xiao 2015 included 120 women that underwent hysteroscopic
adhesiolysis for moderate-to-severe IUAs.
The proportion of subfertile women was as follows:
• 0% (two studies; 72 women; Fuchs 2014; Vercellini 1989);
• less than 50% (six studies; 567 women; Abu Rafea 2013;
Acunzo 2003; Dabir-Ashrafi 1996; Di Spiezio Sardo 2011; Lin
2015b; Roy 2014);
• 100% (two studies; 102 women; Amer 2010; Wang 2016);
• unknown (six studies; 532 women; De Iaco 2003; Do
2005; Gan 2017; Guida 2004; Lin 2015a; Xiao 2015).
Interventions and comparators
See Characteristics of included studies table.
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1. Any intervention versus no treatment or placebo
• Device versus no treatment (Abu Rafea 2013; Lin 2015a).
• Hormonal treatment versus no treatment or placebo
(Dabir-Ashrafi 1996; Roy 2014).
• Device combined with hormonal treatment versus no
treatment (Vercellini 1989).
• Barrier gel versus no treatment (Acunzo 2003; De Iaco
2003; Di Spiezio Sardo 2011; Do 2005; Guida 2004).
2. Any intervention versus any other intervention
• Device with graft versus device without graft (Amer 2010;
Gan 2017; Wang 2016).
• One type of device versus another type of device (Lin
2015b).
• Gel combined with hormonal treatment and antibiotics
versus hormonal treatment combined with antibiotics (Fuchs
2014).
• Device combined with gel versus device (Xiao 2015).
In the previous version of this review Amer 2010 and Fuchs 2014
were erroneously classified under the comparison “Any therapy
versus no treatment or placebo”.
Outcomes
See Characteristics of included studies table.
• Primary outcome
◦ Live birth. No study reported live birth. Five studies
reported a surrogate outcome: term delivery (Abu Rafea 2013;
Wang 2016), or ongoing pregnancy (Amer 2010; Gan 2017;
Roy 2014; Wang 2016).
• Secondary outcomes.
◦ Clinical pregnancy (Abu Rafea 2013; Amer 2010;
Fuchs 2014). Three studies reported pregnancy, not further
defined which we used as a surrogate outcome for clinical
pregnancy (Gan 2017; Roy 2014; Wang 2016).
◦ Miscarriage (Abu Rafea 2013; Amer 2010; Gan 2017;
Roy 2014; Wang 2016).
◦ Presence of IUAs at second-look hysteroscopy (Acunzo
2003; De Iaco 2003; Di Spiezio Sardo 2011; Do 2005; Fuchs
2014; Gan 2017; Guida 2004; Lin 2015a; Lin 2015b; Roy
2014; Vercellini 1989; Wang 2016; Xiao 2015).
◦ Adhesion scores of IUAs at second-look hysteroscopy
(Acunzo 2003; Amer 2010; Gan 2017; Guida 2004; Lin 2015b;
Wang 2016; Xiao 2015).
◦ Severity of IUAs at second-look hysteroscopy (Acunzo
2003; De Iaco 2003; Di Spiezio Sardo 2011; Do 2005; Fuchs
2014; Guida 2004; Roy 2014; Xiao 2015).
While several studies measured outcomes other than the key out-
comes prespecified in our Cochrane Review’s protocol (Amer
2010; Di Spiezio Sardo 2011; Do 2005; Gan 2017; Lin 2015b;
Roy 2014; Vercellini 1989; Wang 2016; Xiao 2015), two studies
reported none of the outcomes relevant for the quantitative syn-
thesis and critical appraisal (Dabir-Ashrafi 1996; Lin 2015a).
Excluded studies
See Characteristics of excluded studies table.
We excluded 15 potentially eligible studies for the following rea-
sons.
• Five were observational studies (Chen 2017; Hu 2014a; Hu
2014b; Liu 2016; NCT02328742).
• Two were quasi-randomised studies (Pabuccu 2008;
Tonguc 2010).
• Seven did not answer the PICO (population, intervention,
comparator, outcome) research questions of this Cochrane
Review (Bednarek 2011; Cheong 2016; Johns 2001; Kurtz 2002;
NTR3120; Tsapanos 2002; Ya ar 2004).
• One study explicitly excluded subfertile women from
participation in the trial (Kim 2012).
Risk of bias in included studies
See the ’Risk of bias’ summary for the review authors’ judgements
about each risk of bias item in the included study (Figure 2).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
See the ’Risk of bias’ graph for the review authors’ judgements
about each risk of bias item presented as percentages across the 16
included studies (Figure 3).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged14of 16 studies at low risk of selectionbias in relation to
random sequence generation because all used computer-generated
randomisation lists (Abu Rafea 2013; Acunzo 2003; Amer 2010;
De Iaco 2003; Di Spiezio Sardo 2011; Fuchs 2014; Gan 2017;
Guida 2004; Lin 2015a; Lin 2015b; Roy 2014; Vercellini 1989;
Wang 2016; Xiao 2015). We judged two studies at unclear risk
of selection bias in relation to random sequence generation: the
study reports claim that both trials were RCTs but did not describe
themethod of randomisation (Dabir-Ashrafi 1996; Do 2005).We
obtained no clarification from the authors of the primary studies
despite several mailings. None of the included studies were at high
risk of selection bias in relation to random sequence generation.
We judged seven of 16 studies at low risk of selection bias in rela-
tion to allocation concealment because investigators used sequen-
tially numbered opaque sealed envelopes containing the allocated
treatment (Amer 2010;Di Spiezio Sardo 2011; Fuchs 2014;Guida
2004; Lin 2015a; Vercellini 1989), or a code referring to the allo-
cated treatment (Roy 2014). We judged eight of 16 studies at un-
clear risk of selection bias in relation to allocation concealment be-
cause study authors did not describe themethod of allocation con-
cealment and did not provide clarification as requested (Acunzo
2003; Dabir-Ashrafi 1996; Do 2005; Lin 2015b; Wang 2016;
Xiao 2015), or provided insufficient information (De Iaco 2003;
Gan 2017). We judged one study at high risk of selection bias in
relation to allocation concealment: randomisation was based on a
computer-generated list of numbers, but study authors reported
that the allocation was unconcealed (Abu Rafea 2013).
Blinding
Performance bias
Five of 16 studies reported live births (or ongoing pregnancy or
term delivery as surrogate outcomes for live birth) (Abu Rafea
2013; Amer 2010; Gan 2017; Roy 2014; Wang 2016), and six
of 16 studies reported clinical pregnancy (or pregnancy not fur-
ther specified a surrogate outcome) (Abu Rafea 2013; Amer 2010;
Fuchs 2014; Gan 2017; Roy 2014; Wang 2016). We judged all
six studies at low risk of performance bias in relation to blinding
of participants and personnel because live birth and clinical preg-
nancy are unequivocal outcomes (Abu Rafea 2013; Amer 2010;
Fuchs 2014; Gan 2017; Roy 2014; Wang 2016). We judged the
remaining 10 studies at low risk as none reported live birth or
clinical pregnancy (or a surrogate for these predefined outcomes).
See Figure 3.
We judged only one of 16 studies at low risk of performance
bias in relation to blinding of participants and personnel for the
key outcome of adhesions as placebo pills containing folic acid
were used for blinding participants and personnel (Roy 2014).We
judged three studies at unclear risk of performance bias in rela-
tion to blinding of participants and personnel for the outcome
of adhesions because the method of blinding of participants and
personnel was not described (Dabir-Ashrafi 1996; Gan 2017), or
was not sufficiently clarified after contact with the study authors
(De Iaco 2003). We judged 12 of 16 studies at high risk of perfor-
mance bias in relation to blinding of participants and personnel
for the outcome of presence of IUAs, as personnel (Amer 2010;
Di Spiezio Sardo 2011; Do 2005; Fuchs 2014; Guida 2004; Lin
2015b; Wang 2016; Xiao 2015), or both participants and person-
nel (Abu Rafea 2013; Acunzo 2003; Lin 2015a; Vercellini 1989),
were not blinded.
Detection bias
Five of 16 studies reported live births (or ongoing pregnancy or
term delivery as surrogate outcomes for live birth) (Abu Rafea
2013; Amer 2010; Gan 2017; Roy 2014; Wang 2016), and six of
16 studies reported clinical pregnancy (or pregnancy not further
specified a surrogate outcome) (Abu Rafea 2013; Amer 2010;
Fuchs 2014; Gan 2017; Roy 2014; Wang 2016). We judged all
six studies at low risk of detection bias in relation to blinding of
outcome assessors because live birth and clinical pregnancy are
unequivocal outcomes (Abu Rafea 2013; Amer 2010; Fuchs 2014;
Gan 2017; Roy 2014; Wang 2016). We judged the remaining 10
studies at low risk as none reported live birth or clinical pregnancy
(or a surrogate for these predefined outcomes). See Figure 3.
We judged nine of 16 studies at low risk of detection bias for the
key outcome of adhesions because outcome assessors were inde-
pendent observers blinded to treatment allocation (Amer 2010;
De Iaco 2003; Di Spiezio Sardo 2011; Fuchs 2014; Gan 2017;
Guida 2004; Lin 2015b; Roy 2014; Xiao 2015). We judged five
of 16 studies to be at unclear risk of detection bias in relation to
blinding of outcome assessors for the key outcome of adhesion
formation because the method of blinding was not reported and
clarification could not be obtained from the authors of the primary
study (Abu Rafea 2013; Acunzo 2003; Do 2005;Wang 2016).We
judged one study at unclear risk of performance and detection bias
in relation to blinding of participants, personnel and outcome as-
sessors for a subjective outcome not prespecified in this Cochrane
Review: the method was unclear, and we obtained no clarification
from the authors (Dabir-Ashrafi 1996). Two studies were at high
risk of detection bias in relation to blinding of outcome assessors
for the outcome of adhesion formation: the outcome assessors in
these two trials were not blinded (Lin 2015a; Vercellini 1989).
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Incomplete outcome data
We judged 12 of 16 studies at low risk of attrition bias because all
participants with relevant outcome data were included in the final
data analysis (Abu Rafea 2013; Di Spiezio Sardo 2011; Vercellini
1989; Wang 2016), or loss to follow-up was small (less than 10%)
without imbalance across comparison groups for numbers or rea-
sons for loss to follow-up (Acunzo 2003; Amer 2010; Do 2005;
Gan 2017; Guida 2004; Lin 2015a; Roy 2014; Xiao 2015). We
judged one study at unclear risk of attrition bias because four of 50
(8%) participants were excluded and distribution among compar-
ison groups was not reported: we obtained no clarification from
the study authors (Dabir-Ashrafi 1996). We judged three of 16
studies at high risk of attrition bias (De Iaco 2003; Fuchs 2014;
Lin 2015b). In one study, loss to follow-up after randomisation
involved 20/60 included participants (De Iaco 2003). The second
study excluded five of 26 participants in the intervention group
and six of 26 participants in the control group after randomisation
from the analysis (11/52 or 21%): reasons for discontinuation of
the trial were not clarified (Fuchs 2014). Loss to follow-up in the
third trial was 19% (Lin 2015b).
Selective reporting
We judged 12 of 16 studies at low risk of reporting bias in re-
lation to selective outcome reporting (Abu Rafea 2013; Acunzo
2003; Amer 2010; Dabir-Ashrafi 1996; De Iaco 2003; Di Spiezio
Sardo 2011; Do 2005; Guida 2004; Roy 2014; Vercellini 1989;
Wang 2016; Xiao 2015). We judged one study at unclear risk
of selective outcome reporting because we noted discrepancies
between outcomes prespecified in the registered study protocol
NCT01167296 and results reported in the abstract and in the
results section (Lin 2015a). We judged three of 16 studies at high
risk of reporting bias in relation to selective outcome reporting
(Fuchs 2014; Gan 2017; Lin 2015b). One study failed to report
data for the primary outcome of live birth despite a study duration
of 27 months (Fuchs 2014). In the study protocol of Gan 2017,
registered as NCT02496052, all secondary outcomes mentioned
in the final study report were not predefined. A third study failed
to report data for pregnancy rates in the published report of the
study, although pregnancy was prespecified as a main outcome in
the study protocol ISRCTN69690272 (Lin 2015b).
Other potential sources of bias
We judged seven of 16 studies at low risk of other potential sources
of bias (Acunzo 2003;Dabir-Ashrafi 1996;Di Spiezio Sardo 2011;
Guida 2004; Lin 2015b; Roy 2014; Xiao 2015). We judged two
of 16 studies to be at unclear risk of other potential sources of bias
(Vercellini 1989; Wang 2016). Vercellini 1989 did not report the
baseline characteristics of both comparison groups. In two women
in the intervention group, the IUD was removed early and in one
woman of the control group had a Foley balloon catheter inserted
for persistent heavy bleeding.These threewomen should have been
excluded from the analysis because these interventions could have
affected the outcomes. We did not do sensitivity analyses com-
paring all data versus data excluding these three participants: the
study was completed almost 30 years ago and it was no longer pos-
sible to retrieve data for individual participant data analysis (IPD).
Wang 2016 offered cotreatment with artificial fertility treatment
but it was unclear if comparable proportions of women received
similar treatments in both comparison groups. We judged seven
of 16 studies at high risk of other potential sources of bias (Abu
Rafea 2013; Amer 2010; De Iaco 2003; Do 2005; Fuchs 2014;
Gan 2017; Lin 2015a). One study excluded four of 28 partici-
pants (14%) from the final analysis after randomisation because
they were not trying to conceive (Abu Rafea 2013). The reason for
this postrandomisation exclusion was a lack of explicit inclusion
and exclusion criteria. Analysis of study results showed that poor
inclusion and exclusion criteria may lead to increased risk of bias.
Moreover, researchers measured outcomes in this study over 12
to 18 months: this could have affected final pregnancy results if
imbalance occurred across comparison groups for the time points
at which this key outcome was measured. Finally, although there
were no evident statistically significant differences in mean age of
participants in both comparison groups, the MD was three years,
and more women of a younger age were included in the interven-
tion group. This baseline imbalance between comparison groups
is clinically relevant, irrespective of P values. Amer 2010 provided
evidence of baseline imbalance among participant characteristics
in relation to differences in the prevalence of prior caesarean sec-
tion as a cause of IUAs. Moreover, investigators provided cotreat-
ment with laparoscopy and in vitro fertilisation (IVF) for some
women but failed to reported data on the distribution in numbers
among comparison groups. De Iaco 2003 recalculated data for the
outcomes of presence of IUAs at second look and severity of IUAs
and reported no statistically significant differences between com-
parison groups, although study authors concluded that the use
of anti-adhesion barrier gel improved outcomes of hysteroscopic
surgery. This conclusion was not based on the available evidence.
Investigators did not report baseline characteristics of both com-
parison groups. Do 2005 is at high risk of selection bias because
there were clinically relevant differences in baseline characteristics
between both comparison groups for age, parity and the number
of miscarriages. Moreover, it was unclear if micro-hysteroscopy or
transvaginal ultrasound was used for outcome assessment of IUAs.
Therefore, it is unclear if this study was at risk for information
bias. Fuchs 2014 at follow-up hysteroscopy offered cotreatment
with hysteroscopic adhesiolysis to women with AFS grade II or
III IUAs. They offered cotreatment to three of 20 (14%) women
in the control group and to one of 21 (4%) women in the inter-
vention group. This may have affected the magnitude and direc-
tion of the treatment effect. For Gan 2017, we had some concerns
for performance bias related to cotreatments with IVF and la-
paroscopy whose proportions in both treatment arms were not re-
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ported. There was no fixed endpoint for measuring the secondary
outcomes: the total duration of follow-up via direct contact or
telephone every three months lasted between six and 12 months.
The longer the follow-up period, the higher the cumulative preg-
nancy rate. Therefore, we judged this study at high risk for detec-
tion bias. We have some concern for imbalance in baseline char-
acteristics between the two comparison groups of Lin 2015a: the
number of participants with IUAs in the intervention group (17/
31 women) was nearly doubled compared to the control group
(10/31 women).
Effects of interventions
See: Summary of findings for the main comparison Any
anti-adhesion therapy versus placebo or no treatment following
operative hysteroscopy; Summary of findings 2 Any anti-
adhesion therapy A versus anti-adhesion therapy B following
operative hysteroscopy
1. Anti-adhesion therapy versus placebo or no
treatment following operative hysteroscopy
We identified 10 studies any intervention versus no treatment or
placebo (Abu Rafea 2013; Acunzo 2003; Dabir-Ashrafi 1996; De
Iaco 2003; Di Spiezio Sardo 2011; Do 2005; Guida 2004; Lin
2015a; Roy 2014; Vercellini 1989).
1.1. Live birth
No study reported live birth, but two studies reported outcomes
that were used as surrogate outcomes for live birth (term delivery
or ongoing pregnancy) (Abu Rafea 2013; Roy 2014). Based on a
pooling of these two small studies, there was insufficient evidence
to determine whether there was a difference in surrogate outcomes
for live birth rate between the use of any intervention compared
to no treatment or placebo (OR 0.94, 95% CI 0.42 to 2.12; 107
women; 2 studies; I² = 0%; very-low-quality evidence; Analysis
1.1). We stratified data according to device versus no treatment or
placebo and hormonal treatment versus no treatment or placebo.
1.1.1. Device versus no treatment and hormonal treatment
versus placebo or no treatment
One study reported data for the outcome of term delivery at 12 to
18 months (Abu Rafea 2013). There was insufficient evidence to
determine whether there was a difference in term delivery rate at
12 to 18 months between the use of an intrauterine Foley catheter
balloon and no treatment following hysteroscopic septum division
(OR 1.00, 95% CI 0.18 to 5.46; 24 women; 1 study; Analysis
1.1).
1.1.2. Hormonal treatment versus placebo or no treatment
Roy 2014 reported data on ongoing pregnancy. We used these
data as a surrogate for live birth. It was unclear whether there
was a difference between treatment with oestradiol valerate 2 mg
daily versus folic acid 5 mg as a placebo for 30 days following
hysteroscopic septum division (OR 0.93, 95% CI 0.37 to 2.33;
83 women; 1 study; Analysis 1.1).
Sensitivity analysis
We conducted a sensitivity analysis for Analysis 1.1. The choice to
include two studies regardless of study quality (Abu Rafea 2013;
Roy 2014), or to include only one study at low risk for selection
bias related to random sequence generation and allocation con-
cealment (Roy 2014), did not affect the direction/magnitude of
the summary effect estimate or the statistical significance tests.
Sensitivity analyses on the choice of the summary effect measure
(OR versus RR) or the analysis model (fixed-effect versus random-
effects model) demonstrated no differences of the direction of the
treatment effect or the statistical significance tests.
In Abu Rafea 2013, some women (4/28 (14%)) were not trying
to conceive after treatment, although they had been randomly as-
signed (1/13 women in the intervention group and 3/15 women
in the control group). As prespecified in the protocol under ’Deal-
ing with missing data,’ we conducted a sensitivity analysis on the
choice to use an available data analysis rather than an ITT analysis
with the imputation that no live births would have occurred in
women without a reported outcome. There was no impact on the
direction/magnitude of the effect size or on the statistical signifi-
cance tests.
1.2. Clinical pregnancy
According to a meta-analysis of Abu Rafea 2013 and Roy 2014,
there was insufficient evidence to determine whether there was
a difference in clinical pregnancy rates between the use of any
intervention compared to no treatment or placebo (OR 0.86, 95%
CI 0.37 to 2.01; 107 women; 2 studies; I² = 0%; Analysis 1.2).We
stratified data according to device versus no treatment or placebo
and hormonal treatment versus no treatment or placebo.
1.2.1. Device versus placebo or no treatment
Abu Rafea 2013 did not define the outcome of pregnancy, and
we obtain no clarification from study authors. Moreover, some
women could have had more than one pregnancy during the fol-
low-up period of 12 to 18 months - a point that could not be
clarified. It was unclear whether there was a difference between the
use of an intrauterine Foley catheter balloon versus no treatment
following hysteroscopic septum division (OR 1.00, 95% CI 0.06
to 18.08; 24 women; 1 study; Analysis 1.2).
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1.2.2. Hormonal treatment versus placebo or no treatment
According to Roy 2014, there was insufficient evidence to de-
termine whether there was a difference between treatment with
oestradiol valerate 2 mg daily versus folic acid 5 mg as a placebo
for 30 days following hysteroscopic septum division (OR 0.85,
95% CI 0.35 to 2.06; 83 women; 1 study; Analysis 1.2).
1.3. Miscarriage
According to a meta-analysis of Abu Rafea 2013 and Roy 2014,
there was insufficient evidence to determine whether there was a
difference in miscarriage rates between the use of any intervention
compared to no treatment or placebo (OR 0.68, 95% CI 0.18 to
2.57; 54 women; 2 studies; I² = 0%; Analysis 1.3). We stratified
data according to device versus no treatment or placebo and hor-
monal treatment versus no treatment or placebo.
1.3.1. Device versus placebo or no treatment
According to Abu Rafea 2013, there was insufficient evidence to
determine whether there was a difference between the use of an
intrauterine Foley catheter balloon versus no treatment following
hysteroscopic septum division (OR 0.66, 95% CI 0.11 to 4.00;
24 women; 22 clinical pregnancies; 1 study; Analysis 1.3).
1.3.2. Hormonal treatment versus placebo or no treatment
According to Roy 2014, there was insufficient evidence to de-
termine whether there was a difference between treatment with
oestradiol valerate 2 mg daily versus folic acid 5 mg as a placebo
for 30 days following hysteroscopic septum division (OR 0.72,
95% CI 0.10 to 5.01; 83 women; 32 clinical pregnancies; 1 study;
Analysis 1.3).
1.4. Presence of intrauterine adhesions at second-look
hysteroscopy
According to a meta-analysis of eight studies, anti-adhesion treat-
ment decreases the occurrence of IUAs at second-look hys-
teroscopy compared to no treatment or placebo (OR0.35, 95%CI
0.21 to 0.60; 560women; 8 studies; I² = 0%; low-quality evidence;
Analysis 1.4) (Acunzo 2003;De Iaco 2003;Di Spiezio Sardo 2011;
Do 2005; Guida 2004; Lin 2015a; Roy 2014; Vercellini 1989).
The number needed to treat for an additional beneficial outcome
(NNTB) was 9 (95% CI 5 to 17). We stratified data according
to device versus no treatment or placebo, device plus hormonal
treatment versus no treatment or placebo, hormonal treatment
versus no treatment or placebo and gel versus no treatment or
placebo.
1.4.1. Device versus placebo or no treatment
There was insufficient evidence from Lin 2015a to determine
whether there was a difference between inserting an intrauterine
balloon stent compared with no treatment following operative
hysteroscopy for decreasing the occurrence of IUAs: there were no
events in both treatment arms (OR not estimable; 60 women; 1
study; Analysis 1.4).
1.4.2. Device plus hormonal treatment versus placebo or no
treatment
There was insufficient evidence fromVercellini 1989 to determine
whether therewas a difference between the insertion of an IUDfol-
lowed by combined oestrogen-progestin treatment for 30 days (in-
tervention) versus no treatment (control) following hysteroscopic
metroplasty for septate uterus in 20 women with two or more un-
explained spontaneous miscarriages. A follow-up HSG was done
to detect uterine cavity abnormalities (residual fundal notch 1 cm
or greater) and hysteroscopy was done in women with a residual
notch (five women in intervention group and six women in con-
trol group). There were no IUAs detected in these 11 women: the
effect size was, therefore, not determined (OR not estimable; 20
women; 1 study; Analysis 1.4).
1.4.3. Hormonal treatment versus placebo or no treatment
Based on the findings of Roy 2014, there is insufficient evidence
to determine whether there is a difference between treatment with
oestradiol valerate 2 mg daily versus folic acid 5 mg as a placebo
for 30 days following hysteroscopic septum division (OR 0.14,
95% CI 0.01 to 2.72; 85 women; 1 study; Analysis 1.4).
1.4.4. Gel versus placebo or no treatment
Based on the pooled data of five studies, the use of gel decreases
the occurrence of IUAs at second-look hysteroscopy compared to
no treatment or placebo (OR 0.37, 95% CI 0.21 to 0.64; 404; 5
studies; I² = 0%; Analysis 1.4) (Acunzo 2003; De Iaco 2003; Di
Spiezio Sardo 2011; Do 2005; Guida 2004).
The NNTB was 7 (95% CI 4 to 14).
Subgroup analyses
A subgroup analysis according to the type of gel used demonstrated
a consistent decrease of the occurrence of IUAs at second-look
hysteroscopy in favour of the use of ACP gel, CMC gel or HA-
CMC gel compared to no gel. There was no evidence for subgroup
differences (Chi² = 0.88, degrees of freedom (df ) = 2; P = 0.65; I²
= 0%). Data from this subgroup analysis should be treated with
caution as subgroup analysis by itself is observational in nature,
and statistical interpretation of results is not without problems.
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1.5. Mean adhesion scores at second-look hysteroscopy in
women not treated for intrauterine adhesions
We aimed to pool the findings of Acunzo 2003 and Guida 2004 to
estimate a summary effect size for the outcome of mean adhesion
scores at second-look hysteroscopy at 12 weeks in women treated
by operative hysteroscopy for any intrauterine pathology after use
of HA gel compared with no treatment. Statistical heterogeneity
beyond chance was very high (I² = 99%) suggesting highly incon-
sistent findings across studies. The reason for this statistical het-
erogeneity was obvious: the prevalence of the outcome of interest
(IUAs) at baseline in Guida 2004 was 0% as opposed to a 100%
prevalence at baseline in Acunzo 2003. The populations were very
different with respect to the risk of the adverse outcomes and the
potential benefit on the adhesion scores. Therefore, we decided
to report data for the mean adhesion scores at second-look hys-
teroscopy in women not treated for IUAs and women treated for
IUAs separately.
1.5.1. Gel versus placebo or no treatment
Guida 2004 demonstrated lower mean adhesion scores at second-
look hysteroscopy after the use of gel compared to no treatment
in women treated for fibroids, endometrial polyps or uterine septa
(MD in adhesion score -1.46, 95%CI -1.64 to -1.29; 132 women;
3 studies; I² = 0%; Analysis 1.5).
1.6. Mean adhesion scores at second-look hysteroscopy in
women treated for intrauterine adhesions
1.6.1. Gel versus placebo or no treatment
Acunzo 2003 reported lower mean adhesion scores at second-look
hysteroscopy after the use of HA gel compared to no gel in women
treated for IUAs (MD in adhesion score -3.30, 95% CI -3.37 to
-3.23, 84 women; 1 study; Analysis 1.6).
1.7. Severity of adhesions at second-look hysteroscopy: mild
Based on a pooling of six studies, there was no clear evidence of
a difference between any anti-adhesion treatment compared to
no treatment or placebo for the occurrence of mild adhesions at
second-look hysteroscopy (OR 1.33, 95% CI 0.68 to 2.61; 494
women; 6 studies; I² = 0%; Analysis 1.7).We stratified the data for
Analysis 1.7 according to hormonal treatment versus no treatment
or placebo and gel versus no treatment or placebo.
1.7.1. Hormonal treatment versus placebo or no treatment
Based on the results of Roy 2014, there was insufficient evidence
to determine whether there was a difference between treatment
with oestradiol valerate 2 mg daily compared to the intake of
folic acid 5 mg as a placebo for 30 days following hysteroscopic
septum division for the occurrence of mild adhesions at second-
look hysteroscopy (OR 0.19, 95% CI 0.01 to 4.10; 90 women; 1
study; Analysis 1.7).
1.7.2. Gel versus placebo or no treatment
Based on the pooled findings of five RCTs, there was no clear
evidence of a difference between the use of any gel versus no gel for
the occurrence of mild adhesions at any second-look hysteroscopy
(OR 1.56, 95% CI 0.77 to 3.18; 404 women; 5 studies; I² = 0%;
Analysis 1.7) (Acunzo 2003;De Iaco 2003;Di Spiezio Sardo 2011;
Do 2005; Guida 2004).
Subgroup analyses
According to a subgroup analysis for Analysis 1.7, there was no
clear evidence of a difference in the type of gel used in the occur-
rence of mild IUAs at second-look hysteroscopy between the use
of ACP gel, CMC gel or HA-CMC gel compared to no gel. There
was no evidence for subgroup differences (Chi² = 0.83, df = 2;
P = 0.66; I² = 0%). Data from this subgroup analysis should be
treated with caution as subgroup analysis by itself is observational
in nature, and statistical interpretation of results is not without
problems.
1.8. Severity of adhesions at second-look hysteroscopy:
moderate or severe
Based on the statistical pooling of the findings of six studies, the use
of anti-adhesion treatment decreases the occurrence ofmoderate or
severe adhesions compared to no treatment or placebo (OR 0.08,
95% CI 0.03 to 0.24; 494 women; 6 studies; I² = 0%; Analysis
1.8) (Acunzo 2003; De Iaco 2003; Di Spiezio Sardo 2011; Do
2005; Guida 2004; Roy 2014).
The NNTB was 6 (95% CI 5 to 10). We stratified data according
to hormonal treatment versus no treatment or placebo and gel
versus no treatment or placebo.
1.8.1. Hormonal treatment versus placebo or no treatment
Based on the results of Roy 2014, there was insufficient evidence
to determine whether there was a difference between treatment
with oestradiol valerate 2 mg daily compared to the intake of folic
acid 5 mg as a placebo for 30 days following hysteroscopic septum
division for the occurrence of moderate or severe adhesions at
second-look hysteroscopy (OR 0.33, 95% CI 0.01 to 8.22; 90
women; 1 study; Analysis 1.8).
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1.8.2. Gel versus placebo or no treatment
Based on the pooled findings of five RCTs, the use of any anti-
adhesion barrier gel decreased the occurrence ofmoderate or severe
adhesions at second-look hysteroscopy (OR 0.07, 95% CI 0.02 to
0.23; 404 women; 5 studies; I² = 0%; Analysis 1.8) (Acunzo 2003;
De Iaco 2003; Di Spiezio Sardo 2011; Do 2005; Guida 2004).
The NNTB was 6 (95% CI 4 to 9).
Subgroup analyses
According to a subgroup analysis for Analysis 1.8, there was a con-
sistent effect in favour of the use of ACP gel, CMC gel or HA-
CMC gel compared to no gel for decreasing the occurrence of
moderate or severe IUAS at second-look hysteroscopy. The sub-
group interaction test did not identify any between-group differ-
ences.
2. Anti-adhesion therapy A versus anti-adhesion
therapy B following operative hysteroscopy
We identified six studies comparing any intervention versus any
other intervention (Amer 2010; Fuchs 2014; Gan 2017; Lin
2015b; Wang 2016; Xiao 2015).
2.1. Live birth
2.1.1. Device plus graft versus device
No study reported live birth, but three studies reported outcomes
that we used as surrogate outcomes for live birth (Amer 2010;
Gan 2017;Wang 2016). The three studies compared the insertion
of a Foley catheter balloon wrapped with fresh or freeze-dried
amniotic graft versus a Foley catheter balloon without graft for one
to two weeks following hysteroscopic adhesiolysis in women with
severe IUAs. Amer 2010 reported data on ongoing pregnancies or
delivered at term.Gan 2017 reported data on ongoing pregnancies
beyond 12 weeks of gestational age. Wang 2016 reported data
on term delivery and ongoing pregnancy (but not yet delivered
at the time of the survey) separately. For reasons of consistency
throughout the review, we extracted data for term delivery and
ongoing pregnancy and used these data as a surrogate for live
birth. There was no clear evidence of a difference between inserting
a Foley catheter balloon with fresh or freeze-dried HAM graft
compared to inserting a Foley catheter balloon only (OR 1.48,
95% CI 0.57 to 3.83; 180 women; 3 studies; I² = 0%; low-quality
evidence; Analysis 2.1).
Sensitivity analysis
We conducted a sensitivity analysis for Analysis 2.1. The choice
to include all studies regardless of study quality or to include only
one study at low risk for selection bias related to random sequence
generation and allocation concealment did not affect the statistical
significance tests. Sensitivity analyses on the choice of the summary
effect measure (OR versus RR) or the analysis model (fixed-effect
versus random-effects model) did not demonstrate differences of
the direction of the treatment effect or the statistical significance
tests.
2.2. Clinical pregnancy
There was no clear evidence of a difference between treatment
A versus treatment B for improving clinical pregnancy rates (OR
1.72, 95% CI 0.89 to 3.33; 221 women; 4 studies; I² = 0%;
Analysis 2.2). We stratified data according to device plus graft
versus device and gel plus hormonal treatment plus antibiotics
versus hormonal treatment plus antibiotics.
2.2.1. Device plus graft versus device
Three studies compared the insertion of a Foley catheter balloon
wrapped with fresh or freeze-dried amniotic graft versus a Foley
catheter balloonwithout graft following hysteroscopic adhesiolysis
in women with severe IUAs (Amer 2010; Gan 2017;Wang 2016).
There was no clear evidence of a difference between inserting a
Foley catheter balloon wrapped with fresh or freeze-fried HAM
graft compared to inserting a Foley catheter for increasing the
chance for a clinical pregnancy (OR 1.53, 95% CI 0.74 to 3.18;
180 women; 3 studies; I² = 0%; Analysis 2.2).
2.2.2. Gel plus hormonal treatment plus antibiotics versus
hormonal treatment plus antibiotics
One study compared the application of Oxiplex gel with sequen-
tial hormonal treatment for three weeks and antibiotic therapy for
one week to sequential hormonal treatment and antibiotic therapy
only in women with confirmed fertility undergoing operative hys-
teroscopy for retained products of conception (Fuchs 2014). This
study reported data on pregnancy without further specification.
We used these data as a surrogate outcome for clinical pregnancy.
There was insufficient evidence from Fuchs 2014 to determine
whether there was a difference between the application of Oxiplex
gel combined with sequential hormonal treatment and antibiotics
compared to sequential hormonal treatment combined with an-
tibiotics (OR 2.83, 95% CI 0.62 to 13.04; 41 women; 1 study; I²
= 0%; Analysis 2.2).
2.3. Miscarriage
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2.3.1. Device plus graft versus device
According to a pooled analysis of data from three studies, there
was no clear evidence of a difference between the insertion of a
Foley catheter balloon wrapped with fresh or freeze-dried amni-
otic graft versus a Foley catheter balloon without graft following
hysteroscopic adhesiolysis in women with severe IUAs for the out-
come miscarriage (OR 0.80, 95% CI 0.20 to 3.19; 180 women;
40 clinical pregnancies; 3 studies; I² = 0%; Analysis 2.3) (Amer
2010; Gan 2017; Wang 2016).
2.4. Presence of intrauterine adhesions at second-look
hysteroscopy
A pooled analysis of five RCTs demonstrated a decrease in the
occurrence of IUAS with anti-adhesion treatment consisting of
barrier gel or intrauterine balloon with or without gel or graft
compared to IUD plus balloon only or hormonal treatment plus
antibiotics (OR0.55, 95%CI 0.36 to 0.83; 451women; 5 studies;
I² = 0%; low-quality evidence; Analysis 2.4) (Fuchs 2014; Gan
2017; Lin 2015b; Wang 2016; Xiao 2015).
The NNTB was 8 (95% CI 5 to 25). We stratified data according
to device versus device, device plus graft versus device, device plus
gel versus device and gel plus hormonal treatment plus antibiotics
versus hormonal treatment plus antibiotics.
2.4.1. Device versus device
There was insufficient evidence from Lin 2015b to determine
whether there was a difference between inserting a specially de-
signed intrauterine balloon compared to the Yantai Contraceptive
Instrument, a heart-shaped copper IUD with thread knitted tail
for decreasing the occurrence of IUAs (OR 0.81, 95% CI 0.42 to
1.57; 162 women; 1 study; I² = 0%; Analysis 2.4).
2.4.2. Device plus graft versus device
Gan2017 studied the rate of IUA reformation inwomenundergo-
ing hysteroscopic adhesiolysis for severe IUAs: a clear definition of
adhesion reformation was not given and further clarification could
not be obtained from the study authors. Wang 2016 presented
data on the recurrence of IUAs grade 5 or greater according to
the 1988 AFS classification as evidence of adhesion reformation in
women treated with hysteroscopic adhesiolysis for moderate or se-
vere IUAs. Based on a pooling of the findings of two studies, it was
unclear whether there was a difference between inserting a Foley
catheter balloon wrapped with HAM versus a Foley catheter bal-
loon without graft following hysteroscopic adhesiolysis in women
with severe IUAs (OR 0.53, 95% CI 0.25 to 1.10; 137 women; 2
studies; I² = 0%; Analysis 2.4) (Gan 2017; Wang 2016).
2.4.3. Device plus gel versus device
Based on the findings of Xiao 2015 the injection of 2 mL of
medical self-cross-linking sodium hyaluronate gel from the lumen
of a Foley balloon catheter left in situ for 72 hours decreased the
occurrence of IUAs compared to a Foley balloon catheter only
following operative hysteroscopy in women with severe IUAs (OR
0.31, 95%CI 0.13 to 0.76; 111 people; 1 study; I² = 0%; Analysis
2.4).
The NNTB is 5 (95% CI 2 to 17).
2.4.4. Gel plus hormonal treatment plus antibiotics versus
hormonal treatment plus antibiotics
Fuchs 2014 compared the application of Oxiplex gel with sequen-
tial hormonal treatment for three weeks and antibiotic therapy for
one week to sequential hormonal treatment and antibiotic ther-
apy only in women with confirmed fertility undergoing operative
hysteroscopy for retained products of conception. There was in-
sufficient evidence to determine whether there was a difference
between groups for decreasing the occurrence of IUAs (OR 0.28,
95% CI 0.03 to 2.98; 41 women; 1 study; I² = 0%; Analysis 2.4).
2.5. Mean adhesion scores at second-look hysteroscopy
We aimed to pool three studies randomly comparing two anti-ad-
hesion treatments head-to-head measuring mean adhesion scores
at second-look hysteroscopy (Lin 2015b;Wang 2016; Xiao 2015).
Statistical heterogeneity beyond chance was very high (I² = 92.1%)
suggesting highly inconsistent findings across studies. The rea-
son for this statistical heterogeneity was obvious: the interventions
were clinically too diverse to allow statistical pooling. We strati-
fied data according to device versus device, device plus graft versus
device and device plus gel versus device.
2.5.1. Device versus device
Lin 2015b reported the median adhesion scores in both compar-
ison groups before the operation and the median reduction of
AFS scores in both groups. According to this study, it was un-
clear whether there was a difference in favour of the insertion of
a specially designed intrauterine balloon compared to the Yantai
Contraceptive Instrument for the median adhesion scores at sec-
ond-look hysteroscopy (Table 1). We considered converting the
medians to means and the 95% CI to SD but the method for
conversion is not robust.
2.5.2. Device plus graft versus device
Two studies reported data on themedian adhesion scores and their
interquartile ranges (IQR) (Amer 2010; Gan 2017).
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We considered converting the medians to means and the 95% CI
to SD but the method for conversion is not robust.
Amer 2010 reported similar median adhesion scores and IQRs
at second-look hysteroscopy across the three intervention arms
(Table 2). In contrast, Gan 2017 demonstrated lower median ad-
hesion scores at second-look hysteroscopy with the use of amni-
otic membrane graft compared to inserting a balloon catheter only
without amnion graft (Table 3).
According to Wang 2016, the mean adhesion scores after insert-
ing a balloon catheter with amniotic graft were significantly lower
compared to inserting a balloon catheter alone without amniotic
graft following hysteroscopic adhesiolysis in women with moder-
ate or severe IUAs (MD in adhesion score -3.10, 95% CI -4.17 to
-2.03; 57 women; 1 study; Analysis 2.5).
2.5.3. Device plus gel versus device
According to Xiao 2015, the injection of 2 mL of medical self-
cross-linking sodium hyaluronate gel from the lumen of a Foley
balloon catheter left in situ for 72 hours was associated with lower
mean adhesion scores at second-look hysteroscopy compared to
a Foley balloon catheter only following operative hysteroscopy in
women with severe IUAs (MD in adhesion score -1.60, 95% CI -
2.32 to -0.88; 111 women; 1 study; Analysis 2.5).
2.6. Severity of adhesions at second-look hysteroscopy: mild
2.6.1. Device plus gel versus device
There was insufficient evidence from Xiao 2015 to determine
whether there was a difference between the injection of 2 mL of
medical self-cross-linking sodium hyaluronate gel from the lumen
of a Foley balloon catheter left in situ for 72 hours compared to
a Foley balloon catheter only following operative hysteroscopy in
women with severe IUAs for the occurrence of mild adhesions at
second-look hysteroscopy (OR 1.11, 95% CI 0.53 to 2.34; 111
women; 1 study; Analysis 2.6).
2.7. Severity of adhesions at second-look hysteroscopy:
moderate or severe
According to a pooling of the findings of two studies, the applica-
tion of a combined anti-adhesion treatment consisting of barrier
gel decreased the occurrence of moderate or severe IUAs follow-
ing operative hysteroscopy compared to anti-adhesion treatment
not consisting of barrier gel (OR 0.25, 95% CI 0.10 to 0.61; 152
women; 2 studies; I² = 0%; Analysis 2.7) (Fuchs 2014; Xiao 2015).
The NNTB was 5 (95% CI 3 to 12). We stratified data according
to device plus gel versus device and gel plus hormonal treatment
plus antibiotics versus hormonal treatment plus antibiotics.
2.7.1. Device plus gel versus device
Based on the findings of Xiao 2015, the injection of 2 mL of
medical self-cross-linking sodium hyaluronate gel from the lumen
of a Foley balloon catheter left in situ for 72 hours decreased
the occurrence of moderate or severe IUAs compared to a Foley
balloon catheter only following operative hysteroscopy in women
with severe IUAs (OR 0.24, 95% CI 0.09 to 0.63; 111 women; 1
study; I² = 0%; Analysis 2.7).
The NNTB was 4 (95% CI 2 to 12).
2.7.2. Gel plus hormonal treatment plus antibiotics versus
hormonal treatment plus antibiotics
There was insufficient evidence from Fuchs 2014 to determine
whether there was a difference between the application of Oxiplex
gel with sequential hormonal treatment for three weeks and antibi-
otic therapy for one week to sequential hormonal treatment and
antibiotic therapy only in women with confirmed fertility under-
going operative hysteroscopy for retained products of conception
(OR 0.28, 95% CI 0.03 to 2.98; 41 women; 1 study; Analysis
2.7).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Any anti- adhesion therapy A versus anti- adhesion therapy B following operative hysteroscopy
Patient or population: women treated by operat ive hysteroscopy for uterine pathology
Settings: mult icentric, Hysteroscopy Unit of Department of Obstetrics and Gynaecology of a university, university-af f il iated or non-university tert iary care hospital
Intervention: ant i-adhesion therapy A
Comparison: ant i-adhesion therapy B
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Anti- adhesion therapy
B
Anti- adhesion therapy
A
Live birth a Device Device + graf t OR 1.48
(0.57 to 3.83)
180
(3 RCTs)
⊕⊕©©
Low c,d
-
98 per 1000 b 138 per 1000
(60 to 315)
Presence of intrauter-
ine adhesions at sec-
ond- look hysteroscopy
(6-12 weeks)
Device or hormonal
treatment with ant ibi-
ot ics
Device ± graf t / gel or gel
+ hormonal treatment +
and ant ibiot ics
OR 0.55 (0.36 to 0.83) 451
(5 RCTs)
⊕⊕©©
Low f,g
-
Low- risk population e
0 per 1000 0 per 1000
Medium- risk population e
545 per 1000 403 per 1000
(327 to 496)
High- risk population e
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* The basis for the assumed risk is provided in the footnotes. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a The three included studies reported term delivery (Wang 2016) or ongoing pregnancy (Amer 2010; Gan 2017; Wang 2016),
which we used as a surrogate outcome for live birth.
b The assumed risk for the average-risk populat ion is the pooled risk of all the live births in the control groups of the three
included studies.
c Downgraded one level for serious risk of bias: despite several lim itat ions none of the studies was at high risk for select ion
bias related to random sequence generat ion or allocat ion concealment.
d Downgraded one level for serious imprecision- only 21 events in total.
e The assumed risk for low/ medium/ high-risk populat ion is based on the presence of intrauterine adhesions following
hysteroscopic removal of endometrial polyps/ following removal of submucous f ibroids and IUAs (mean of both)/ removal of
uterine septum, respect ively, based on f indings of a prospect ive cohort study (Yang 2013).
f Downgraded one level for serious risk of bias: despite several lim itat ions none of the studies was at high risk for select ion
bias related to random sequence generat ion or allocat ion concealment.
g Downgraded one level for serious indirectness because, in two of f ive studies, less than 50% of part icipants were subfert ile;
in one of f ive studies, it was unclear if subfert ile women were included and in two of f ive studies, the proport ion of infert ile
women was not reported.
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D I S C U S S I O N
Summary of main results
This systematic review aimed to investigate whether the use of
anti-adhesion therapy following operative hysteroscopy made a
difference in themain outcomes of live birth or ongoingpregnancy,
clinical pregnancy and miscarriage, or in the prevalence, extent or
severity of IUAs in women with subfertility.
We searched for studies randomly comparing any anti-adhesion
therapy versus no treatment or placebo or any other anti-adhesion
treatment in subfertile women following operative hysteroscopy.
We retrieved 16 studies involving 1273 women randomly com-
paring the use of a device versus no treatment (two studies; 90
women), hormonal treatment versus no treatment or placebo (two
studies; 136 women), device combined with hormonal treatment
versus no treatment (one study; 20 women), barrier gel versus no
treatment (five studies; 464 women), device with graft versus de-
vice without graft (three studies; 190 women), one type of device
versus another device (one study; 201 women), gel combined with
hormonal treatment and antibiotics versus hormonal treatment
with antibiotics (one study; 52 women) or device combined with
gel versus device (one study; 120 women). Only two of 16 studies
included 100% infertile women; in all other studies, the propor-
tion of infertile women was variable or unknown. Most studies
(14/16) had at least one item at high risk of bias, and nine of 16
studies had two or more items at high risk of bias. Seven studies
were at low risk for selection bias related to random sequence gen-
eration and allocation concealment (Amer 2010; Di Spiezio Sardo
2011; Fuchs 2014; Guida 2004; Lin 2015a; Roy 2014; Vercellini
1989). Only one study had all items at low risk of bias (Roy 2014).
Anti-adhesion therapy versus placebo or no
treatment following operative hysteroscopy
Based on a pooled analysis of the results from two studies there was
insufficient evidence to determine whether there was a difference
between inserting a device in the uterine cavity or starting hor-
monal treatment compared to no treatment or placebo for increas-
ing the chance for term delivery or ongoing pregnancy (Figure 4).
Figure 4. Forest plot of comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following
operative hysteroscopy, outcome: 1.1 Live birth.
The pooled findings from eight studies demonstrated a summary
effect in favour of the insertion of a device with or without hor-
monal treatment or hormonal treatment or anti-adhesion barrier
gels compared to no treatment or placebo for decreasing the oc-
currence of IUAs at any second-look hysteroscopy (Figure 5). For
the use of anti-adhesion treatment in a medium-risk population,
we would expect that out of 1000 women treated by operative
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hysteroscopy, between 153 and 365 women would develop IUAs,
compared with 545 women when no anti-adhesion treatment was
used (Figure 6).
Figure 5. Forest plot of comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following
operative hysteroscopy, outcome: 1.4 Presence of intrauterine adhesions at second-look hysteroscopy.
30Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 6. Cates’ plot of numbers needed to treat for an additional beneficial outcome (NNTB) for Analysis
1.4 assuming medium risk of 545 women per 1000 with intrauterine adhesions at second-look hysteroscopy in
the control group (no treatment or placebo). Randomly compared to control, the use of device with or
without hormonal treatment or hormonal treatment or barrier gels (intervention) decreased the number of
women with intrauterine adhesions at second-look hysteroscopy to 234 women per 1000 (95% confidence
interval 153 to 365 women per 1000). Figure drawn using www.nntonline.net.
Anti-adhesion therapy versus any other therapy
following operative hysteroscopy
According to the pooled findings of three studies there was no clear
evidence of a difference between the insertion of a Foley catheter
balloon wrapped in amniotic membrane versus the insertion of a
Foley catheter balloon without amniotic membrane for improving
the ongoing pregnancy rates.
A meta-analysis of the findings of five trials demonstrated differ-
ences head-to-head between the use of a device with or without
graft/gel or gel plus hormonal treatment plus antibiotics randomly
compared to the use of a device only or hormonal treatment plus
antibiotics for decreasing the occurrence of IUAs at second-look
hysteroscopy. The findings of this meta-analysis were not robust
and highly affected by evidence quality.
Overall completeness and applicability of
evidence
We retrieved only one small study that randomly compared the
insertion of an IUD versus no treatment (Vercellini 1989). In
everyday clinical practice, worldwide an IUD is very often inserted
following the hysteroscopic treatment of IUAs or the resection of
an intrauterine septum.
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Only five of 16 studies reported data on the primary outcome of
live birth but all five used surrogate outcomes. Only five of 16
studies reported data on an adverse reproductive outcome (mis-
carriage). Thirteen of 16 trials reported the secondary outcomes of
prevalence, mean adhesion scores and severity of IUAs at second-
look hysteroscopy.
Only eight of 16 studies reported data on the proportion of women
with subfertility. Out of 682 participants from these eight studies,
only 247 women had subfertility (36%). Therefore, the evidence
retrieved in this Cochrane Review is indirect for the target popu-
lation of subfertile women undergoing operative hysteroscopy.
Therewere differences in theHAanti-adhesion gel used byAcunzo
2003 and Guida 2004 compared to Xiao 2015. Xiao 2015 sug-
gested that the use of their gel (a newly developed highly vis-
cous and elastic self-cross-linking sodium hyaluronate gel, which
uses fermentation technology on natural sodium hyaluronate gel)
may bemore advantageous: animal-derivedHAmay stimulate im-
munological rejection and provoke inflammation.
We did not find any cost-effectiveness studies on the use of anti-
adhesion treatment followingoperative hysteroscopy in a subfertile
population.
In conclusion, we judged that the body of evidence retrieved was
insufficient to address all research questions that were predefined
for this Cochrane Review.
Quality of the evidence
Several limitations at study and outcome levels were related to
performance bias, other potential sources of bias, attrition bias,
and reporting and selection bias in decreasing order of frequency.
Reasons for risk of bias at the study level and across studies are
discussed in detail in the Risk of bias in included studies section
and are graphically presented in Figure 2 and Figure 3.
Anti-adhesion therapy versus placebo or no
treatment following operative hysteroscopy
See Summary of findings for the main comparison.
We graded the overall quality of the evidence as very low for the
outcome of live birth. The main limitations were serious risk for
selection bias related to allocation concealment, serious impreci-
sion and serious indirectness.
For the outcome of IUAs at second-look hysteroscopy, we graded
the overall quality of the evidence as low.Themain limitationswere
high risk of performance bias related to blinding of participants/
personnel and serious indirectness.
Anti-adhesion therapy versus any other therapy
following operative hysteroscopy
See Summary of findings 2.
We graded the overall quality of the evidence as low for the out-
come of live birth. The main limitations were high risk of bias for
selective outcome reporting and serious imprecision.
For the outcome of IUAs at second-look hysteroscopy, we graded
the overall quality of the evidence as very low. Themain limitations
were high risk of bias for selective outcome reporting and serious
indirectness.
Potential biases in the review process
Limitations at the review level include the following.
• We conducted no formal study of reporting bias because we
retrieved a limited number of studies (fewer than 10 studies) for
each randomised comparison. Nevertheless, we aimed to
minimise the potential impact of reporting and publication bias
by conducting a comprehensive search for all potentially eligible
studies, and by staying alert for duplication of data as predefined
in the protocol of this Cochrane Review (Bosteels 2013a). We
consistently searched for related articles in published and
secondary reports of included studies. We contacted all authors
of included studies to ask if they were aware of any published or
ongoing trials; we also contacted experts in the field.
• We rigorously subjected to sensitivity analyses all choices to
include only studies at low risk of bias versus all studies, to use
available data analyses rather than ITT analyses or to exclude
participants who were treated by an intervention not indicated
for treating subfertility; we considered any observed substantial
changes when interpreting results.
• We used surrogate outcomes for the primary outcome of
live birth: term delivery at 12 to 18 months for Abu Rafea 2013,
ongoing pregnancies or delivered at term for Amer 2010,
ongoing pregnancies beyond 12 weeks of gestational age for Gan
2017, and ongoing pregnancy for Roy 2014 and Wang 2016.
• We used surrogate outcomes for the secondary outcome of
clinical pregnancy: pregnancy without clear definition for Amer
2010, Fuchs 2014, Gan 2017, and Wang 2016.
• At least two review authors independently and
simultaneously extracted all data for the previous version of this
Cochrane Review: JB extracted data from all studies, and TD/
FB/JK/SW divided all studies between them, and each extracted
data from only a portion of all the finally included studies. For
the present update (five additional studies retrieved), JB extracted
data from all five additional studies while independently and
simultaneously HT (three), SW (three) and SJC (two) extracted
data from some studies divided between them. In case of
disagreement, BWM acted as a third review author for
arbitration. This implies that JB may have had a larger influence
than any one of all the authors involved in data extraction on the
final decisions concerning this part of the review.
• One of the Cochrane authors (SJC) translated two Chinese
articles into English to allow data extraction and assessment of
the risk of bias (Wang 2016; Xiao 2015). Queries in English and
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Chinese were sent to Lin 2015b, Wang 2016, and Xiao 2015.
Despite several queries, we were able to obtain answers from the
authors of primary study reports in six of 15 included studies
(40%). For nine of 15 (60%) included studies, several queries
remained unanswered. As predefined in the study protocol, we
classified these items as ’unclear evidence’ or ’unclear risk of bias.’
Agreements and disagreements with other
studies or reviews
We found six systematic reviews that have summarised and criti-
cally appraised the available evidence on the effectiveness of anti-
adhesion therapy.
• One Cochrane Review included 18 RCTs in 1262 women
undergoing gynaecological pelvic surgery by laparoscopy (eight
RCTs) or laparotomy (10 RCTs) (Ahmad 2015). The authors
found no evidence on the effects of barrier agents used during
pelvic surgery on either pain or fertility outcomes in women of
reproductive age. The quality of the evidence ranged from very
low to moderate. The most common limitations were
imprecision and poor reporting of study methods. Most studies
were commercially funded, and publication bias could not be
ruled out.
• Mais 2012 was a systematic review with a meta-analysis
performed to study the effectiveness of ACP gel for adhesion
prevention in laparoscopic and hysteroscopic surgery. Data from
three RCTs included in the Cochrane Review were pooled
(Acunzo 2003; De Iaco 2003; Guida 2004): the proportion of
women with adhesions at second look was significantly lower in
women who received ACP gel than in the control group (RR
0.50, 95 % CI 0.31 to 0.85; P = 0.009; 3 studies; 256 women).
Mais 2012 used the Jadad scale (an older and less valid tool for
assessing the validity of intervention studies) and not the
Cochrane ’Risk of bias’ tool leading to ’high quality’ for the three
studies in Mais 2012 as opposed to the grading of the available
evidence in the present Cochrane Review for the outcome of
IUAs at second-look hysteroscopy as ’low quality.’
• Healy 2015 was a systematic review partially sponsored by a
grant from the Intramural research program of the Program in
Reproductive and Adult Endocrinology, National Institute of
Child Health and Human Development (NICHD), National
Institutes of Health (NIH). The review included 13 studies.
Seven studies that compared similar treatment methods were
statistically pooled. The authors concluded that the use of HA
gel or Intercoat gel after operative hysteroscopy may decrease
IUA formation. According to their meta-analysis, the data does
not support the use of oestrogen therapy. Additional quality
RCTs are needed to further establish better preventive measures
of IUA formation.
• Healy 2016 was a systematic review including 12 studies.
Nine studies included by Healy 2016 were also included in this
Cochrane Review (Acunzo 2003; Amer 2010; Dabir-Ashrafi
1996; De Iaco 2003; Di Spiezio Sardo 2011; Fuchs 2014; Guida
2004; Roy 2014; Vercellini 1989); three studies included by
Healy 2016 were excluded from this Cochrane review for being
non-randomised (Pabuccu 2008; Tonguc 2010) or excluding
subfertile women (Kim 2012). Three studies demonstrating a
benefit with the gels in preventing adhesion formation were all
conducted by the same research group (Acunzo 2003; Di Spiezio
Sardo 2011; Guida 2004); according to Healy 2016 these
beneficial results have not been confirmed by other research
groups. The final conclusion of Healy 2016 stated that there was
a lack of definitive evidence to conclude that any treatment was
effective in preventing IUAs following operative hysteroscopy.
The available literature “has significant heterogeneity and a high
risk of bias, making any definitive conclusions difficult.”
• Di Spiezio Sardo 2016 was a systematic review including 29
studies. Eight studies included by Di Spiezio Sardo 2016 were
included in this Cochrane Review (Acunzo 2003; Amer 2010;
De Iaco 2003; Di Spiezio Sardo 2011; Do 2005; Fuchs 2014;
Guida 2004; Roy 2014). Three studies included by Di Spiezio
Sardo 2016 were excluded from this Cochrane Review for being
non-randomised (Pabuccu 2008; Tonguc 2010) or excluding
subfertile women (Kim 2012). Eighteen studies were
observational studies that were not eligible for this Cochrane
Review. Di Spiezio Sardo 2016 concluded that “robust and high
quality randomized trials to assess the effectiveness of different anti-
adhesion therapies are still needed before one or more of these
strategies may be strongly recommended for improving clinical
outcomes in women treated by operative hysteroscopy.”
• One systematic review by Salma 2014 including 28
observational studies of 1806 women with meta-analysis of five
studies and qualitative assessment of 23 studies reported a
clinical benefit with the insertion of an IUD for all women with
IUAs regardless of their severity. In the opinion of the authors of
this review, use of IUDs should be combined with other anti-
adhesion therapies “to obtain maximal outcomes, in particular in
patients with moderate to severe IUAs.” This review had several
methodological limitations, including the lack of a formal
assessment of risk of bias, lack of appreciation of the role of
confounding variables, lack of adjustment for confounders in
data calculation for pooled analyses, evidence of substantial
statistical heterogeneity for pooled analyses of the five included
studies and lack of formal assessment of reporting bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The quality of the body of evidence retrieved for all outcomes was
low to very low and no studies reported live birth. For daily clinical
practice, there is no clear evidence on the safety and effectiveness
of anti-adhesion treatment for improving rates of term delivery
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or ongoing pregnancy, or for decreasing intrauterine adhesions
following operative hysteroscopy in subfertile women.
Implications for research
More research is needed to assess the comparative safety and
(cost)effectiveness of different anti-adhesion treatments compared
to no treatment or other interventions for improving key live birth
and pregnancy rates in subfertile women.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abu Rafea 2013
Methods Parallel-group randomised controlled trial.
Single centre, Obstetrics and Gynecology Department, King Saud University, Riyadh,
Saudi Arabia
Protocol approved by IRB: yes.
Unclear whether statistical power calculation done (query not answered)
Unclear about funding and conflicts of interest (query not answered)
Participants Number recruited: not stated.
Number randomly assigned: 28 women.
Number excluded after randomisation: 4 women.
Number analysed: 24 women.
Women with infertility, adverse pregnancy outcomes (diagnosed with intrauterine sep-
tum by HSG, sonohysterography, hysteroscopy or a combination of these), or both
Inclusion and exclusion criteria: ill defined. Some women (1 in intervention group; 3
in control group) not trying to conceive after treatment, indicating poor definition of
inclusion and exclusion criteria
Mean age and range (years): 29 (23-38) years in intervention group; 32 (22-40) years in
control group
Study duration: not reported (query not answered).
Number of subfertile women: 3 in intervention group; 2 in control group; most women
had history of adverse pregnancy outcomes (miscarriage or preterm delivery)
Interventions Paediatric Foley catheter balloon for 5 days (intervention: n = 13) vs no catheter/
balloon (control: n = 15)
Cervix dilated to 10 mm, and all uterine septa divided using 26 French (9 mm diameter)
resectoscope and a 30-degree lens (Karl Storz, Tuttlingen, Germany) with monopolar
electrode utilising 1.5% glycine as distension medium via an electronic fluid manage-
ment system (Endomat, Karl Storz, Tuttlingen, Germany) and 120 Watts low-voltage
(cutting current mode) waveform delivered by an ICC 350 Erbe electrosurgical unit
(Erbe, Tuttlingen, Germany). Resectoscopic metroplasty carried out using a Collin (Karl
Storz, Tuttlingen, Germany) monopolar knife electrode at 90 degrees. All women had
general anaesthesia and concomitant laparoscopy and treatment of pelvic pathology in-
cluding adhesiolysis or reduction/excision of endometriosis, or both, when indicated
using a CO2 laser or electrosurgery, or both. No-one received preoperative endometrial
thinning, antibiotic prophylaxis or adjuvant postoperative hormonal therapy
No specific timing was used to perform the surgery with regards to the menstrual cycle
Although reported that 2 women in intervention group and 1 in control group conceived
after ART, whether other fertility treatments were offered and how these cotreatments
were distributed among comparison groups (query not answered) remained unclear
Outcomes Length of residual septum: measured by HSG 12 weeks after operative hysteroscopy
First-trimester loss, second-trimester loss, preterm delivery, term delivery, ectopic preg-
nancy: measured at 12-18 months after operative hysteroscopy
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Abu Rafea 2013 (Continued)
Notes No distinction between primary and secondary outcomes. Whether reproductive out-
comes were measured at 1 or > 1 time points unclear; variation in time points at which
reproductive outcomes measured was 6 months
Some women (1 in intervention group; 3 in control group) were not trying to conceive
after treatment; they should have been excluded from analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was based on a
computer generated list of numbers (un-
concealed).”
Comment: probably done.
Allocation concealment (selection bias) High risk Quote: “Randomization was based on a
computer generated list of numbers (un-
concealed).”
Comment: no allocation concealment.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “After ethics approval and informed
consent, 28womenwere randomized in the
operating room into having a no. 14 pae-
diatric Foley catheter/balloon for five days
(N = 13) versus no catheter/balloon (N =
15) following resectoscopic septum divi-
sion. The Foley balloon was inflated with
5 mL of normal saline solution.”
Quote: “All patients were discharged the
same day, and the patients with the Fo-
ley catheter/balloon were instructed to cut
with scissors the end of the catheter at
5 days at home and remove the catheter
themselves.”
Comment: physicians and personnel not
blinded to intervention
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “They were also instructed to avoid
pregnancy until their first assessment in 3
months by HSG, and they were reassessed
at 6 and 12 to 18 months for pregnancy
outcomes.”
Comment: unequivocal outcome.
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Abu Rafea 2013 (Continued)
Blinding of outcome assessment (detection
bias)
Adhesions
Unclear risk Quote: “They were also instructed to avoid
pregnancy until their first assessment in 3
months by HSG, and they were reassessed
at 6 and 12 to 18 months for pregnancy
outcomes.”
Quote: “We could not be certain that the <
1 cm septum, reported by the radiologist,
in the balloon group was a recurrence or
incomplete division at the time of metro-
plasty, but in the intention-to-treat (ITT)
analysis, we considered this cavity as nor-
mal.”
Comment: no blinding of outcome asses-
sors reported; unclear who did the assess-
ment (query not answered)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “We could not be certain that the <
1 cm septum, reported by the radiologist,
in the balloon group was a recurrence or
incomplete division at the time of metro-
plasty but in the intention-to-treat (ITT)
analysis, we considered this cavity as nor-
mal.”
Comment: no incomplete outcome data.
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias High risk Quote: “Fertility and pregnancy outcomes
at 12 to 18 months post metroplasty are
shown in Table 4.”
Comment: reproductive outcomes mea-
sured over considerable time period rather
than at 1 predefined time point. Unclear
whether more measurements were taken at
18 months in 1 of the comparison groups
Comment: although it reported that 2
women in intervention group and 1 in con-
trol group conceived after ART, whether
other fertility treatmentswere provided and
how these cotreatments were distributed
among comparison groups was unclear
Somewomen (1 in intervention group; 3 in
control group) were not trying to conceive
after treatment; they should have been ex-
cluded fromfinal analysis because conduct-
ing an ITT on the basis of poor inclusion
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Abu Rafea 2013 (Continued)
and exclusion criteria can increase risk of
bias
Comment: according to Table 1 of pub-
lication, mean age (range) in intervention
was 29 (23-38) years and control was 32
(22-40) years with P = 0.59. Mean age
difference should not be considered clini-
cally irrelevant. We judged that some ev-
idence suggested baseline imbalance be-
tween comparison groups
Comment: high risk of selection, perfor-
mance and detection bias
Acunzo 2003
Methods Parallel-group randomised controlled trial.
Single centre, Hysteroscopic Unit at the University of Naples Frederico II, Naples, Italy
Protocol approved by IRB: yes.
Unclear whether statistical power calculation was done (query not answered)
Funding and conflicts of interest not reported (query not answered)
Participants Number recruited: 92 women.
Number randomly assigned: 92 women.
Number lost to follow-up: 8 women.
Number analysed: 84 women.
92 women with irregular menses and IUAs at diagnostic hysteroscopy
Inclusion criterion:
• hysteroscopic diagnosis of IUAs.
Exclusion criteria:
• aged > 50 years;
• weight > 100 kg;
• menopause (FSH > 40 mIU/mL, 17β-oestradiol < 20 pg/mL);
• pregnancy (positive β-hCG test);
• presence of uterovaginal prolapse and severe urinary symptoms;
• presence of malignancy;
• presence of severe intercurrent illness (coagulation disorders, systemic disease,
severe cardiopathy);
• presence of other intrauterine lesions (i.e. polyps, myomata, septa).
Study duration: 15 months (June 2001 to September 2002).
Mean age (± SD): 30.1 (± 3.5) years.
Number of subfertile women: 18 in intervention group; 16 in control group
Interventions ACP gel (intervention: n = 46) vs no application of ACP gel (control: n = 46)
Intervention group: received intrauterine applicationof 10mLofACPgel (Hyalobarrier
Gel; Baxter, Pisa, Italy) under hysteroscopic view after operative hysteroscopy
Control group: only received hysteroscopic resection of IUAs.
Diagnostic hysteroscopy performed with a 3.5-mm instrument (Gynecare Versascope;
Gynecare, Ethicon Inc., Somerville, NJ, USA) with normal saline solution (sodium
chloride 0.9%) used as distension medium
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Acunzo 2003 (Continued)
Operative hysteroscopy was performed with a rigid resectoscope (Karl Storz, Tuttlingen,
Germany) with a 12-degree fore-oblique telescope and a hook-shaped monopolar elec-
trode
Women in both groups received oral antibiotics (cefixime 400 mg/day) (Cefixoral;
Menarini, Firenze, Italy) for 3 days after surgery
Outcomes Incidence of de novo adhesions, mean adhesion score and severity of adhesions according
to the 1988 AFS classification system; all outcomes measured after 3 months
Notes Individual data on subfertile women not presented separately (query not answered)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Follow-
ing diagnostic hysteroscopy, patients were
randomized into two groups: group A (N =
46), the treatment group, and group B (N
= 46), the control group, using a computer-
generated randomisation list.”
Comment: probably done, as the same
team of investigators published data from
similar randomised trial
Allocation concealment (selection bias) Unclear risk Comment: method not described (query
not answered).
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “Ultrasound scans were performed
in each patient from group A immediately
after ACP gel application and after 24, 48
and 72 hours. The gel-related hyperechoic
thickness that seemed to separate endome-
trial walls was the mean evaluated parame-
ter.”
Comment: no blinding of participants and
personnel.
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of outcome assessment (detection
bias)
Adhesions
Unclear risk Quote: “Both the initial diagnostic hys-
teroscopy and the 3-month follow-up di-
agnostic hysteroscopy were performed by
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Acunzo 2003 (Continued)
the same operator (G.A.). G.A. evaluated
the adhesion score for each patient and was
blind for patients’ randomized allocation,
whilst operative hysteroscopies and appli-
cation of ACP gel were performed by a dif-
ferent operator (M.G.).”
Comment: method not described (query
not answered).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Eight women (three from group
A [intervention] and five from group B
[control]) did not attend for follow-up hys-
teroscopy.”
Comment: unlikely to cause substantial at-
trition bias.
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias Low risk Comment: no evidence of imbalance in
baseline participant characteristics - no
cotreatment
Amer 2010
Methods Parallel-group randomised controlled trial with 3 comparison groups
Single centre, Department of Obstetrics and Gynecology of the Ain Shams Medical
School, Cairo, Egypt
Protocol approved by IRB: yes.
No statistical power calculation (query clarified by Dr Mohamed Amer)
No external funding and no conflicts of interest (query clarified by Dr Mohamed Amer)
Participants Number recruited: 45 women.
Number randomly assigned: 45 women.
Number lost to follow-up: 2 women.
Number analysed: 43 women
Inclusion criteria:
• severe IUAs diagnosed at clinic hysteroscopy;
• infertility was primary symptom, followed by hypomenorrhoea or amenorrhoea;
• comprehensive infertility workup performed.
Exclusion criteria:
• other causes of subfertility;
• adhesions limited to the lower uterine segment or the upper cervical canal.
Study duration: 62 months (from June 2004 to August 2009)
Median age (range): 30.4 (26-40) years.
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Amer 2010 (Continued)
Interventions Intrauterine balloon without amniotic graft (group 1; n=15) vs intrauterine balloon
with fresh amnion (group 2; n=15) vs intrauterine balloon with dried amnion (group
3; n=15)
2 × misoprostol 200 mg tablets inserted vaginally the night before operation to facilitate
cervical dilation
Operative hysteroscopy performed under general anaesthesia in follicular phase of men-
strual cycle; however, for women with amenorrhoea, no special time was chosen. Si-
multaneous laparoscopy performed in women with infertility if they had not undergone
a laparoscopy before, in women with previous complications of hysteroscopy such as
uterine perforation and in women in whom uterine perforation occurred during the
present procedure. Hysterometry with uterine sounding was followed by lysis of IUAs
using 5-French pointed tip semirigid scissors in 5-mm rigid clinic hysteroscope, based
on a 2.9-mm telescope (Karl Storz GmbH & Co. KB). In women with thick fibrous
adhesions, adhesiolysis performed using 9-mm working element along with sheath and
4-mm 30-degree telescope (Karl Storz GmbH&Co. KB) equipped with a hysteroscopic
monopolar knife (Collin operating knife) after cervical dilation to Hegar 9. Visualised
adhesions incised with 50- to 100-W cutting current, adjusted according to visual tissue
effects, from an isolated electrosurgical generator (Valleylab SSE2L; Valleylab, Inc., Boul-
der, CO, USA). Glycine 1.5% (Glycocolle 1.5%; Aguettant Laboratory, Lyon, France)
used as distension medium, with intrauterine pressure 120-150 mmHg, automatically
controlled using a Hamou Hysteromat (Karl Storz GmbH& Co. KB) with termination
of procedure if fluid deficit exceeded 1 L
Freeze-dried amniotic membrane hydrated using normal saline solution in a pan for 10
minutes before use
Previously prepared fresh amniotic graft was washed several times with sterile normal
saline solution before application. Amniotic graft was cut to form a 5 × 5-cm piece.
This was spread on the balloon end of an 8-French paediatric Foley catheter, so that
the epithelial or basement membrane surface would be on top facing outwards, where
the inflated balloon acts as a mould for the amnion. The catheter tip with the amnion
on its surface was then introduced into inside of uterine cavity with aid of straight
artery forceps. Balloon inflated with 3 mL to 5 mL of saline solution. A loose knot
was made in catheter stem, which was then slipped upwards to just below the inflated
balloon, then was tightened with aid of artery forceps, and catheter stem was cut with
scissors just below knot after catheter stem was stretched so that balloon with graft on its
surface was kept intrauterine. In women with a patulous cervix that would not keep the
inflated balloon inside uterus, a cervical cerclage using braided polyester tape (Matrix
Health Care SAE, Ameco, Egypt) was applied; it was removed later with the balloon.
Postoperatively, ethinyl oestradiol 50 µg/day tablets (Laboratoires Cassenne, Puteaux,
France) administered for 50 days
2 weeks postoperatively, balloon was removed transcervically with crocodile forceps and
with participant under paracervical anaesthesia (lidocaine 2%, 6 mL, plus atropine 0.5
mg in the same syringe), as an outpatient procedure without cervical dilation. In women
who had cervical cerclage, tape was removed at time of balloon extraction
Second-look hysteroscopy performed 2-4 months postoperatively by independent ob-
server blinded to method. Outcome measures included improvement in adhesion grade,
improvement in menstruation, increased uterine length at sounding and complications.
Subsequently, follow-up provided via direct contact or telephone every 3 months for a
mean (range) of 28 (6-60) months for menstrual pattern and fertility
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Amer 2010 (Continued)
Outcomes Ongoing pregnancy rate, clinical pregnancy rate, adhesion score, duration of menstru-
ation, improvement in menstruation, uterine length, uterine length increase, adhesion
score improvement; some outcomes (improvement in adhesion grade, improvement
in menstruation, increased uterine length at sounding and complications) assessed 2-4
months after surgery, whereas other outcomes assessed via direct contact or telephone
every 3 months for a mean (range) of 28 (6-60) months for menstrual pattern and fer-
tility
Notes * Correspondence with authors on 4 January 2015.
Dear Dr. Jan Bosteels,
Thanks for your e-mail and being interested in intrauterine adhesions management.
1. The first study is a pilot study and not a randomized study (Amer MI, Abd-El-Maeboud
KH. Amnion graft following hysteroscopic lysis of intrauterine adhesions J Obstet Gynaecol
Res 2006; 32(6): 559-66).
2. I confirm that these two studies are different and no patients in the second study were
involved in the first study.
3. It was a single-blinded; only the first surgeon knew if the graft was used or not and which
type; also the patient, but the assessor, did not know which group of patients he is assessing.
4. Analyses were conducted using commercially available software (SPSS for Windows, release
15.0; SPSS, Inc., Chicago, IL). All P values refer to 2-tailed tests of significance, with P <0.
05 considered significant. Data are given as count and percentage for categorical variables.
Groups were compared using the c2 test and Fisher’s exact test for categorized variables. For
comparison of menstruation, uterine length and adhesion score, the Kruskal-Wallis test was
used. Data are given as median (interquartile range [IQR]; 25th to 75th percentile). Pairwise
comparison was performed using the Mann-Whitney test with Bonferroni correction. The
critical level of significance was <0.02).
5. There was no funding for the present study.
6. There was no conflict of interest.
7. To my knowledge, I do not know that there are new anti-adhesion therapy following
operative hysteroscopy.
With my best wishes.
Dr. Mohamed I Amer.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized preop-
eratively using a computer-generated ran-
domisation sheet into 3 groups of 15
women each.”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote: “Allocation to any group was con-
cealed in an opaque envelope, which was
opened at the time of operation.”
Comment: probably done.
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Amer 2010 (Continued)
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “It was a single blinded, only the
first surgeon that know if the graft used or
not and which type also the patient, but
the assessor did not know which group of
patients he is assessing” (query clarified by
Dr Mohamed Amer)
Comment: method of blinding of partici-
pants and personnel not described
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “This was a pilot, randomized,
comparative study with blinded indepen-
dent evaluation of changes in adhesion
grade, menstruation, uterine length, num-
ber of operations needed to achieve a
functional uterine cavity, reproductive out-
come, and complications.”
Quote: “A second-look hysteroscopy was
performed 2 to 4 months postoperative by
an independent observer blinded to the
method.”
Comment: unequivocal outcome.
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “This was a pilot, randomized,
comparative study with blinded indepen-
dent evaluation of changes in adhesion
grade, menstruation, uterine length, num-
ber of operations needed to achieve a
functional uterine cavity, reproductive out-
come, and complications.”
Quote: “A second-look hysteroscopy was
performed 2 to 4 months postoperative by
an independent observer blinded to the
method.”
Quote: “It was single blinded - only the
first surgeon knew if the graft was used or
not and which type, also the patient, but
the assessor did not know which group of
patients he was assessing” (query clarified
by Dr Mohamed Amer)
Comment: probably done.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of the 45 patients included in the
study, 2 were lost to follow-up (1 each in
groups 1 and 2) and were excluded from
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analysis.”
Comment: unlikely to cause attrition bias.
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias High risk Baseline imbalance in participant charac-
teristics concerning caesarean section likely,
as cause of IUAs
Quote: “Simultaneous laparoscopy was
performed in women with infertility if they
did not undergo laparoscopy before, in
those with previous complications of hys-
teroscopy such as uterine perforation or
if uterine perforation occurred during the
present procedure.”
Comment: cotreatment by laparoscopy
and distribution in numbers among com-
parison groups not stated
Quote: “All pregnancies were spontaneous
except 3 that were achieved after in vitro
fertilization (IVF). One pregnancy was ter-
minated at 7 weeks’ gestation because of
a blighted ovum. Two patients underwent
IVF treatment twice, but did not conceive.
The other patients could not afford the cost
of IVF.”
Comment: cotreatment with IVF in some
women, resulting in 3 pregnancies; no
available data on distribution of cotreat-
ment among the 3 comparison groups. Po-
tential for performance bias
Dabir-Ashrafi 1996
Methods Parallel-group randomised controlled trial.
Single centre, national referral university hospital in Tehran, Iran
Protocol approved by IRB: not reported (query not answered).
Unclear whether statistical power calculation done (query not answered)
Funding and conflicts of interest not reported (query not answered)
Participants Number recruited: 59 women.
Number excluded before randomisation: 13 women (9 women had abnormal findings
at workup; 4 women excluded because angle between cervix and corpus could not be
corrected)
Number randomly assigned: 46 women.
Number lost to follow-up: 0 women.
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Number analysed: 46 women.
Women with subfertility (15 women) and habitual abortion (44 women) with fundal
defect on HSG. Underwent workup that included sperm analysis, assessment for infec-
tious diseases (toxoplasmosis,Listeriamonocytogenes,Mycoplasma hominis, syphilis), kary-
otyping, hormone profile (thyroxine, tri-iodothyronine, thyroid-stimulating hormone,
T3 resin uptake, prolactin) and mid-luteal progesterone assay. The 50 women whose
examinations were normal and in whom diagnosis of septate uterus was confirmed by
laparoscopy participated
Study duration: start and end dates not reported.
Age: 26.7 ± 6.5 years in intervention group; 28.4 ± 4.5 years in control; note: not reported
whether these numbers are means or medians with SDs
Interventions Oestrogen (intervention: n = 23) vs no oestrogen (control: n =23)
All women underwent hysteroscopic incision of septum with mini-scissors by 1 surgeon
who was unaware of treatment group. Ampicillin 1 g injected 1 hour before operations
performed under general endotracheal anaesthesia. Distending medium 5% dextrose in
water. Blood pressure cuff wrapped around plastic bottle to raise pressure of medium.
Procedures performed with 7-mm hysteroscope under laparoscopic guidance
Intervention group: conjugated oestrogen 1.25 mg/day 30 days beginning on day of
operation. For last 7 days, they also took medroxyprogesterone acetate tablet 2 × 5-mg/
day
Control group: no hormone.
Neither group used a splint.
Outcomes Difference between ratios of length of septum to length of uterus in HSGs obtained
preoperatively and postoperatively, directly measured on HSG on cessation of menstru-
ation 1 month after procedure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomized
into two groups of 23 women each.”
Comment: method not stated (query not
answered).
Allocation concealment (selection bias) Unclear risk Quote: “All septal incisions were per-
formed by one surgeon, who was unaware
of the group to which a patient had been
assigned.”
Comment: method not stated (query not
answered).
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome; no live
birth or pregnancy rates reported
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Blinding of participants and personnel
(performance bias)
Adhesions
Unclear risk Quote: “The patients were randomized
into two groups of 23 women each. Group
1 [intervention] received conjugated oe-
strogen 1.25 mg/d 30 days beginning on
the day of the operation. For the last 7
days, they also took medroxyprogesterone
acetate two 5-mg tablets/d. Group 2 [con-
trol] received no hormone.”
Comment: unclear whether placebo pills
used to blind participants and personnel
(query not answered)
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome; no live
birth or pregnancy rates reported
Blinding of outcome assessment (detection
bias)
Adhesions
Unclear risk Quote: “Directly on cessation of menstrua-
tion 1month after the procedure,HSGwas
done and the results were compared with
those of the preoperative HSG.”
Comment: outcome assessors not identi-
fied in report, method of blinding not re-
ported (query not answered)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Four were omitted from the anal-
ysis because the angle between the cervix
and the uterine corpus could not be cor-
rected, as shown by HSG.”
Comment: 4/50 (8%) women were ex-
cluded; distribution among comparison
groups not reported (query not answered)
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias Low risk No evidence of baseline imbalance in par-
ticipant characteristics
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Methods Parallel-group randomised controlled trial.
Single centre, Department of Obstetrics and Gynecology of the University of Bologna,
Bologna, Italy
Protocol approved by IRB: yes.
No statistical power calculation for all outcomes (query clarified by Dr Pierandrea De
Iaco)
No external funding and no conflicts of interest (query clarified by Dr Pierandrea De
Iaco)
Participants Number recruited: 60 women.
Number randomly assigned: 60 women.
Number lost to follow-up: 20 women.
Number analysed: 40 women.
Quote: “Women were eligible for inclusion if theywere undergoing endometrial ablation
or hysteroscopic removal of submucosal fibroids, endometrial polyps, septate uterus or
intrauterine synechiae.”
Comment: source population not adequately described in numbers and characteristics
Quote: “Despite this, newly induced synechiae were less severe in the Hyalobarrier
gel treated patients, thus reducing the risk of pregnancy morbidity and improving the
outcomes of hysteroscopic surgery.”
Comment: not mentioned whether women were infertile, and if so, how many; some
subfertile women might have been included
Study duration: 36 months: 1998 to 2001 (query clarified by Dr Pierandrea De Iaco)
Age: 18-65 years.
Interventions Application of Hyalobarrier gel (intervention: n = 18 women analysed) vs no adhesion
prevention (control: n = 22 women analysed)
Number of women randomly assigned to each group not reported and not clarified by
study authors
Intervention group: gel applied with 20-cm cannula with 5-mm diameter to cover
entire uterine cavity. Mean (± SD) volume 10.5 ± 5.5 mL Hyalobarrier gel (range 5 to
20 mL) applied in uterine cavity
Control group: no adhesion prevention measures.
An 8-mm hysteroscopic resectoscope (Storz, Tuttlingen, Germany) with electrosurgical
tips used. In all cases, sorbitol-mannitol (Clear-Flex, Baxter SA, Lessines, Belgium) used
as distension medium; fluid intake and output continuously monitored (Hysteromat,
Storz)
Second-look hysteroscopy undertaken 9 weeks after initial procedure by blinded inves-
tigator after insertion into uterine cavity with a 5-mm hysteroscope (Storz) with CO2
distension.
Outcomes Incidence of de novo adhesions and severity of adhesions according to ASRM* modified
scoring system: all outcomes measured after 9 weeks
Notes *ASRM modified scoring system distinguishes only between stage I (mild) and stage II
(severe) adhesions (different from the AFS 1988 classification system for IUAs)
Correspondence with authors on 9 December 2014.
Dear Dr. Jan Bosteels
I have to admit that I have some difficulties in finding the data you are asking about research
details. Anyway, these are my answers:
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1. no statistical power had been used before the trial.
2. no funding, nor conflict of interest were present.
3. I have some difficulties in telling the precise period. I say: 1998-2001.
4. patients were randomly allocated using a random table (from literature).
5. Dr. De Iaco performed the hysteroscopic surgery, while Dr. Muzzupapa performed the
second-look hysteroscopy without knowing the group of treatment.
6. I am not aware of ongoing studies about the same issue.
Sincerely yours
Pierandrea
Dr. Pierandrea De Iaco
Responsabile SSD Oncologia Ginecologica
Policlinico Sant’Orsola-Malpighi
Via Massarenti 13 - 40138 Bologna
Fax 0516364392
Cell. 3356666354
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After completion of the surgical
procedure, the patients who met the inclu-
sion criteria were randomly assigned either
to the treatment with Hyalobarrier gel or
to the control group, according to a com-
puter-generated randomisation schedule.”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomly allocated
using a random table” (query clarified by
Dr Pierandrea De Iaco)
Comment: method of allocation conceal-
ment not described.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
Unclear risk Quote: “Dr. De Iaco performed the hys-
teroscopic surgery, while Dr. Muzzupapa
performed the second-look hysteroscopy
without knowing the group of treatment”
(query clarified by Dr Pierandrea De Iaco)
Comment: method of blinding of partici-
pants and personnel not described
54Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Iaco 2003 (Continued)
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “Second look hysteroscopy was un-
dertaken nine weeks after the initial proce-
dure by a blinded investigator after inser-
tion in the uterine cavity of a 5 mm hys-
teroscope (Storz) with CO2 distension.”
Quote: “Dr. De Iaco performed the hys-
teroscopic surgery, while Dr. Muzzupapa
performed the second-look hysteroscopy
without knowing the group of treatment”
(query clarified by Dr Pierandrea De Iaco)
Comment: probably done.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Sixty patients aged from 18 to 65
years old were enrolled in the study and
written, informed consent was obtained
from each patient.”
Quote: “A total of 40 patients attended the
postoperative diagnostic hysteroscopy, 18
in the intervention and 22 in the control
group.”
Comment: loss to follow-up of 20/60 en-
rolled participants, very likely to cause sub-
stantial attrition bias
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias High risk Quote: “In conclusion, the authors recog-
nize that the data reported lack statisti-
cal significance given the small sample size
of the population evaluated. Despite this,
newly induced synechiae were less severe in
the Hyalobarrier gel treated patients, thus
reducing the risk of pregnancy morbidity
and improving the outcomes of hystero-
scopic surgery.”
Comment: our own recalculation demon-
strated that differences were not statistically
significant; primary study authors’ conclu-
sions were not based on results
Baseline characteristics in both comparison
groups not explicitly presented; P values
not given
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Methods Parallel-group randomised controlled trial.
Single centre, Hysteroscopic Unit of the University of Naples Frederico II, Naples, Italy
Protocol approved by IRB: yes.
Statistical power calculation for primary outcome of incidence of de novo adhesions
(query clarified by Dr Attilio DiSpiezio Sardo)
No external funding and no conflicts of interest (query clarified by Dr Attilio DiSpiezio
Sardo)
Participants Number recruited: 136 women.
Number excluded before randomisation: 26women (8womendeclined after explanation
of study protocol; 18 women excluded because they were unwilling to undergo surgery)
Number randomly assigned: 110 women.
Number lost to follow-up: 0 women.
Number excluded after randomisation: 24women. In intervention group, 11/55women,
and in control group, 13/55 women, treated with endometrial ablation for resistant
dysfunctional bleeding; these 24participantswere excluded fromanalyses, as endometrial
ablation/resection is not indicated as a fertility-enhancing surgical intervention. This
judgement was subjected to several sensitivity analyses
Number analysed: 86 women.
Premenopausal women diagnosed at clinic diagnostic hysteroscopy (n = 136) with single
or multiple lesions suitable for surgical treatment or with resistant dysfunctional uter-
ine bleeding requiring endometrial ablation invited to participate. Of 26 women who
declined, 8 declined after explanation of study protocol, and 18 were excluded because
they were unwilling to undergo surgery. Between September 2008 and June 2009, 110
premenopausal women were enrolled in study
Exclusion criteria:
• body mass index > 30;
• menopause (FSH > 40 mIU/mL and 17β-oestradiol < 20 pg/mL);
• pregnancy (positive β-hCG);
• uterovaginal prolapse and severe urinary symptoms;
• malignancy or other serious concurrent condition (e.g. coagulation disorders,
systemic disease, severe cardiac disease);
• pre-existing IUAs because evaluation of re-formed IUAs was not focus of study.
Number of subfertile women with or without abnormal uterine bleeding: 12 in inter-
vention group; 9 in control group; not possible to obtain individual outcome data for
this small subgroup of subfertile women for IPD analysis (query clarified by Dr Attilio
DiSpiezio Sardo)
Duration of study: 10 months: September 2008 to June 2009.
Mean age (± SD) in intervention group: 37 (± 3.1) years.
Mean age (± SD) in control group: 36 (± 2.9) years.
Interventions Intercoat gel (intervention: n = 55) vs no gel (control: n = 55)
Intervention group: after surgery, women underwent intrauterine application of 10 mL
Intercoat gel under hysteroscopic guidance through inflow channel of resectoscope while
operator gradually moved resectoscope from fundus of uterus back to external uterine
ostium to apply gel throughout cavity and cervical canal. Procedure considered complete
when, under hysteroscopic visualisation, gel seemed to have replaced all liquid medium,
and cavity appeared completely filled by gel from tubal ostia to external uterine orifice
Control group: hysteroscopic surgery alone.
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Clinic diagnostic hysteroscopy performed with 5-mm continuous-flow hysteroscope
with oval profile, a 30-degree fore-oblique telescope and a 5-F operating channel (Karl
Storz GmbH&Co. KG, Tuttlingen, Germany). Sodium chloride 0.9% solution used as
distension medium and administered through electronic system of irrigation/aspiration
(Endomat; Karl Storz GmbH & Co. KG)
Operative hysteroscopy performed with rigid 27-F resectoscope with 30-degree fore-
oblique telescope with various bipolar loops and a bipolar energy source (Versapoint;
Gynecare, division of Ethicon, Inc.). Sodium chloride 0.9% solution used as distension
medium
Administration of antibiotics not reported.
Outcomes Incidence of de novo adhesions, severity of adhesions according to 1988AFS classification
system and improvement of degree of patency of internal uterine ostium; all outcomes
measured after 4 weeks (during early proliferating phase of following menstrual cycle)
Notes * Correspondence with authors on 27 December 2014:
1. Which method was used for a statistical power calculation before the trial?
Our primary outcome was measured by the incidence of de novo IUA. On the basis of data
previously published by our group [Guida M, Acunzo G, Di Spiezio Sardo A, Bifulco G,
Piccoli R, Pellicano M, Cerrota G, Cirillo D, Nappi C. Effectiveness of auto-cross-linked
hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic adhesiolysis:
a prospective randomized, controlled study. Hum Reprod 2004;19:1461-1464; Acunzo G,
GuidaM, Pellicano M, Tommaselli GA, Di Spiezio Sardo A, Bifulco G, Cirillo D, Taylor A,
NappiC. Effectiveness of auto-cross-linked hyaluronic acid gel in the prevention of intrauterine
adhesions after hysteroscopic adhesiolysis: a prospective randomized, controlled study. Hum
Reprod 2003;18:1918-1921], we expected the incidence of adhesions at follow-up in patients
undergoing hysteroscopic procedures with the application of the gel to be 10%, and without to
be 28%, respectively. These figures are consistent with current literature, which shows a mean
incidence of IUA of 25% after common resectoscopic procedures (polypectomy, myomectomy
and metroplasty) if adjusted by taking into account that our study was meant to include more
adhesiogenic procedures such as endometrial ablation. For the probability of a type 1 statistical
error to be less than 0.05, we calculated that a sample of 55 patients per group would provide
80% of statistical power.
2. Was there any funding for the present study? Was there any conflict of interest?
The studywas not funded by an external source. All authors had no conflict of interest regarding
this study at that time.
3. Is it possible to provide the outcome data of the infertile women included in this study to
be able to analyse them on an individual level?
Unfortunately it is not possible. However the infertile patients were only a small proportion
(12 Group 1 [intervention]; 9 Group 2 [control]).
4. Which method was used to conceal the allocation to one of the two interventions?
The allocation sequence was concealed from the researchers (S.M, B.M, S.M.) who enrolled
and assessed the participants and attached a sequentially numbered, opaque, sealed and
stapled envelope containing the allocated treatment to the clinical record of the patient after
having signed the informed consent. The envelope was opened immediately after the surgical
removal of the intrauterine removal of the removal of the intrauterine lesion, in order for the
surgeon (A.D.S.S.) to either inject the gel (group 1 [intervention]) or not (group 2 [control])
. Patients were blinded to the procedure until the end of the study. This single-blind study
design was adopted to reduce bias derived from the patient’s knowledge of which procedure
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she underwent.
5. How were the study participants, the treating physicians and the outcome assessors blinded?
Who did the outcome assessments? Finally, are you aware of any ongoing research on anti-
adhesion therapy following operative hysteroscopy?
Patients were blinded since they underwent operative hysteroscopy in general anaesthesia
or loco-regional anaesthesia (they were awake but couldn’t see the monitor) and were kept
blinded until the three months follow-up visit. The treating physician (A.D.S.S.) was blinded
until removal of the intrauterine lesion or after endometrial ablation, when he was informed
whether to inject or not the intrauterine gel. The assessor (M.G.) was blinded since he
performed the baseline and the follow-up hysteroscopies and did not participate to the operative
hysteroscopies, so he was completely unaware of the allocation of patients. This single-blind
study designwas adopted to reduce bias derived from the patient’s knowledge of which procedure
she underwent.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After diagnostic hysteroscopy, pa-
tients were randomized via computer-gen-
erated randomisation list into group 1
(treatment group: operative hysteroscopy
plus intrauterine application of Intercoat
gel; N = 55) and group 2 (control group:
operative hysteroscopy alone; N = 55).”
Comment: probably done, as the same
team of investigators has published data on
a similar randomised trial
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was con-
cealed from the researchers (S.M, B.M, S.
M.) who enrolled and assessed the partic-
ipants and attached a sequentially num-
bered, opaque, sealed, and stapled envelope
containing the allocated treatment to the
clinical record of the patient after having
signed the informed consent” (query clari-
fied by Dr Attilio DiSpiezio Sardo)
Comment: probably done.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “Patients were blinded since they
underwent operative hysteroscopy in gen-
eral anaesthesia or loco-regional anaesthe-
sia (they were awake but couldn’t see the
monitor) and were kept blinded until the
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three months follow-up visit” (query clari-
fied by Dr Attilio DiSpiezio Sardo)
Quote: “The envelope was opened imme-
diately after the surgical removal of the in-
trauterine removal of the removal of the in-
trauterine lesion, in order for the surgeon
(A.D.S.S.) to either inject the gel (group
1) or not (group 2)” (query clarified by Dr
Attilio DiSpiezio Sardo)
Comment: personnel not blinded; partici-
pants blinded (query clarified by Dr Attilio
DiSpiezio Sardo)
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “Both the initial and follow-up di-
agnostic hysteroscopy were performed by
the same surgeon (M.G.), who, blinded to
patients’ randomized allocation, also eval-
uated the rate and severity of adhesions in
each patient.”
Quote: “The assessor (M.G.) was blinded
since he performed the baseline and the fol-
low-up hysteroscopy and did not partici-
pate to the operative hysteroscopy, so he
was completely unaware of the allocation
of patients” (query clarified by Dr Attilio
DiSpiezio Sardo)
Comment: probably done.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Intention-to-treat was the analysis
method used; however, there were no devi-
ations from random allocation.”
Comment: probably done; unlikely to
cause attrition bias.
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias Low risk Comment: no evidence of imbalance
in baseline participant characteristics; no
cotreatment
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Methods Parallel-group randomised controlled trial.
Single centre, Hallym University Kangdong Sacred Heart Hospital, Seoul, South Korea
Protocol approved by IRB: not reported; no contact possible due to absence of contact
details
Statistical power calculation not reported; no contact possible due to absence of contact
details
External funding and conflicts of interest not reported; no contact possible due to absence
of contact details
Participants Number recruited: 64 women.
Number randomly assigned: 64 women.
Number excluded: 2 women, reason for exclusion not reported.
Number lost to follow-up: 0 women.
Number analysed: 62 women.
Inclusion criterion:
• aged 20-44 years.
Exclusion criteria:
• women wishing to become pregnant within 1 month after intrauterine surgery;
• severe liver or renal disease;
• coagulation disorders or under treatment with anticoagulant drugs;
• diabetes;
• autoimmune disease.
Proportion of women with infertility: unclear if infertile women were included or ex-
cluded
Study duration of study: 10 months.
Mean age (range): 28 (22-43) years.
Mean age in intervention group: 26 years.
Mean age in control group: 31 years.
Interventions HA/CMC gel (intervention: n = 32) vs saline (control: n = 30)
Intervention group: after intrauterine surgery, 10 mL of HA + CMC applied on uterine
cavity
Control group: 10 mL of saline applied.
After surgery, antibiotics injected for 1 day, and then oral antibiotics administered for 3
days.Women who underwent dilatation and curettage were discharged on 1st postopera-
tive day, and women who underwent hysteroscopy were discharged on 2nd postoperative
Outcomes Frequency and severity of IUAs compared by microhysteroscopy on 4th postoperative
week, severity of IUAs classified in accordance with AFS 1988 guidelines
Notes No contact data of the primary study authors reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized to 32
patients of study group (group A) and 32
patients of control group (group B) each.”
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Comment: method not described; unclear
if stratified randomisation was used; no
contact possible
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not de-
scribed; no contact possible
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “After intrauterine surgery, in group
A [intervention], 10ml of Hyaluronic acid
+ Sodium Carboxymethyl Cellulose (HA +
CMC) was applied on uterine cavity, and
in group B [control], 10ml of saline was
applied.”
Comment: surgeons not blinded; easy to
distinguish saline from gel
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “After intrauterine surgery, in group
A, 10ml of Hyaluronic acid + Sodium Car-
boxymethyl Cellulose (HA + CMC) was
applied on uterine cavity, and in group B,
10ml of saline was applied.”
Comment: surgeons not blinded; easy to
distinguish saline from gel
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Not reported if gynaecologists who per-
formed second-look procedure 4 weeks af-
ter surgery were blinded or not; no contact
possible
Blinding of outcome assessment (detection
bias)
Adhesions
Unclear risk Not reported if gynaecologists who per-
formed second-look procedure 4 weeks af-
ter surgery were blinded or not; no contact
possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “In total 64 patients, 62 patients
were followed up postoperatively. Group A
was 32 patients, Group B was 30 patients,
and 2 patients were excluded during study.
”
Comment: reasons for postrandomisation
exclusion not reported
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias High risk Quote: “See table of baseline characteristics
Age in years group A [intervention]: 26
Age in years group B [control]: 31
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Parity in group A: 0.8
Parity in group B: 1.5
Abortion in group A: 1.0
Abortion in group B: 1.8.”
Comment: high risk of selection bias.
Quote: “As a result of transvaginal sonog-
raphy, intrauterine adhesion was observed
at 4 patients (13%) out of 32 patients in
group A and had mild intrauterine adhe-
sions.”
Comment: unclear if micro-hysteroscopy
or transvaginal ultrasound used for out-
come assessment of IUAs. High risk of in-
formation bias
Fuchs 2014
Methods Parallel-group randomised controlled trial.
Single centre, gynaecologic endoscopy unit of a tertiary care medical centre in Zerifin,
Israel
Protocol approved by IRB: yes.
Post hoc statistical power calculation; non-inferiority design
No external funding and no conflicts of interest (query clarified by Dr Moty Pansky)
Participants Number recruited: 110 women.
Number excluded before randomisation: 58 women (14 did not meet inclusion criteria;
37 declined to participate; 7 excluded for other reasons)
Number randomly assigned: 52 women.
Number lost to follow-up: 11 women.
Number analysed: 41 women.
Women who underwent hysteroscopic surgery because of suspected RPOC between
September 2009 and June 2012 invited to participate in study, and enrollees gave signed
informed consent
Inclusion criteria:
• aged 18-50 years;
• suspicion of RPOC on transvaginal ultrasound, diagnostic clinic hysteroscopy, or
both.
Study duration: 34 months; September 2009 to June 2012.
Mean age (± SD) in intervention group: 29.5 (± 5.1) years.
Mean age (± SD) in control group: 31.4 (± 6.5) years.
Quote: ”The study didn’t include women with primary subfertility“ (query clarified by
Dr Moty Pansky)
Comment: only women with confirmed fertility included in study
Interventions Oxiplex gel (intervention: n = 21) vs no gel (control: n = 20)
All hysteroscopic procedures performed under general anaesthesia. Pelvic bimanual ex-
amination performed under anaesthesia, and findings recorded in the medical records.
Uterus considered enlargedwhen uterine funduswas palpated above pelvic brim. Sodium
chloride 0.9% solution used as distension medium. Suspected RPOC removed via blunt
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dissection, with 4-mm loop resectoscope (Stryker Corp., Kalamazoo, MI, USA) as a
curette and under direct hysteroscopic view. All specimens sent for pathological analysis
Intervention group: after completion of hysteroscopic dissection, Oxiplex gel inserted
into uterine cavity, up to complete filling of the cavity or up to 10 mL gel, whichever
occurred first. All women discharged from the hospital several hours after procedure
Control group: no gel.
Both intervention and control groups received sequential hormonal treatment (oestradiol
valerate 2 mg/day for 11 days, followed by oestradiol valerate 2 mg/day + norgestrel 0.5
mg/day for 10 days) and antibiotic therapy (amoxicillin-clavulanic acid, 875 mg, twice
daily for 7 days). All women underwent diagnostic clinic hysteroscopy at 6-8 weeks after
operative procedure, performed by a surgeon blinded to treatment group
Outcomes Intraoperative and postoperative complication rates, incidence of moderate or severe
adhesions and pregnancy defined as a positive heartbeat (query clarified by Dr Moty
Pansky)
Comment: primary and secondary outcomes not determined.
Notes Quote: ”Because this was a pilot study using a non-inferiority design, post hoc power
analysis was performed. This calculation showed that the power for detection of a statis-
tically significant difference in rates of intrauterine adhesions between the 2 groups was
24%.“
Comment: study was substantially underpowered for the outcome of incidence of mod-
erate or severe IUAs
* Correspondence with authors on 19 January 2015:
1. The first citation is an interim analysis that included 30 women, and was presented
at AAGL [American Association of Gynecologic Laparoscopists] on 2011. The second
citation is the final analysis that was published in JMIG [Journal of Minimally Invasive
Gynecology] 2014 and included 52 women. The study population of the second citation
includes all 30 women from the first one and 22 additional women.
2. Allocation was based on a computer-generated randomisation scheme that was prepared
in advance by the study coordinator. Sealed envelopes containing allocation were opened only
following consent by the treating physician. The study coordinator documented the allocation
on a password protected computer.
3. The control group receivedNS [normal saline] at the end of the procedure. The participants
didn’t know which group they were allocated to, nor did the outcome assessors. Naturally, the
treating physician at time of procedurewas aware of the treatment. Treating physicians’ identity
was documented and the study coordinator made sure that different physicians performed the
treatment and the assessment per patient.
4. The gel was provided by J&J [Johnson & Johnson]. There was no funding for the study.
There was no conflict of interest.
5. The study didn’t include women with primary subfertility.
6. This was a pilot study designed to assess safety, hence there was no distinction between
primary and secondary outcomes.
7. Pregnancy was defined as a positive heartbeat.
8. We are not aware of any ongoing research on anti-adhesion therapy following operative
hysteroscopy.”
Risk of bias
63Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fuchs 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The study entrants, in blocks of
12, were randomly allocated via a com-
puter-generated randomisation schedule,
using institutional computer software, to
treatment with (study group) or without
(control group) Oxiplex gel.”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote: “Allocation was based on a com-
puter generated randomisation scheme that
was prepared in advance by the study coor-
dinator. Sealed envelopes containing allo-
cation were opened only following consent
by the treating physician.The study coordi-
nator documented the allocation on a pass-
word protected computer” (query clarified
by Dr Moty Pansky)
Comment: probably done.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “Different surgeons performed the
operative hysteroscopy and the follow-up
diagnostic hysteroscopy. Both the patients
and the surgeons who performed the fol-
low-up studies were unaware of patient
group assignment.”
Quote: “The participants didn’t know
which group they were allocated to, nor
did the outcome assessors. Naturally, the
treating physician at time of procedure was
aware of the treatment. Treating physicians’
identity was documented and the study co-
ordinator made sure that different physi-
cians performed the treatment and the as-
sessment per patient” (query clarified byDr
Moty Pansky)
Comment: participants probably blinded,
as they were under general anaesthesia, but
treating physicians not blinded
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
64Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fuchs 2014 (Continued)
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “Different surgeons performed the
operative hysteroscopy and the follow-up
diagnostic hysteroscopy.”
Quote: “All patients underwent diagnos-
tic office hysteroscopy at 6 to 8 weeks af-
ter the operative procedure, performed by a
surgeon who was blinded to the treatment
group.”
Quote: “The participants didn’t know
which group they were allocated to, nor
did the outcome assessors. Naturally, the
treating physician at time of procedure was
aware of the treatment. Treating physicians’
identity was documented and the study co-
ordinator made sure that different physi-
cians performed the treatment and the as-
sessment per patient” (query clarified byDr
Moty Pansky)
Comment: probably done.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote from the figure 1 CONSORT flow
diagram of the study report: “In the inter-
vention group five women were excluded
from analysis after randomisation: the in-
tervention was discontinued but no further
clarification was given.”
Quote from the figure 1 CONSORT flow
diagram of the study report: “In the control
group six women were excluded from anal-
ysis after randomisation: lost to follow-up
(3) and discontinuation of the intervention
(3) without further clarification.”
Comment: likely to cause attrition bias.
Selective reporting (reporting bias) High risk Comment: at high risk of selective outcome
reporting, as live birth rates not reported
for a study from September 2009 to June
2012, and publication of the final study
report in 2014
Other bias High risk Quote: “Patients with a diagnosis of adhe-
sions (AFS grade 1) were offered an addi-
tional procedure for adhesiolysis.”
Quote: “At follow-up hysteroscopy, 3 pa-
tients in the control group (14%) had AFS
stage 2 or 3 (moderate to severe) intrauter-
ine adhesions, compared with 1 woman in
the study group (4%), who had AFS stage
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3 intrauterine adhesions (P = 0.30).”
Comment: imbalance between groups for
a cointervention.
Gan 2017
Methods Parallel-group randomised controlled trial.
Single centre,Department ofMinimally Invasive Gynecologic Center, BeijingObstetrics
and Gynecology Hospital, Capital Medical University, Beijing, China
Protocol approved by IRB: yes.
Study protocol registered as NCT02496052 in ClinicalTrials.gov
Statistical power calculation reported; sample size determined based on findings of a
pilot study
External funding: supported by grants from Beijing Municipal Administration of
Hospitals Clinical Medicine Development of Special Funding Support (Grant No.
ZYLX201406), Capital Health Research and Development of Special (Grant No. 2014-
1-2112) and National Science and Technology Infrastructure Program (Grant No.
2014BAI05B03)
Conflicts of interest reported: authors had no conflicts of interest
Participants Number recruited: 88 women.
Number randomly assigned: 88 women.
Number excluded: 2 women; 1 per treatment arm; reason: protocol violation
Number lost to follow-up: 6 women. Intervention group: 3 women lost to follow-up;
2 not undergo second hysteroscopy and 1 had incomplete data collection for defaulted
follow-up. Control group: 3 women lost to follow-up; 3 did not undergo second hys-
teroscopy
Number analysed: 80 women.
Consecutive series of women who fulfilled the recruitment criteria were invited to par-
ticipate in the study until the enrolment target was met. All women had severe IUAs
confirmed by outpatient diagnostic hysteroscopy and AFS IUA score ≥ 8
Inclusion criteria:
• age < 40 years;
• hypomenorrhoea or amenorrhoea;
• infertility or spontaneous abortion (≥ 1);
• baseline AFS IUA score ≥ 8.
Exclusion criteria:
• premature menopause;
• presence of other intrauterine lesions (e.g. polyps, myoma or septa);
• severe intercurrent disease (e.g. systemic disease, coagulation disorders or severe
disease of the kidneys or liver).
Precise proportion of women with infertility not reported in this mixed population of
women with infertility or ≥ 1 spontaneous miscarriage
Study duration: 12 months.
Mean age (± SD) in intervention group: 29.6 (± 3.7) years.
Mean age (± SD) in control group: 30.8 (± 3.7) years.
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Interventions Freeze-dried amnion graft using a modified Foley catheter balloon as a scaffold
(intervention: n = 40) vs Foley catheter balloon without amniotic grafting (control:
n = 40)
Hysteroscopic adhesiolysis performed under general anaesthesia by 1 experienced hys-
teroscopic operator. 2 × misoprostol 200 µg tablets administered vaginally the night
before surgery for cervical priming. A bipolar resectoscope with a 9-mm sheath and a
4-mm 12-degree telescope (Olympus Optical Company, Tokyo, Japan) used after cer-
vical dilation with a 10 Hegar cervix dilator. Ultrasonographic guidance routinely used
during procedure. Laparoscopy used to inspect pelvis and rule out pathology, such as
endometriosis, and to verify tubal patency at end of hysteroscopic surgery. Normal saline
used as distention medium and delivered through automated hysteroscopic distension
pump at 260 mL/minute, under 100 mmHg of intrauterine pressure. Once location,
extent and severity of IUAs had been assessed, they were resected using a needle or loop
diathermy with electrosurgical generator voltage set at 320 W for the cutting mode and
160W for the coagulation mode. Fluid volume recorded using modified automated fluid
management system. Operating surgeon assessed when complete adhesiolysis had been
achieved for all participants during surgery, and this was verified using normal panoramic
view of uterine cavity under direct hysteroscopic visualisation; adhesiolysis characterised
by adequate uterine cavity, no evidence of IUA and visible bilateral uterine horn, with
or without tubal ostium
Following surgery, a 20 Foley catheter, with tip distal to balloon cut away, used as a
scaffold for insertion of the amnion graft into uterine cavity
Intervention: balloon portion of Foley catheter covered with sterilised freeze-dried am-
nion graft (Jiangxi Rui Ji Biotechnology, Jiangxi, China) and hydrated in sterile normal
saline for 10 minutes before use. Size of each amnion graft 30 × 20 mm. 2 amnion grafts
applied to Foley catheter, with epithelial amnion membrane surface facing outwards.
Foley catheter was inserted into uterine cavity under ultrasonographic guidance. Balloon
was initially inflated with 8-10 mL of normal saline for 2-3 minutes to ensure that am-
nion graft fully adhered to uterine cavity. Afterwards, 3-5 mL of normal saline solution
was withdrawn, leaving a mean of 5 mL within balloon
Control: protocol for insertion of Foley catheter and inflation of balloon was same as
that used in intervention group; however, amnion grafting was not used
All images were digitally captured for further review and comparison using an integrated
operating room (Karl Storz, Tuttlingen, Germany). Foley catheter remained in place for
1 week, after which time balloon was deflated and catheter removed as an outpatient
procedure. All participants treated with daily dose of intravenous cefmetazole sodium 2 g
for 7 days until the Foley catheter was removed. They also received cyclical postoperative
therapy with oestrogens and progestogens as standard. Hormone therapy comprised oral
oestradiol valerate 4 mg, which was administered daily for 21 days, with the addition of
oral dydrogesterone 20 mg daily on days 12-21 of menstrual cycle
Outcomes Primary outcome: AFS IUA score at follow-up hysteroscopy 3 months after surgery
Secondary outcomes: changes in menstruation measured by PBAC score, IUA reforma-
tion rate, pregnancy rate
Follow-up of the secondary outcomes conducted via direct contact or telephone contact
every 3 months to assess menstrual pattern and reproductive outcomes. Total duration
of follow-up: 6-12 months
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Before surgery, the participants
were randomly assigned to either the am-
nion group or the control group in a 1:1
ratio using a computer-generated randomi-
sation sheet.“
Comment: probably done.
Allocation concealment (selection bias) Unclear risk Quote: ”Group allocation was concealed
using sealed opaque envelopes that were
opened at the time of operation by the co-
ordinator.“
Comment: probably done-unclear if se-
quentially numbered opaque sealed en-
velopes were used
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Quote: ”Group assignment was not
masked; however, the surgeons who per-
formed the follow-up hysteroscopy were
blinded to both randomisation and alloca-
tion.“
Comment: surgeons and personnel not
blinded, unclear if participants were
blinded or not; query not answered
Blinding of participants and personnel
(performance bias)
Adhesions
Unclear risk Quote: ”Group assignment was not
masked; however, the surgeons who per-
formed the follow-up hysteroscopy were
blinded to both randomisation and alloca-
tion.“
Comment: surgeons and personnel not
blinded, unclear if participants were
blinded or not; query not answered
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: ”Group assignment was not
masked; however, the surgeons who per-
formed the follow-up hysteroscopy were
blinded to both randomisation and alloca-
tion.“
Comment: outcome assessors blinded.
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: ”Group assignment was not
masked; however, the surgeons who per-
formed the follow-up hysteroscopy were
blinded to both randomisation and alloca-
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tion.“
Comment: outcome assessors blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”Of the 88 women recruited, 80
were included in the final analysis (40 in
each group).“
Comment: intervention group: 4 women
excluded or lost to follow-up; 2 did not un-
dergo second hysteroscopy, 1 protocol vi-
olation and 1 incomplete data collection
for defaulted follow-up. Control group: 4
women excluded or lost to follow-up; 3
did not undergo second hysteroscopy and
1 protocol violation
Selective reporting (reporting bias) High risk Quote: ”The primary efficacy outcome
was the AFS IUA score at follow-up hys-
teroscopy. This outpatient procedure was
performed under local anaesthesia at 3
months after surgery using 4.5-mm con-
tinuous perfusion hysteroscopy (30°) with
settings, intrauterine pressure, and irriga-
tion rates similar to those used during the
initial hysteroscopic surgery. The extent
and severity of any reformed IUAs was
recorded. Lesions were scored according to
the AFS system.“
Secondary outcomes were changes in men-
struation, which were evaluated according
to PBAC score, IUA reformation rate and
pregnancy rate.”
Comment: in study protocol registered
as NCT02496052 all secondary outcomes
mentioned in the published study report
were not predefined
Other bias High risk Quote: “During the follow-up period, nine
women in the amnion group achieved preg-
nancy; six of these pregnancies occurred
naturally, whereas three occurred follow-
ing in vitro fertilization and embryo trans-
fer. Spontaneous abortion during the first
trimester was reported among three of the
nine pregnancies in the amnion group. The
remaining six pregnancies were ongoing at
the time of final follow-up (twopregnancies
at <12 weeks and four pregnancies at >24
weeks). Seven pregnancies were reported
in the control group: five had occurred
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naturally and two had occurred following
in vitro fertilization and embryo transfer.
Among these seven pregnancies, four spon-
taneous abortions were reported during the
first trimester, whereas the remaining three
pregnancies were ongoing (>18 weeks) at
the time of final follow-up. As shown in
Table 1, the pregnancy rate in the amnion
group (23%) was not statistically different
from that the control group (18%).”
Comment: it is unclear if all women of this
mixed population infertility/spontaneous
miscarriage were trying to conceive. Pro-
portions of women treated with IVF/em-
bryo transfer vs natural conception not re-
ported; query not answered
Quote: “Laparoscopy was used to inspect
the pelvis and rule out pathology, such as
endometriosis, and to verify tubal patency
at the end of the hysteroscopic surgery.”
Comment: differences in proportions of
cotreatmentwith laparoscopy not reported;
query not answered
Quote: “Secondary outcomes were changes
in menstruation, which were evaluated ac-
cording to pictorial blood-loss assessment
chart (PBAC) score the IUA reformation
rate, and the pregnancy rate. Follow-up
was conducted via direct contact or tele-
phone contact every 3 months to assess
menstrual pattern and reproductive out-
comes. The total duration of follow-up was
6-12 months.”
Comment: at high risk of detection bias
if not all women were followed up until
12 months given that there was no fixed
endpoint to measure secondary outcomes
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Methods Parallel-group randomised controlled trial after stratification according to type of pathol-
ogy
Single centre, Hysteroscopic Unit of University of Naples Frederico II, Naples, Italy
Protocol approved by IRB: yes.
Statistical power calculation for primary outcome of incidence of de novo adhesions
(query clarified by Dr Attilio DiSpiezio Sardo)
No external funding and no conflicts of interest (query clarified by Dr Attilio DiSpiezio
Sardo)
Participants Number recruited: 164 women.
Number excluded before randomisation: 26 women (18 refused to undergo operative
hysteroscopy; 8 refused to participate after explanation of the study protocol)
Number randomly assigned: 138 women.
Number lost to follow-up: 6 women.
Number analysed: 132 women.
All participants with surgically remediable single lesions (myomas, polyps and uterine
septa, subgroups I-III) at diagnostic hysteroscopy were invited to participate. Between
September 2002 and June 2003, 164 women met the study’s inclusion criteria and were
invited to participate. Of these, 26 did not participate: 18 refused to undergo operative
hysteroscopy, and 8 refused after explanation of the study protocol
Inclusion criterion:
• hysteroscopic diagnosis of submucous myomas or endometrial polyps or uterine
septa.
Exclusion criteria:
• age > 50 years;
• weight > 100 kg;
• menopausal (FSH > 40 mIU/mL, 17β-oestradiol < 20 pg/mL);
• pregnancy (positive β-hCG test);
• uterovaginal prolapse and severe urinary symptoms;
• malignancy;
• severe intercurrent illness (coagulation disorders, systemic disease, severe
cardiopathy);
• association of equal or different intrauterine remediable lesions or presence of
IUAs.
Study duration: 10 months (September 2002 to June 2003).
Mean age (± SD) in intervention group: 37 (± 3.2) years.
Mean age (± SD) in control group: 36 (± 2.8) years.
Number of subfertile participants and individual outcome data not available for further
IPD analysis (query clarified by Dr Attilio DiSpiezio Sardo)
Interventions ACP gel (intervention: n = 69) vs no treatment (control: n = 69)
After diagnostic hysteroscopy and after written consent form was signed, women from
each pathology subgroup (submucous myomas, endometrial polyps, septa) were ran-
domly assigned to 2 groups using a computer-generated randomisation list
Intervention group: intrauterine application of 10 mL of ACP gel (Hyalobarrier Gel;
Baxter, Pisa, Italy) under hysteroscopic view after operative hysteroscopy
Control group: hysteroscopic surgery alone.
Diagnostic hysteroscopy performed with a 3.5-mm instrument (Gynecare Versascope;
Gynecare, Ethicon Inc., Somerville, NJ, USA) and sodium chloride 0.9% solution as
distension medium
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Operative hysteroscopy performed using a rigid resectoscope (Karl Storz, Tuttlingen,
Germany) with 12-degree fore-oblique telescope with hook-shapedmonopolar electrode
Both groups received oral antibiotics (cefixime 400 mg/day) (Cefixoral; Menarini,
Firenze, Italy) for 3 days after surgery
Outcomes Incidence of de novo adhesions, mean adhesion score and severity of adhesions according
to 1988 AFS classification system; all outcomes measured after 3 months
Notes * Correspondence with authors on 27 December 2014:
1. Which method was used for a statistical power calculation before the trial?
Primary outcome was the incidence of adhesion formation at three month follow-up in the
two groups (hysteroscopy plus gel vs. hysteroscopy only). We assumed that difference between
the two groups in term of de novo intrauterine adhesion formation would be 15% with an
incidence of de novo adhesion formation in the hysteroscopy only group of 25% (Taskin et al.
J Am Assoc Gynecol Laparosc 2000; 7: 351-354). For the probability of a type I error to be
less than .05, we calculated that a sample of 136 patients (68 per group) would provide 80%
statistical power. In the study, 138 patients were enrolled and unfortunately, 6 dropped out,
leaving 67 patients in the hysteroscopy plus gel group and 65 in the hysteroscopy only group.
For this reason, 80% power of the study using the per-protocol sample size analysis was not
reached. Nevertheless, the post-hoc power analysis revealed that the study reached an 80%
power.
2. Was there any funding for the present study? Was there any conflict of interest?
The studywas not funded by an external source. All authors had no conflict of interest regarding
this study at that time.
3. Is it possible to provide the outcome data of the infertile women included in this study to
be able to analyse them separately?
Unfortunately it is not possible.
4. Which method was used to conceal the allocation to one of the two interventions?
The allocation sequence was concealed from the researchers (G.A., G.B., R.P., M.P.), who
enrolled and assessed the participants and attached a sequentially numbered, opaque, sealed,
and stapled envelope containing the allocated treatment to the clinical record of the patient
after having signed the informed consent. The envelope was opened immediately after the
surgical removal of the intrauterine removal of the removal of the intrauterine lesion, in order
for the surgeon (M.G.) to either inject the gel (group A) or not (group B). Patients were
blinded to the procedure until the end of the study. This single-blind study design was adopted
to reduce bias derived from the patient’s knowledge of which procedure she underwent.
5. How were the outcome assessors blinded? Finally, are you aware of any ongoing research on
anti-adhesion therapy following operative hysteroscopy?
The researcher who assessed the de novo formation of intrauterine adhesion (G.A.) was the one
who performed the baseline diagnostic hysteroscopy and, successively, performed the 3 month
follow-up hysteroscopy. He did not participate to any of the operative hysteroscopies, when the
patients were allocated to group A or B and, thus, he was completely unaware to which group
the patients were allocated.
We are not aware of any ongoing research on anti-adhesion therapy following operative
hysteroscopy.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “After diagnostic hysteroscopy and
after the written consent form was signed,
patients from each pathology subgroup
(submucous myomas, endometrial polyps,
septa) were randomized into two groups,
group A (treatment [intervention] group)
(N = 69) and group B (control group) (N =
69), using a computer-generated randomi-
sation list.”
Comment: probably done, as the same
team of investigators published data on a
similar randomised trial
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was con-
cealed from the researchers (G.A., G.B., R.
P.,M.P.), who enrolled and assessed the par-
ticipants and attached a sequentially num-
bered, opaque, sealed, and stapled envelope
containing the allocated treatment to the
clinical record of the patient after having
signed the informed consent” (query clari-
fied by Dr Attilio DiSpiezio Sardo)
Comment: probably done.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “The envelope was opened imme-
diately after the surgical removal of the in-
trauterine removal of the removal of the in-
trauterine lesion, in order for the surgeon
(M.G.) to either inject the gel (group A) or
not (group B). Patients were blinded to the
procedure until the end of the study. This
single blind study design was adopted to re-
duce bias derived from the patient’s knowl-
edge of which procedure she underwent”
(query clarified by Dr Attilio DiSpiezio
Sardo)
Comment: personnel not blinded; partici-
pants blinded.
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
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Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “Both the initial diagnostic hys-
teroscopy and the follow-updiagnostic hys-
teroscopy were performed by the same op-
erator (G.A.). G.A. evaluated the adhesion
score for each patient and was blind for pa-
tients’ randomized allocation, whilst opera-
tive hysteroscopies and application of ACP
gel were performed by a different operator
(M.G.).”
Quote: “The researcher who assessed the
de novo formation of intrauterine adhe-
sion (G.A.) was the one who performed the
baseline diagnostic hysteroscopy and, suc-
cessively, performed the 3 month follow-
up hysteroscopy. He did not participate to
any of the operative hysteroscopies, when
the patients were allocated to group A [in-
tervention] or B [control] and, thus, he was
completely unaware towhich group the pa-
tients were allocated” (query clarified byDr
Attilio DiSpiezio Sardo)
Comment: probably done.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Sixwomen (two from groupA [in-
tervention] and four from group B [con-
trol]) did not attend for follow-up hys-
teroscopy.”
Comment: unlikely to cause substantial at-
trition bias.
Selective reporting (reporting bias) Low risk Comment: no evidence of selective out-
come reporting when abstract, methods
and results were compared
Other bias Low risk Comment: no evidence of imbalance
in baseline participant characteristics; no
cotreatment
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Methods Parallel-group randomised controlled trial.
Single centre, tertiary medical centre, Shin KongWuHo-Su Memorial Hospital, Taipei,
Taiwan
Protocol approved by IRB: yes.
Study protocol registered as NCT01167296 in ClinicalTrials.gov
Statistical power calculation done before start of trial.
No conflicts of interest declared by study authors.
External funding not reported.
Participants Number recruited: 68 women.
Number excluded before randomisation: 6women (5 refused to participate; 1 had history
of PID)
Number randomly assigned: 62 women.
Number lost to follow-up: 2 women.
Number analysed: 60 women.
Inclusion criterion:
• aged 20-45 years undergoing hysteroscopic surgery.
Exclusion criteria:
• history of PID;
• evidence of PID or vaginitis.
Study duration: 8 months; trial recruited from July 2010 to April 2011
Mean age (± SD) in intervention group: 33.4 (± 4.8) years.
Mean age (± SD) in control group: 35.4 years (± 7.2) years.
Unclear whether participants had subfertility, and if so, how many (query not clarified
by study authors)
Interventions Balloon uterine stent (intervention: n = 31) vs no stent (control: n = 31)
Randomisation based on a 1:1 computer-generated scheme in balanced blocks of 4.
Randomisation codes sealed in sequentially numbered opaque envelopes by study co-
ordinator. Immediately before surgery, co-ordinator opened envelope and assigned par-
ticipants to receive balloon uterine stent insertion (intervention) or not (control)
Intervention group: uterine stent present for 30 days after surgery. Endometrium
swabbed before and 30 days after surgery, and stent removed and sent for bacterial culture
Control group: endometrial swabbing done before and 30 days after surgery, but no
stent was inserted
Co-ordinator, participants and gynaecologists were not blinded to intervention after
assignment
Per routine practice, women self-administered misoprostol 400 µg (Cytotec; Pharmacia)
into vagina 24 hours and 12 hours before surgery to prime cervix. After anaesthesia, per-
ineum and vagina disinfected and draped. Cervix and vagina subsequently thoroughly
disinfected with povidone-iodine, as in vaginal surgery. Applicator swab (Copan Venturi
Transystem; Copan Italia) then inserted into uterine cavity, with care taken to avoid con-
tact with vaginal wall. Whole endometrium swabbed from fundus to cervix. Applicator
swab placed in a transport tube and sent to laboratory immediately for bacterial culture
Operative hysteroscopies performed with 22-F resectoscope (Karl Storz) and 5% glucose
solution for uterine distension and irrigation. For women in intervention group, stent
was inserted into uterine cavity at conclusion of hysteroscopy, and balloon inflated
with 8 mL sterile water. Postoperatively, women were prescribed 3 days of diclofenac
(Cataflam; Novartis Farma) for pain relief. Prophylactic antibiotics were not given. 1
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surgeon performed all operative procedures and swabbing. Women instructed to return
if any symptoms of PID developed 30 days after surgery, all participants returned to
hospital for bacterial culture and second-look hysteroscopy. After disinfection of vagina
and cervix with povidone-iodine, endometrium was swabbed. For intervention group,
after balloon was deflated, stent was removed carefully without touching the vaginal wall.
Balloon was cut from stem and placed in a sterile jar. Then endometrium was swabbed
and balloon and swab sent to laboratory immediately for bacterial culture. After cultures
were collected, all participants underwent second-look hysteroscopy for assessment of
endometrium
Outcomes Primary outcome: incidence of bacterial colonisation of the uterus
Secondary outcomes: pain intensity on VAS scale used to record worst pain score from
3 days to 30 days following surgery; species of colonising bacteria
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was based on a 1:
1 computer generated scheme in balanced
blocks of four.”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote: “Randomization codes were sealed
in sequentially numbered opaque en-
velopes by the study coordinator.”
Comment: probably done.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “The coordinator, patients, and gy-
naecologists were not blinded to interven-
tion after assignment.”
Comment: unequivocal outcome.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “The coordinator, patients, and gy-
naecologists were not blinded to interven-
tion after assignment.”
Comment: no blinding of participants,
personnel and outcome assessors
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “The coordinator, patients, and gy-
naecologists were not blinded to interven-
tion after assignment.”
Comment: unequivocal outcome.
Blinding of outcome assessment (detection
bias)
Adhesions
High risk Quote: “The coordinator, patients, and gy-
naecologists were not blinded to interven-
tion after assignment.”
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Comment: no blinding of participants,
personnel and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “A total of 62womenwere included
in the study, and 31 women were assigned
to each group. The balloon uterine stent
fell out after a week in one woman in the
stent group, and one woman in the control
group was lost to follow-up. Both of these
patients were excluded from analysis. Data
for 60 women were analysed.”
Comment: unlikely to cause substantial at-
trition bias.
Selective reporting (reporting bias) Unclear risk Quote: “Main outcome measure(s): The
primary outcome was the incidence of bac-
terial colonization of the uterus. Secondary
outcomes were pain intensity and species
of colonizing bacteria.”
Quote: “All second-look hysteroscopies re-
vealed a normal endometrium. No woman
had IUAs.”
Comment: according to registered proto-
col, predefined outcomes were:
• primary outcome measures:
intrauterine bacteria count;
• secondary outcome measures: IUA.
Published report stated in results section
that no participant had IUAs at second-
look hysteroscopy, but this important find-
ing was not explicitly stated in abstract
Other bias High risk Number of participants with IUAs twice
as high in intervention group (17/31) vs
control group (10/31)
Comment: imbalance in baseline charac-
teristics between comparison groups
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Methods Parallel-group randomised controlled trial.
Single centre, university referral centre, Reproductive Medicine Centre of the Sir Run
Run Shaw Hospital, Hangzhou, China
Protocol approved by IRB: yes.
Study protocol registered as ISRCTN69690272 in ISRCTN Registry
Statistical power calculation done before start of trial.
No conflicts of interest declared by authors.
External funding: National Science Foundation of China (81270657), Zhejiang Public
Welfare Technology Application Research Project (2013C33236), and Zhejiang Key
Science and Technology Innovation Team Project (2011R50013-26)
Participants Number recruited: 207 women.
Number excluded before randomisation: 6 women (3 surgical complications; 3 declined
to participate)
Number randomly assigned: 201 women.
Number excluded after randomisation: 5 women (1 intervention group; 4 control group)
with reason: protocol violation
Number lost to follow-up: 34 women (16 intervention group; 18 control group) with
reason: no second-look hysteroscopy in time
Number analysed: 162 women (82 intervention group, 80 control group)
Inclusion criteria:
• aged 18-40 years;
• moderate-to-severe IUA (AFS score ≥ 5);
• no previous history of hysteroscopic adhesiolysis;
• written consent obtained;
• agreement to undergo second-look hysteroscopy.
Exclusion criteria:
• minimal adhesion (AFS score < 5);
• previous hysteroscopic adhesiolysis.
Mean age (± SD) in intervention group: 29.7 (± 4.3) years.
Mean age (± SD) in control group: 30.1 (± 5.1) years.
Proportion of women with infertility in intervention group: 21/82 (26%)
Proportion of women with infertility in control group: 18/80 (22%)
Primary vs secondary infertility: not reported.
Study duration: 20 months.
Interventions Intrauterine balloon (intervention: n = 82) vs IUD (control: n = 80)
Hysteroscopic adhesiolysis carried out by 1 of 2 experienced hysteroscopic surgeons
with use of 4.5-mm rigid hysteroscope (Storz) with 5% mannitol perfusion under 100
mmHg pressure. Procedure performed under general anaesthesia in a day surgery unit.
Ultrasonographic guidance routinely used; in some cases, laparoscopywas also performed
either in exceptionally difficult cases or when there was a need to inspect pelvic organs
to rule out pathology such as endometriosis or to verify tubal patency. Once the extent
and severity of uterine adhesion had been assessed, adhesions were divided with use of
hysteroscopic scissors until normal uterine anatomy was achieved
Intervention group: immediately following operative hysteroscopy specially designed
intrauterine balloon (Cook Medical) inflated with 3-5 mL normal saline fitted into
uterine cavity
Control group: immediately following operative hysteroscopy heart-shaped copper IUD
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(Yantai Contraceptive Instrument) with thread knitted tail fitted into uterine cavity
Both devices were removed after 1 week in outpatient department. All participants
were treated with oral cefuroxime combined with metronidazole for 7 days. In all cases,
hormone therapy was also begun from the day of operation, consisting of oestradiol
valerate 6 mg/day for 21 days, with medroxyprogesterone acetate 6 mg/day for the last
7 days of the oestrogen therapy. After withdrawal bleed, hormone therapy repeated for
another cycle
Second-look hysteroscopy carried out in early proliferating phase, 1-2 months after
initial operation. After assessment of extent and severity of any reformed adhesions,
hysteroscopic adhesiolysis was also carried out at time of second-look procedure, if
adhesions had recurred
Outcomes Primary outcomes: adhesion reformation, measured by second-look hysteroscopy 1-2
months after surgery. Power calculation done before start of trial; reduction in adhesion
scores, measured by second-look hysteroscopy 1-2 months after surgery. Severity and
extent of IUAs scored according to AFS 1988 classification
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After the completion of hys-
teroscopic adhesiolysis, recruited patients
were randomized to one of the two treat-
ment groups by computer-generated num-
bers…”
Comment: probably done; low risk of bias.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported.
Comment: unclear risk of bias; query not
answered.
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Blinding of surgeons impossible since bal-
loon and IUD were easily recognised as be-
ing different. Blinding of participants not
reported but device removed after 1 week
at the outpatient department
Comment: probably no blinding of partic-
ipants and personnel.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Blinding of surgeons impossible since bal-
loon and IUD were easily recognised as be-
ing different. Blinding of participants not
reported but device removed after 1 week
at the outpatient department
Comment: probably no blinding of partic-
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ipants and personnel.
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “The surgeon who later performed
the second-look hysteroscopy was blinded
to the randomisation.”
Comment: probably done; low risk of bias.
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “The surgeon who later performed
the second-look hysteroscopy was blinded
to the randomisation.”
Comment: probably done; low risk of bias.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “There were 39 women who were
subsequently excluded from the study for
the following reasons. In the balloon group,
1 woman was excluded because of proto-
col violation, in addition to 16 withdrawals
because they did not proceed to second-
look hysteroscopy within the specified time
frame. In the IUDgroup, 4womenwere ex-
cluded because of protocol violation, in ad-
dition to 18 withdrawals because they did
not proceed to second-look hysteroscopy
within the specified time frame.”
Comment: proportion of women lost fol-
low-up 34/201 (17%) women; high risk of
attrition bias
Selective reporting (reporting bias) High risk According to study protocol registered as
ISRCTN69690272, secondary outcome
was pregnancy rate after surgery. Not re-
ported in study report
Comment: at high risk of selective outcome
reporting since duration of study was 20
months and no data reported in final re-
view of secondary outcome predefined in
registered study protocol
Other bias Low risk Quote: “No difference in baseline char-
acteristics. Co-treatment with antibiotics
and hormone therapy in both comparison
groups.”
Comment: no evidence for other potential
sources of bias.
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Methods Parallel-group randomised controlled trial.
Single centre, Department of Obstetrics and Gynecology, All India Institute of Medical
Sciences, New Delhi, India
Protocol approved by IRB: yes.
No statistical power calculation (query clarified by Dr Murali Subbaiah)
No funding (query clarified by Dr Murali Subbaiah).
No conflict of interest (query clarified by Dr Murali Subbaiah)
Participants Number recruited: 100 women.
Number excluded before randomisation: 10 women.
Number randomly assigned: 90 women.
Number lost to follow-up: 5 women did not attend for second-look hysteroscopy and
were excluded from analysis of second-look hysteroscopy findings; 2 women did attend
for second-look hysteroscopy but were lost to follow-up for assessment of reproductive
outcome
Number analysed: 85 women for second-look hysteroscopy findings; 83 women for
reproductive outcomes
Inclusion criteria:
• septate uterus with history of miscarriage or subfertility. All subfertile women
underwent diagnostic laparoscopy to rule out other causes of subfertility;
• hysteroscopic diagnosis of uterine septa;
• negative urine pregnancy test;
• written informed consent.
Exclusion criteria:
• aged > 35 years;
• acute cervicitis;
• presence of any other known cause of infertility or abortion.
90 original participants aged 20-35 years with history of infertility (n = 31) or abortion (n
= 59); of these, 40 had first-trimester and 19 had second-trimester spontaneous abortions
Study duration: 12 months; January 2011 to December 2011.
Mean duration of infertility (± SD) in intervention group: 5.9 (± 1.8) years
Mean age (± SD) in intervention group: 28.7 (± 4.8) years.
Mean duration of infertility (± SD) in control group: 6.2 (± 1.1) years
Mean age (± SD) in control group: 27.3 (± 3.9) years.
Comment: mixed population of primary/secondary subfertility and miscarriage. Clari-
fied by Dr Murali Subbaiah, quoting: “only 30 infertile patients were included - the rest
had abortions.”
Interventions Oestrogen therapy (intervention: n = 42) vs placebo (control: n = 43)
Hysteroscopic resection of septum under general anaesthesia by single operator in early
proliferating phase ofmenstrual cycle.Operative hysteroscopy by rigid resectoscope (Karl
Storz Endoskope, Germany) with 30-degree telescope, equipped with a hysteroscopic
monopolar (Collin’s) knife.Cutting current set at 60Watts. After 10-mmcervical dilation
achieved using Hegar’s dilator, uterine cavity distended by glycine solution (1.5%)
Intervention group: after septal resection, oestradiol valerate 2 mg once daily for 30
days
Control group: folic acid 5 mg tablet for 30 days.
Second-look hysteroscopy performed by same operator after 2 months to check for
residual septum and uterine cavity adhesions. Performed as an outpatient procedure with
a 4-mm, 30-degree angled lens
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Outcomes IUAs at second-look hysteroscopy after 2 months, classified according to AFS classifi-
cation; remnant septum defined as septum > 1 cm at second-look hysteroscopy after
2 months; pregnancy, ongoing pregnancy and miscarriage measured after contact by
telephone on a 3-month basis during 12- to 24-month period of follow-up
Notes Answers to queries on 6 December 2014:
“Respected Sir,
I would like to apologize for the delay in response. This was a small study and only 30 infertile
patients were included (The rest had abortions). Fertility outcome after septal resection in
infertile women was not separately analysed (Numbers are too small and the period of follow
up is also less). Power calculation was not done for this study.
There was no funding or conflict of interest.
The two groups were coded as A and B and were concealed in separate covers. A third person
who was not involved in the study was asked to choose one of the concealed covers randomly,
and this was assigned. The investigators and patients were blinded to treatment allotment.
I am not aware of any ongoing research on anti-adhesion therapy following operative hys-
teroscopy.
Yours sincerely,
Dr. Murali Subbaiah”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “They were prospectively random-
ized into two groups, group A (treatment
group) (N = 45) and group B (control
group) (N = 45), using a computer-gener-
ated randomisation list.”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote: “The investigators and patients
were blinded to treatment allotment.”
Comment: “The two groups were coded as
A andBandwere concealed in separate cov-
ers. A third person who was not involved
in the study was asked to choose one of the
concealed covers randomly, and this was as-
signed. The investigators and patients were
blinded to treatment allotment” (method
clarified by Dr Murali Subbaiah)
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
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Blinding of participants and personnel
(performance bias)
Adhesions
Low risk Quote: “The investigators and patients
were blinded to treatment allotment.”
Quote: “After septal resection, the treat-
ment group received 2 mg of oestradiol
valerate, once daily for 30 days; in the con-
trol group, folic acid tablet (5mg)was given
as a placebo for 30 days.”
Comment: probably done.
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Comment: unequivocal outcome.
Blinding of outcome assessment (detection
bias)
Adhesions
Low risk Quote: “The investigators and patients
were blinded to treatment allotment.”
Quote: “After septal resection, the treat-
ment group received 2 mg of oestradiol
valerate, once daily for 30 days; in the con-
trol group, folic acid tablet (5mg)was given
as a placebo for 30 days.”
Comment: probably done.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Five women (three from group A
and two from group B) did not attend for
follow-up hysteroscopy and were excluded
from the study. Further, two patients (one
from each group) were lost to follow up.”
Comment: no ITT analysis, but numbers
of women excluded after randomisation or
lost to follow-up and reasons were balanced
between comparison groups
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing.
Other bias Low risk No evidence of baseline imbalance.
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Methods Parallel-group randomised controlled trial.
Single centre, university referral centre, 1.a. Clinica Ostetrica e Ginecologica ”L. Man-
giagalli“ dell Università di Milano, Milan, Italy
Ethical board/IRB approval: Council of the Institute of the First Obstetrics and Gyne-
cologic Department of the Università degli Studi, Milan (query clarified by Paolo Ver-
cellini)
Study protocol registered in a clinical trial register: not registered (query clarified by
Paolo Vercellini)
Statistical power calculation before start of the trial: pilot study without preplanned
power calculation (query clarified by Paolo Vercellini)
Conflicts of interest: none (query clarified by Paolo Vercellini)
External funding: investigator-driven non-commercial study (query clarified by Paolo
Vercellini)
Participants Number recruited: 20 women.
Number randomly assigned: 20 women.
Number excluded after randomisation: 0 women.
Number lost to follow-up: 0 women.
Number analysed: 20 women (intervention: IUD + hormone treatment: n = 10; control:
no IUD or hormone treatment: n = 10)
Inclusion criteria:
• aged 25-36 years;
• ≥ 2 unexplained spontaneous abortions;
• double uterine cavity at HSG;
• ultrasonographic evidence of a normal uterine fundus.
Exclusion criteria: not reported.
Mean age (range): 29 (25-36) years.
Proportion of women with infertility: all (query clarified by Paolo Vercellini)
Primary vs secondary infertility: not applicable.
Study duration: 24 months; January 1986 to December 1987.
Interventions IUD + hormone treatment (intervention: n = 10) vs no additional treatment (control:
n = 10)
Hysteroscopic incision in uterine septum scheduled for the early proliferating phase of
the menstrual cycle. Participants allocated randomly to 2 groups
Intervention group: IUD (MLCU 205, Multilan S.A., Pfäffikon, Switzerland) inserted
postoperatively + conjugated oestrogen 1.25 mg twice daily for 30 days + medroxypro-
gesterone acetate 10 mg/day on days 26-30. Follow-up HSG scheduled after withdrawal
bleeding and IUD removal
Control group: no other therapeutic measures.
In both groups a follow-up HSG was scheduled after the first spontaneous menstrual
period with repeat hysteroscopy in the next cycle in the case of abnormal HSG findings
Outcomes Main outcomes: residual fundal notch ≥ 5 cm, incidence of IUAs
No prioritisation of outcomes reported.
Notes * Correspondence with authors on 17 March 2017:
Dear Professor Bosteels,
1. Can you describe the method used to randomly allocate the study participants to one of
both treatment groups?
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Computer generated randomisation list.
2. Can you describe the method that you used to make the surgeons unaware of the treatment
allocation? Did you use sequentially numbered opaque sealed envelopes? Did you phone to a
central randomisation trial office? Other method?
Sequentially numbered opaque sealed envelops.
3. Were the outcome assessor who evaluated the HSG or did the second look hysteroscopy in
case of abnormal HSG the same surgeons that performed the septum resection?
Yes, they were the same surgeons that performed the septum resection.
4. Do you have any baseline characteristics data of both comparison groups e.g. mean age of
women in either group, length of septum, etc…?
Unfortunately I am unable to retrieve these data. The study was completed almost 30 years
ago.
5. Two women had their IUD removed early in the intervention group and in 1 woman in
the control group a balloon catheter was left in situ for 24 hours because of bleeding. What
was the outcome regarding normality of the cavity in these 3 women?
See reply to point 4.
6. Is it correct that this is a single centre study conducted at 1.a. ClinicaOstetrica eGinecologica
”L. Mangiagalli” dell Università di Milano?
Yes, it is correct.
7. Were the study participants all women of proven fertility or did the study also include
women with infertility with two miscarriages?Do you have data on the proportions of infertile
women in both comparison groups?
The study participants were all fertile.
8. Was there IRB/Ethical committee approval for this clinical trial?
Yes, the study was approved by the Council of the Institute of the First Obstetrics and Gyne-
cologic Department of the Università degli Studi, Milan.
9. Was the study funded by a research grant or was it an investigator-driven non- commercial
study?
It was an investigator-driven non-commercial study.
10. Was a power calculation done before the conduct of the study?
It was a pilot study and no pre-planned power calculation was performed.
Thank you for your interest in our study and best wishes for your work.
Paolo Vercellini
Department of Clinical Sciences and Community Health, Università degli Studi di Milano
and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Commenda 12,
20122 Milan, Italy.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were allocated ran-
domly to two groups.”
Comment: computer-generated randomi-
sation list (query clarified by Paolo Ver-
cellini)
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Allocation concealment (selection bias) Low risk Quote: “method of allocation concealment
not reported.”
Comment: sequentially numbered opaque
sealed envelops (query clarified by Paolo
Vercellini)
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “An IUD (ML CU 205, Multi-
lan S.A., Pfäffikon, Switzerland) was in-
serted postoperatively in the ten women in
group I; they also received conjugated es-
trogens, 1.25 mg twice daily for 30 days,
with medroxyprogesterone acetate, 10 mg/
d on days 26-30. The ten women in group
II were followed without other therapeutic
measures.”
Quote: “Follow-up HSG was scheduled
for after withdrawal bleeding and IUD re-
moval in group I and after the first spon-
taneous menstrual period in group II, with
repeat hysteroscopy in the next cycle in the
case of abnormal HSG findings.”
Comment: neither physicians nor partici-
pants were blinded.
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “An IUD (ML CU 205, Multi-
lan S.A., Pfäffikon, Switzerland) was in-
serted postoperatively in the ten women in
group I; they also received conjugated es-
trogens, 1.25 mg twice daily for 30 days,
with medroxyprogesterone acetate, 10 mg/
d on days 26-30. The ten women in group
II were followed without other therapeutic
measures.”
Quote: “Follow-up HSG was scheduled
for after withdrawal bleeding and IUD re-
moval in group I and after the first spon-
taneous menstrual period in group II, with
repeat hysteroscopy in the next cycle in the
case of abnormal HSG findings.”
Comment: neither physicians nor partici-
pants were blinded.
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “Follow-up HSG was scheduled
for after withdrawal bleeding and IUD re-
moval in group I and after the first spon-
taneous menstrual period in group II, with
repeat hysteroscopy in the next cycle in the
case of abnormal HSG findings.”
Comment: outcome assessors who evalu-
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atedHSG or did second-look hysteroscopy
in case of abnormal HSG were same sur-
geons who performed septum resection
(query clarified by Paolo Vercellini)
Blinding of outcome assessment (detection
bias)
Adhesions
High risk Quote: “Follow-up HSG was scheduled
for after withdrawal bleeding and IUD re-
moval in group I and after the first spon-
taneous menstrual period in group II, with
repeat hysteroscopy in the next cycle in the
case of abnormal HSG findings.”
Comment: outcome assessors who evalu-
atedHSG or did second-look hysteroscopy
in case of abnormal HSG were same sur-
geons who performed septum resection
(query clarified by Paolo Vercellini)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “From January 1986 to Decem-
ber 1987 we studied 20 women aged 25-
36 years (mean, 29) with two or more un-
explained spontaneous abortions, a dou-
ble uterine cavity at hysterosalpingography
(HSG) and ultrasonographic evidence of a
normal uterine funduswith a half-full blad-
der (Ansaldo 920 real-time scanner with 3.
5-MHz convex transducer).”
Quote: “At follow-up HSG, five group I
women had a regular uterine cavity and five
a residual fundal notch ≥ 1 cm. In group
II four had a normal uterine cavity and six
a residual fundal notch ≥ 1 cm. No IUAs
were detected in any of the patients.”
Comment: no exclusion; no loss-to-follow-
up.
Selective reporting (reporting bias) Low risk Quote: “No intrauterine adhesions were
detected in any of the patients. IUD in-
sertion and hormonal therapy after hys-
teroscopic metroplasty do not seem to be
needed to prevent septal fusion.”
Comment: no difference between out-
comes reported in abstract vs results section
Other bias Unclear risk Quote: “In three group I and two group
II patients, undue bleeding occurred,
mainly from small, traumatized sites in the
surrounding endometrium. Postoperative
bleeding was observed in two women in
group I [intervention] and one in group
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II [control]; the IUD was removed from
the two group I patients 8 and 11 hours
postoperatively, and methylergonovine, 0.
2 mg intramuscularly, was administered.
That was sufficient to arrest the bleeding in
those cases whereas in the group II patient
we had to insert in the uterine cavity a no.
16 Foley catheter distended with 5 mL of
fluid; it remained there for 24 hours. The
subsequent course was uneventful.”
Comment: baseline characteristics not re-
ported. Sensitivity analyses of an ITT anal-
ysis vs a per-protocol analysis not possi-
ble since outcomes of these 3 women were
not reported. These 3 women should have
been excluded since early removal of IUD
in intervention group and leaving a balloon
catheter in situ for 24 hours could have
affected outcomes. Since study was com-
pleted in the late 1980s, it is no longer pos-
sible to retrieve these data (query clarified
by Paolo Vercellini)
Wang 2016
Methods Parallel-group randomised controlled trial.
Single centre, university referral centre:GynecologicalMinimally InvasiveCenter, Beijing
Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
Ethical board/IRB approval: yes.
Study protocol registered in a clinical trial register: not reported; query not answered
Statistical power calculation before start of the trial: not reported; query not answered
Conflicts of interest: not reported; query not answered.
External funding: Beijing Municipal Administration of Hospitals Clinical Medicine De-
velopment of Special Funding (zylx201406); The Capital Health Research and Devel-
opment of Special (2014-1-2112); National Science and Technology Infrastructure Pro-
gram (2004BAI05B02)
Participants Number recruited: 57 women.
Number randomly assigned: 57 women.
Number excluded after randomisation: 0 women.
Number lost to follow-up: 0 women.
Number analysed: 57 women (intervention: amniotic scaffold balloon, n = 29; control:
Foley’s balloon without amniotic membrane: n = 28)
57 women with IUA score ≥ 10 on hysteroscopy selected at the Beijing Maternity
Hospital (affiliated to the Beijing Medical University)
Inclusion criterion:
• IUA score ≥ 10, IUA diagnosis and grading according to 1988 AFS grading
method, scores assigned according to extent of adhesions and menstrual pattern: 1-4
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(mild), 5-8 (moderate), 9-12 (severe).
Exclusion criterion:
• couples with male factor infertility and all other causes of infertility or menstrual
abnormalities.
Mean age (± SD) in intervention group: 29 (± 3) years.
Mean age (± SD) in control group: 31 (± 3) years.
Proportion of women with infertility: all women had infertility related to severe IUAs
Primary vs secondary infertility: not reported.
Study duration: recruitment of 12 months; June 2013 to June 2014
Follow-up: 12-18 months. Mean (± SD) follow-up 14.6 (± 2.7) months
Interventions Foley balloon catheter wrapped in amniotic membrane (intervention: n = 29) vs
Foley balloon without amniotic membrane (control: n = 28)
Tracheal intubation combined with intravenous general anaesthesia. Routine cervi-
cal priming performed preoperatively. Hysteroscopic adhesiolysis combined with la-
paroscopy and B-mode ultrasound. In hysteroscopy, uterine cavity inspected looking
for sites and severity of adhesions or anatomical abnormality. Adhesiolysis performed
with needle electrodes and loop electrodes until normal morphology of uterine cavity
restored, both uterine horns were visible and fallopian tube opening visible or invisible,
or both. Emphasis placed on preserving residual endometrium. Amniotic membranes
used were obtained from the Jiangxi Ruizeng Biological Engineering Technology Co.,
Ltd., specifications for the 30 mm × 20 mm dry sterilised biological amniotic membrane
Intervention group: before operation, 2 sheets of amniotic membrane were soaked in
25-30 °C normal saline for 15-20 minute to allow for rehydration and wrapped onto
surface of a Foley catheter. Cervix dilated using Hegar 12 dilators, following which any
fluid/gas was aspirated by the Foley catheter. Subsequently, balloon catheter was inflated
with 8-10 mL saline resulting in amniotic membrane products adhering completely to
the uterine wound. After waiting 1-2 minutes, residual volume of 3-4 mL was retained
in balloon catheter to maintain a separation between uterine walls. Catheter was left in
place attached to an external drainage bag for 7 days, and routine antibiotic prophylaxis
given. Balloon removed 7 days postoperatively
Control group: treatment as in intervention group except Foley balloon catheter alone
had no external wrapping of amniotic membrane
Outcomes No prioritisation of the outcomes reported.
Menstrual flow changes; 1 month and 3 months postoperatively; IUA score by hys-
teroscopy performed after 3 cycles. If IUA score ≥ 5, participants were considered to
have recurrence of adhesions, thereafter, participants were followed up every 3months by
telephone call or outpatients visits where pregnancy rates were recorded; IUA diagnosis
and grading according to 1988 AFS grading method, which is a summation of adhesion
score by hysteroscopy and menstrual pattern score by WHO menstrual blood loss chart
(PBAC); reformation of IUAs scored by hysteroscopy; pregnancy; not further specified;
ongoing pregnancy; spontaneous miscarriage; preterm birth; reformation of IUAs scored
by hysteroscopy
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “57 IUA patients with IUA score
≥10 on hysteroscopy were selected from
June 2013 to June 2014 at the Beijing Ma-
ternity Hospital (affiliated to the Capital
Medical University). Using the SPSS ran-
dom number generator, patients were di-
vided into 2 groups.”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported; query not answered
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Surgeons were not blinded. Unclear if
women were blinded to allocated treat-
ment; query not answered
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Surgeons were not blinded. Unclear if
women were blinded to allocated treat-
ment; query not answered
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Unclear if surgeons performing second-
look hysteroscopy were different from sur-
geons who performed hysteroscopic adhe-
siolysis; query not answered
Blinding of outcome assessment (detection
bias)
Adhesions
Unclear risk Unclear if surgeons performing second-
look hysteroscopy were different from sur-
geons who performed hysteroscopic adhe-
siolysis; query not answered
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up.
Selective reporting (reporting bias) Low risk Registration of study protocol not re-
ported. Data collected as mentioned in
methods section were all reported in results
section
Other bias Unclear risk Quote: “All patients were taking artificial
cycle treatment.”
Comment: all women were cotreated with
fertility treatment but unclear if this means
that all women were offered same treat-
ment regimen (e.g. all women received
clomiphene with or without IUI or go-
nadotropin treatment with or without IUI
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or IVF) and that the proportions of dif-
ferent treatment regimens with different
fertility prognoses were equally distributed
among both groups; query not answered
Xiao 2015
Methods Parallel-group randomised controlled trial.
Multicentre, Third Xiangya Hospital of Central South University, Changsha 410013,
China, Beijing, China and 2 affiliated hospitals: Hunan Provincial People’s Hospital and
Hunan First People’s Hospital of Chenzhou City, China
Ethical board/IRB approval: yes.
Study protocol registered in clinical trial register: not reported; query not answered
Statistical power calculation before start of trial: not reported; query not answered
Conflicts of interest: not reported; query not answered.
External funding: not reported; query not answered.
Participants Number recruited: 120 women.
Number randomly assigned: 120 women.
Number excluded after randomisation: 0 women.
Number lost to follow-up: 9 women.
Number analysed: 111 women (intervention group: n = 55; control group: n = 56)
From November 2011 to November 2012, women with IUA from 3 hospitals affiliated
with Xiangya Medical College and other hospitals who fulfilled inclusion criteria were
included
Inclusion criteria:
• aged 20-40 years of childbearing age, with newly diagnosed moderate-to-severe
adhesions by hysteroscopy according to the AFS score criteria;
• no serious systemic disease;
• no contraindication to surgery.
Exclusion criteria:
• HA allergy;
• inflammation of the lower genital tract;
• PID;
• genital malignancy;
• abnormal uterine bleeding caused by systemic disease;
• uterine cavity malformations.
Mean age (± SD) in intervention group: 33 (± 5) years.
Mean age (± SD) in control group: 33 (± 5) years.
Proportion of women with infertility: not reported; unclear if infertile women were
included; query not answered
Primary vs secondary infertility: not reported.
Study duration: recruitment of 12 months.
Interventions Foley balloon catheter + AC HA gel (intervention: n = 55) vs Foley balloon catheter
only (control: n = 56)
Participants with moderate-to-severe IUAs underwent routine hysteroscopic adhesioly-
sis. After surgery, participants randomly assigned into intervention and control groups
according to treatment allocation table
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Intervention group: Foley balloon catheter placed in uterine cavity, 3 mL saline injected
to inflate balloon to seal mouth of cervix. Then, 2 mL medical self-cross-linking sodium
hyaluronate gel (product of Changzhou Biarui Biomedical Co., Ltd.) injected from
another lumen of Foley balloon catheter to fill uterine cavity and cover surgical wound
Control group: Foley balloon catheters placed in uterine cavity in same manner as
intervention group with no self-cross-linking sodium hyaluronate gel
According to literature, after 72 hours, Foley balloon catheters were removed from and
same routine postoperative treatment given to all participants
At 1 and 3 months, participants attended for clinical follow-up 3-7 days after menstrual
bleeding had stopped for that cycle. Participant’s general condition, symptoms, signs and
possible complications checked and recorded
At thirdmonth of follow-up, second-look hysteroscopy performed and IUAswere graded
(light, moderate and severe) according to AFS criteria
Outcomes Primary outcome: effectiveness of treatment as seen by recurrence of adhesions on hys-
teroscopy 3 months after surgery. Treatment success defined as decrease in total AFS
score of ≥ 4 points. Formula to calculate rate of treatment success: cases with AFS total
score < 4 divided by total number of cases × 100%
Secondary outcomes: comparison of AFS score, including extent of IUAs, adhesion type;
menstrual pattern score before and after surgery, and between groups
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After the surgery, the patients were
randomly assigned into treatment and con-
trol groups according to a treatment allo-
cation table.”
Comment: probably done.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment was not
reported; query not answered
Blinding of participants and personnel
(performance bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “The surgeons performing the sec-
ond hysteroscopy at 3monthswere blinded
to the choice of treatment of the patient.
In addition, patients were also blinded to
allocation to treatment or control. There-
fore, this study can still be defined as dou-
ble-blinded (those assessing treatment re-
sponse and those receiving treatment did
not know of the treatments). Due to the
properties of the self-crosslinking sodium
hyaluronate gel material, no gel material
with the same properties can be used as a
control. In addition, blank control material
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was not used in order to ensure efficacy of
treatment and adherence to medical ethics.
As a result, the surgeon performing adhesi-
olysis was not blinded.”
Comment: surgeons performing surgery
not blinded but participants were blinded
Blinding of participants and personnel
(performance bias)
Adhesions
High risk Quote: “The surgeons performing the sec-
ond hysteroscopy at 3monthswere blinded
to the choice of treatment of the patient.
In addition, patients were also blinded to
allocation to treatment or control. There-
fore, this study can still be defined as dou-
ble-blinded (those assessing treatment re-
sponse and those receiving treatment did
not know of the treatments). Due to the
properties of the self-crosslinking sodium
hyaluronate gel material, no gel material
with the same properties can be used as a
control. In addition, blank control material
was not used in order to ensure efficacy of
treatment and adherence to medical ethics.
As a result, the surgeon performing adhesi-
olysis was not blinded.”
Comment: surgeons performing surgery
not blinded but participants were blinded
Blinding of outcome assessment (detection
bias)
Live birth, pregnancy or miscarriage
Low risk Quote: “The surgeons performing the sec-
ond hysteroscopy at 3monthswere blinded
to the choice of treatment of the patient.
In addition, patients were also blinded to
allocation to treatment or control. There-
fore, this study can still be defined as dou-
ble-blinded (those assessing treatment re-
sponse and those receiving treatment did
not know of the treatments). Due to the
properties of the self-crosslinking sodium
hyaluronate gel material, no gel material
with the same properties can be used as a
control. In addition, blank control material
was not used in order to ensure efficacy of
treatment and adherence to medical ethics.
As a result, the surgeon performing adhesi-
olysis was not blinded.”
Comment: surgeons performing second-
look hysteroscopy were blinded
Blinding of outcome assessment (detection
bias)
Low risk Quote: “The surgeons performing the sec-
ond hysteroscopy at 3monthswere blinded
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Adhesions to the choice of treatment of the patient.
In addition, patients were also blinded to
allocation to treatment or control. There-
fore, this study can still be defined as dou-
ble-blinded (those assessing treatment re-
sponse and those receiving treatment did
not know of the treatments). Due to the
properties of the self-crosslinking sodium
hyaluronate gel material, no gel material
with the same properties can be used as a
control. In addition, blank control material
was not used in order to ensure efficacy of
treatment and adherence to medical ethics.
As a result, the surgeon performing adhesi-
olysis was not blinded.”
Comment: surgeons performing second-
look hysteroscopy were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The study period was from
November 2011 to November 2012. 120
subjects were randomized into the experi-
mental group and the control group of 60
cases each.”
Quote: “Therewere 111patientswho com-
pleted follow-up and met the requirements
of statistical analysis, including 55 patients
in the trial group and 56 patients in the
control group.”
Comment: 9 participants lost to follow-up
or excluded (5 in intervention and 4 in con-
trol group; reasons not reported)
Selective reporting (reporting bias) Low risk Results of all predefined endpoints were all
reported.
Other bias Low risk No statistically significant differences in
age, weight, height, number of previous
pregnancies and preoperative AFS score
No cotreatments.
ACP: auto-cross-linked polysaccharide; AFS: American Fertility Society; ART: assisted reproductive technology; ASRM: American
Society for Reproductive Medicine; CMC: carboxymethyl cellulose; β-hCG: beta-human chorionic gonadotropin; FSH: follicle-
stimulating hormone; HA: hyaluronic acid; HSG: hysterosalpingography; IPD: individual participant data; IRB: institutional review
board; ITT: intention to treat; IUA: intrauterine adhesion; IUD: intrauterine device; IVF: in vitro fertilisation; n: number of
women; PBAC: pictorial blood-loss assessment chart; PID: pelvic inflammatory disease; RPOC: retained products of conception;
SD: standard deviation; VAS: visual analogue scale; WHO: World Health Organization.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bednarek 2011 Quote: “We performed a randomised non-inferiority trial involving women undergoing uterine aspiration for
induced or spontaneous abortion at 5 to 12 weeks of gestation who desired an IUD. Subjects were randomly
assigned (in a 5:6 ratio) to IUD insertion immediately after the procedure or 2 to 6 weeks afterward (delayed
insertion). The primary outcome was the rate of IUD expulsion 6 months after IUD insertion.”
Comment: not answering PICO research question.
Chen 2017 Quote: “Effects of aspirin and intrauterine balloon on endometrial repair and reproductive prognosis in patients
with severe intrauterine adhesion: a prospective cohort study.”
Comment: observational study.
Cheong 2016 Quote: “The use of Hyalobarrier post salpingo-ovariolysis did not influence follicular development as inferred
from the results of the day 21 progesterone and folliculogram on day 10-12 3-month postsurgery.”
Comment: not answering PICO research question.
Hu 2014a Intervention: hysteroscopic adhesiolysis followed by collagen scaffold loaded with autologous bone marrow stem
cell treatment. Study design: observational; case series
Comment: observational study.
Hu 2014b Intervention: hysteroscopic adhesiolysis followed by collagen scaffold loaded with umbilical cord blood-derived
mesenchymal stem cell treatment. Study design: observational; case series
Comment: observational study.
Johns 2001 Quote: “OBJECTIVE: To assess the safety and efficacy of the Intergel adhesion prevention solution, a 0.5% ferric
hyaluronate gel, in reducing adhesions in patients undergoing peritoneal cavity surgery by laparotomy with a
planned second-look laparoscopy. DESIGN: Randomized, third-party blinded, placebo-controlled, parallel group.
SETTING: Eleven centres in the United States, and five centres in Europe. PATIENT(S): Women aged 18-46
years who wanted to retain their fertility. INTERVENTION(S): Patients received 300 mL of Intergel solution
(N = 143) or lactated Ringer’s solution (N = 138) as an intraperitoneal instillate at the completion of surgery.
MAIN OUTCOME MEASURE(S): At second-look laparoscopy 6-12 weeks later, the presence of adhesions was
evaluated at 24 abdominal sites.”
Comment: not answering PICO research question.
Kim 2012 Quote: “The exclusion criteria were women who planned to use an intrauterine device for contraception during
the study period; (...); women who were pregnant or who planned pregnancy during the study period (...).”
Comment: excluded women with subfertility.
Kurtz 2002 Quote: “This randomised controlled blind prospective study is undertaken to evaluate the safety and efficacy of
Seprafilm™ - a novel bioresorbable membrane of chemicallymodified hyaluronic acid and carboxymethylcellulose
- in prevention and reduction of postoperative endometrial and endocervical synechiae formation after general
suction evacuation or curettage for incomplete, missed, and recurrent abortion.”
Comment: not answering PICO research question.
Liu 2016 Quote: “A retrospective analysis was carried out to explore the clinical data of 120 cases of severe IUA patients
who were treated in Woman and Infant Hospital of Zhengzhou and The Third Affiliated Hospital of Zhengzhou
University during the period between January 2010 and December 2013.”
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(Continued)
Comment: observational study.
NCT02328742 Quote: “The main objective of this study is to describe the level of expression of the biological factors involved in
the formation of adhesions (Transforming growth factor beta, Activin A, inhibin) at the time of a first diagnostic
hysteroscopy amongwomenwith synechia, another intracavitary disease or no intracavitary disease”; “Study design:
observational model: cohort; time perspective: prospective.”
Comment: observational study.
NTR3120 Quote: “Consented patients, who had at least one previous suction or abrasive (blunt or sharp) curettage for
a miscarriage in the history, visiting the outpatient clinic with a miscarriage and planned for curettage, will be
included in the study. The ultrasound is a key in the diagnosis of miscarriage; at least one recent ultrasound
examination (made within 7 days before randomisation) is required for inclusion. The maximum gestational age
at inclusion is 14 weeks.”
Comment: not answering PICO research question.
Pabuccu 2008 Quote: “We randomized patients sequentially, according to their entry into the study, after the study started.”
Comment: quasi-randomised study.
Tonguc 2010 Quote: “A statistician allotted the participants to their postsurgical treatment groups according to their application
numbers.”
Comment: quasi-randomised study.
Tsapanos 2002 Quote: “This randomised controlled blind prospective study is undertaken to evaluate the safety and efficacy of
Seprafilm™ - a novel bioresorbable membrane of chemicallymodified hyaluronic acid and carboxymethylcellulose
- in prevention and reduction of postoperative endometrial and endocervical synechiae formation after general
suction evacuation or curettage for incomplete, missed, and recurrent abortion.”
Quote: “Endometrial synechiae formation was evaluated with the use of hysterosalpingography (HSG) in patients
of all groups without pregnancy success 8 months after the intervention.”
Comment: not answering PICO research question.
Ya ar 2004 Quote: “OBJECTIVE: To evaluate the role of prophylactic estrogen administration on preventing intrauterine
adhesion formation following D&C [dilatation and curettage].”
Comment: not answering PICO research question.
IUD: intrauterine device; PICO: population, intervention, comparator, outcome.
Characteristics of studies awaiting assessment [ordered by study ID]
Hanstede 2016
Methods Parallel-group randomised controlled trial.
Single centre, referral centre, the Netherlands.
Participants 110 women undergoing hysteroscopic adhesiolysis for intrauterine adhesions
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Hanstede 2016 (Continued)
Interventions IUD, Cu-IUD flexi-T with copper removed, inserted in uterine cavity in both groups
Intervention: hormone treatment with schedule of oestrogen + norethisterone
Control: no hormone treatment.
Outcomes Primary outcome: recurrence of IUAs.
Secondary outcomes: pregnancy, restoration of menstrual flow and endometrial thickness
Notes Study results and conclusions presented as an abstract at an ESGE meeting. Authors are preparing a publication in a
peer-reviewed journal
ESGE: European Society for Gynaecological Endoscopy; IUA: intrauterine adhesion; IUD: intrauterine device.
Characteristics of ongoing studies [ordered by study ID]
NCT01464528
Trial name or title Safety Study of Use of Hyaluronic Acid Gel to Prevent Intrauterine Adhesions in Hysteroscopic Surgery
Methods Allocation: randomised.
Endpoint classification: safety study.
Intervention model: parallel assignment.
Masking: single-blind (participant).
Primary purpose: prevention.
Participants Inclusion criteria:
• aged ≥ 18 years;
• need of hysteroscopic surgery.
Exclusion criteria:
• preoperative fever or infection;
• malignancy;
• previous PID;
• contraindications for anaesthesia;
• pregnancy;
• aged < 18 years;
• unable to read or understand (or both) informed consent;
• taking medicine other than oral contraceptives.
Interventions Intervention: hyaluronic acid gel.
Control: no hyaluronic acid gel.
Outcomes Primary outcome: participant satisfaction following gel application
Starting date November 2011.
Estimated recruitment: 10 women.
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NCT01464528 (Continued)
Contact information Ariel Revel, MD.
Hadassah Medical Organization, Israel.
Telephone: 97226777111 ext 76389.
e-mail: arielr2@hadassah.org.il.
Notes 7 May 2017: overall status: not yet recruiting. The completion date has passed and the status has been last
updated on 2 November 2011
NCT01637974
Trial name or title Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hystero-
scopic Surgery
Methods Allocation: randomised.
Endpoint classification: efficacy study.
Intervention model: parallel assignment.
Masking: double-blind (participant, carer).
Primary purpose: prevention.
Participants Inclusion criteria:
• aged 18-50 years;
• must be able to understand, read and sign consent form.
Exclusion criteria:
• signs of infection upon admission;
• ongoing pregnancy;
• carcinoma of the uterus or cervix;
• recurrent PID;
• women admitted for endometrial ablation;
• women who gave birth 6 weeks ago;
• women participating in another study.
Interventions Intervention: injection of Intercoat into the uterine cavity at the end of hysteroscopy
Control: no injection of Intercoat.
Outcomes Not provided.
Starting date December 2012.
Status on 7 May 2017: still recruiting the estimated sample size of 130 women
Contact information Moran Paz, MD.
Carmel Medical Center, Israel.
Telephone: 972-4-8250637.
e-mail: MORANPA@CLALIT.GOV.IL.
Notes Estimated primary completion date according to ClinicalTrials.gov was March 2016. Last update received 30
July 2015
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PID: pelvic inflammatory disease.
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 2 107 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.42, 2.12]
1.1 Device vs no tx 1 24 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.18, 5.46]
1.2 Hormonal tx vs placebo/
no tx
1 83 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.37, 2.33]
2 Clinical pregnancy 2 107 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.37, 2.01]
2.1 Device vs no tx 1 24 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 18.08]
2.2 Hormonal tx vs placebo 1 83 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.35, 2.06]
3 Miscarriage 2 54 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.18, 2.57]
3.1 Device vs no tx 1 22 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 4.00]
3.2 Hormonal tx vs placebo 1 32 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.10, 5.01]
4 Presence of intrauterine
adhesions at second-look
hysteroscopy
8 560 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.21, 0.60]
4.1 Device vs no tx 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Device + hormonal tx vs
placebo/no tx
1 11 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Hormonal tx vs placebo 1 85 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.72]
4.4 Gel vs no tx 5 404 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.21, 0.64]
5 Mean adhesion scores at
second-look hysteroscopy
in women not treated for
intrauterine adhesions
1 132 Mean Difference (IV, Fixed, 95% CI) -1.46 [-1.64, -1.29]
5.1 Gel vs no tx 1 132 Mean Difference (IV, Fixed, 95% CI) -1.46 [-1.64, -1.29]
6 Mean adhesion scores at
second-look hysteroscopy in
women treated for intrauterine
adhesions
1 84 Mean Difference (IV, Fixed, 95% CI) -3.3 [-3.37, -3.23]
6.1 Gel vs no tx 1 84 Mean Difference (IV, Fixed, 95% CI) -3.3 [-3.37, -3.23]
7 Mild adhesions at second-look
hysteroscopy
6 494 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.68, 2.61]
7.1 Hormonal tx vs placebo/
no tx
1 90 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.10]
7.2 Gel vs no tx 5 404 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [0.77, 3.18]
8 Moderate or severe adhesions at
second-look hysteroscopy
6 494 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.03, 0.24]
8.1 Hormonal tx vs placebo/
no tx
1 90 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
8.2 Gel vs placebo/no tx 5 404 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.02, 0.23]
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Comparison 2. Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 3 180 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.57, 3.83]
1.1 Device + graft vs device 3 180 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.57, 3.83]
2 Clinical pregnancy 4 221 Odds Ratio (M-H, Fixed, 95% CI) 1.72 [0.89, 3.33]
2.1 Device + graft vs device 3 180 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.74, 3.18]
2.2 Gel + hormone tx (HT) +
antibiotics vs HT + antibiotics
1 41 Odds Ratio (M-H, Fixed, 95% CI) 2.83 [0.62, 13.04]
3 Miscarriage 3 40 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.20, 3.19]
3.1 Device + graft vs device 3 40 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.20, 3.19]
4 Presence of intrauterine
adhesions at second-look
hysteroscopy
5 451 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.36, 0.83]
4.1 Device vs device 1 162 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.42, 1.57]
4.2 Device + graft vs device 2 137 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.25, 1.10]
4.3 Device + gel vs device 1 111 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.13, 0.76]
4.4 Gel + HT + antibiotics vs
HT + antibiotics
1 41 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.98]
5 Mean adhesion scores in
women treated for intrauterine
adhesions
3 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Device vs device 1 162 Mean Difference (IV, Random, 95% CI) 0.0 [-0.68, 0.68]
5.2 Device + graft vs device 1 57 Mean Difference (IV, Random, 95% CI) -3.10 [-4.17, -2.03]
5.3 Device + gel vs device 1 111 Mean Difference (IV, Random, 95% CI) -1.6 [-2.32, -0.88]
6 Mild adhesions at second-look
hysteroscopy
1 111 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.53, 2.34]
6.1 Device + gel vs device 1 111 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.53, 2.34]
7 Moderate or severe adhesions at
second-look hysteroscopy
2 152 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.10, 0.61]
7.1 Device + gel vs device 1 111 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.09, 0.63]
7.2 Gel + HT + antibiotics vs
HT + antibiotics
1 41 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.98]
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Analysis 1.1. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 1 Live birth.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 1 Live birth
Study or subgroup Tx Placebo/no tx Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device vs no tx
Abu Rafea 2013 (1) 8/12 8/12 22.0 % 1.00 [ 0.18, 5.46 ]
Subtotal (95% CI) 12 12 22.0 % 1.00 [ 0.18, 5.46 ]
Total events: 8 (Tx), 8 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Hormonal tx vs placebo/no tx
Roy 2014 (2) 13/41 14/42 78.0 % 0.93 [ 0.37, 2.33 ]
Subtotal (95% CI) 41 42 78.0 % 0.93 [ 0.37, 2.33 ]
Total events: 13 (Tx), 14 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 53 54 100.0 % 0.94 [ 0.42, 2.12 ]
Total events: 21 (Tx), 22 (Placebo/no tx)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours tx Favours placebo/no tx
(1) Term delivery
(2) Ongoing pregnancy
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Analysis 1.2. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 2 Clinical pregnancy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 2 Clinical pregnancy
Study or subgroup Tx Placebo/no tx Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device vs no tx
Abu Rafea 2013 11/12 11/12 7.9 % 1.00 [ 0.06, 18.08 ]
Subtotal (95% CI) 12 12 7.9 % 1.00 [ 0.06, 18.08 ]
Total events: 11 (Tx), 11 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Hormonal tx vs placebo
Roy 2014 15/41 17/42 92.1 % 0.85 [ 0.35, 2.06 ]
Subtotal (95% CI) 41 42 92.1 % 0.85 [ 0.35, 2.06 ]
Total events: 15 (Tx), 17 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 53 54 100.0 % 0.86 [ 0.37, 2.01 ]
Total events: 26 (Tx), 28 (Placebo/no tx)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours tx Favours placebo/no tx
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Analysis 1.3. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 3 Miscarriage.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 3 Miscarriage
Study or subgroup Tx Placebo/no tx Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device vs no tx
Abu Rafea 2013 3/11 4/11 54.4 % 0.66 [ 0.11, 4.00 ]
Subtotal (95% CI) 11 11 54.4 % 0.66 [ 0.11, 4.00 ]
Total events: 3 (Tx), 4 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 Hormonal tx vs placebo
Roy 2014 2/15 3/17 45.6 % 0.72 [ 0.10, 5.01 ]
Subtotal (95% CI) 15 17 45.6 % 0.72 [ 0.10, 5.01 ]
Total events: 2 (Tx), 3 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 26 28 100.0 % 0.68 [ 0.18, 2.57 ]
Total events: 5 (Tx), 7 (Placebo/no tx)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.4. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 4 Presence of intrauterine adhesions at second-look hysteroscopy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 4 Presence of intrauterine adhesions at second-look hysteroscopy
Study or subgroup Tx Placebo/no tx Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device vs no tx
Lin 2015a (1) 0/30 0/30 Not estimable
Subtotal (95% CI) 30 30 Not estimable
Total events: 0 (Tx), 0 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Device + hormonal tx vs placebo/no tx
Vercellini 1989 0/5 0/6 Not estimable
Subtotal (95% CI) 5 6 Not estimable
Total events: 0 (Tx), 0 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Hormonal tx vs placebo
Roy 2014 0/42 3/43 7.1 % 0.14 [ 0.01, 2.72 ]
Subtotal (95% CI) 42 43 7.1 % 0.14 [ 0.01, 2.72 ]
Total events: 0 (Tx), 3 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
4 Gel vs no tx
Acunzo 2003 (2) 6/43 13/41 23.8 % 0.35 [ 0.12, 1.03 ]
De Iaco 2003 (3) 5/18 7/22 9.5 % 0.82 [ 0.21, 3.23 ]
Di Spiezio Sardo 2011 (4) 1/44 6/42 12.5 % 0.14 [ 0.02, 1.21 ]
Do 2005 (5) 4/32 8/30 15.0 % 0.39 [ 0.10, 1.48 ]
Guida 2004 (6) 7/67 17/65 32.1 % 0.33 [ 0.13, 0.86 ]
Subtotal (95% CI) 204 200 92.9 % 0.37 [ 0.21, 0.64 ]
Total events: 23 (Tx), 51 (Placebo/no tx)
Heterogeneity: Chi2 = 2.18, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.57 (P = 0.00035)
Total (95% CI) 281 279 100.0 % 0.35 [ 0.21, 0.60 ]
Total events: 23 (Tx), 54 (Placebo/no tx)
Heterogeneity: Chi2 = 2.62, df = 5 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.82 (P = 0.00014)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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(1) It is not clear if and how many participants suffered from subfertility (query not clarified by the study authors).
(2) HA gel at 9-12 weeks
(3) HA gel at 9-12 weeks
(4) Poly gel at 0-4 weeks
(5) HA-CMC gel at 4 weeks
(6) HA gel at 9-12 weeks
Analysis 1.5. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 5 Mean adhesion scores at second-look hysteroscopy in women not treated for
intrauterine adhesions.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 5 Mean adhesion scores at second-look hysteroscopy in women not treated for intrauterine adhesions
Study or subgroup Tx Placebo/no tx
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gel vs no tx
Guida 2004 (1) 25 2.25 (0.5) 24 3.5 (1.19) 11.1 % -1.25 [ -1.76, -0.74 ]
Guida 2004 (2) 8 4 (0.1) 8 5.33 (1.15) 4.6 % -1.33 [ -2.13, -0.53 ]
Guida 2004 (3) 34 2 (0.1) 33 3.5 (0.54) 84.2 % -1.50 [ -1.69, -1.31 ]
Total (95% CI) 67 65 100.0 % -1.46 [ -1.64, -1.29 ]
Heterogeneity: Chi2 = 0.91, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 16.70 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours treatment Favours placebo/no tx
(1) Women with fibroids
(2) Women with uterine septa
(3) Women with endometrial polyps
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Analysis 1.6. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 6 Mean adhesion scores at second-look hysteroscopy in women treated for
intrauterine adhesions.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 6 Mean adhesion scores at second-look hysteroscopy in women treated for intrauterine adhesions
Study or subgroup Tx Placebo/no tx
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Gel vs no tx
Acunzo 2003 43 2 (0.1) 41 5.3 (0.2) 100.0 % -3.30 [ -3.37, -3.23 ]
Total (95% CI) 43 41 100.0 % -3.30 [ -3.37, -3.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 94.94 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 1.7. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 7 Mild adhesions at second-look hysteroscopy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 7 Mild adhesions at second-look hysteroscopy
Study or subgroup Tx Placebo/no tx Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hormonal tx vs placebo/no tx
Roy 2014 0/45 2/45 16.7 % 0.19 [ 0.01, 4.10 ]
Subtotal (95% CI) 45 45 16.7 % 0.19 [ 0.01, 4.10 ]
Total events: 0 (Tx), 2 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 Gel vs no tx
Acunzo 2003 (1) 6/43 3/41 17.8 % 2.05 [ 0.48, 8.83 ]
De Iaco 2003 (2) 4/18 2/22 9.4 % 2.86 [ 0.46, 17.80 ]
Di Spiezio Sardo 2011 (3) 1/44 1/42 6.7 % 0.95 [ 0.06, 15.75 ]
Do 2005 (4) 4/32 4/30 24.4 % 0.93 [ 0.21, 4.10 ]
Guida 2004 (5) 6/67 4/65 24.9 % 1.50 [ 0.40, 5.58 ]
Subtotal (95% CI) 204 200 83.3 % 1.56 [ 0.77, 3.18 ]
Total events: 21 (Tx), 14 (Placebo/no tx)
Heterogeneity: Chi2 = 1.15, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 249 245 100.0 % 1.33 [ 0.68, 2.61 ]
Total events: 21 (Tx), 16 (Placebo/no tx)
Heterogeneity: Chi2 = 2.86, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.71, df = 1 (P = 0.19), I2 =42%
0.01 0.1 1 10 100
Favours tx Favours placebo/no tx
(1) HA gel at 9-12 weeks
(2) HA gel at 9-12 weeks
(3) Poly gel at 0-4 weeks
(4) HA-CMC gel at 4 weeks
(5) HA gel at 9-12 weeks
108Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative
hysteroscopy, Outcome 8 Moderate or severe adhesions at second-look hysteroscopy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 1 Anti-adhesion therapy versus placebo or no treatment (tx) following operative hysteroscopy
Outcome: 8 Moderate or severe adhesions at second-look hysteroscopy
Study or subgroup Tx Placebo/no tx Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hormonal tx vs placebo/no tx
Roy 2014 0/45 1/45 3.8 % 0.33 [ 0.01, 8.22 ]
Subtotal (95% CI) 45 45 3.8 % 0.33 [ 0.01, 8.22 ]
Total events: 0 (Tx), 1 (Placebo/no tx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Gel vs placebo/no tx
Acunzo 2003 (1) 0/43 10/41 26.9 % 0.03 [ 0.00, 0.61 ]
De Iaco 2003 (2) 1/18 5/22 10.8 % 0.20 [ 0.02, 1.90 ]
Di Spiezio Sardo 2011 (3) 0/44 5/42 14.1 % 0.08 [ 0.00, 1.43 ]
Do 2005 (4) 0/32 4/30 11.6 % 0.09 [ 0.00, 1.76 ]
Guida 2004 (5) 1/67 13/65 32.9 % 0.06 [ 0.01, 0.48 ]
Subtotal (95% CI) 204 200 96.2 % 0.07 [ 0.02, 0.23 ]
Total events: 2 (Tx), 37 (Placebo/no tx)
Heterogeneity: Chi2 = 1.07, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 4.58 (P < 0.00001)
Total (95% CI) 249 245 100.0 % 0.08 [ 0.03, 0.24 ]
Total events: 2 (Tx), 38 (Placebo/no tx)
Heterogeneity: Chi2 = 1.72, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
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Favours tx Favours placebo/no tx
(1) HA gel at 9-12 weeks
(2) HA gel at 9-12 weeks
(3) Poly gel at 0-4 weeks
(4) HA-CMC gel at 4 weeks
(5) HA gel at 9-12 weeks
109Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 1 Live birth.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 1 Live birth
Study or subgroup Intervention A Intervention B Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device + graft vs device
Amer 2010 (1) 3/29 1/14 16.9 % 1.50 [ 0.14, 15.87 ]
Gan 2017 (2) 4/40 3/40 37.8 % 1.37 [ 0.29, 6.56 ]
Wang 2016 (3) 6/29 4/28 45.2 % 1.57 [ 0.39, 6.27 ]
Total (95% CI) 98 82 100.0 % 1.48 [ 0.57, 3.83 ]
Total events: 13 (Intervention A), 8 (Intervention B)
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours B Favours A
(1) Ongoing pregnancy
(2) Ongoing pregnancy
(3) Term delivery
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Analysis 2.2. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 2 Clinical pregnancy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 2 Clinical pregnancy
Study or subgroup Intervention A Intervention B Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device + graft vs device
Amer 2010 8/29 2/14 14.1 % 2.29 [ 0.42, 12.56 ]
Gan 2017 9/40 7/40 39.2 % 1.37 [ 0.45, 4.12 ]
Wang 2016 8/29 6/28 31.9 % 1.40 [ 0.41, 4.71 ]
Subtotal (95% CI) 98 82 85.2 % 1.53 [ 0.74, 3.18 ]
Total events: 25 (Intervention A), 15 (Intervention B)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Gel + hormone tx (HT) + antibiotics vs HT + antibiotics
Fuchs 2014 (1) 7/21 3/20 14.8 % 2.83 [ 0.62, 13.04 ]
Subtotal (95% CI) 21 20 14.8 % 2.83 [ 0.62, 13.04 ]
Total events: 7 (Intervention A), 3 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI) 119 102 100.0 % 1.72 [ 0.89, 3.33 ]
Total events: 32 (Intervention A), 18 (Intervention B)
Heterogeneity: Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.48), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 2.3. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 3 Miscarriage.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 3 Miscarriage
Study or subgroup Intervention A Intervention B Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device + graft vs device
Amer 2010 5/8 1/2 13.5 % 1.67 [ 0.07, 37.73 ]
Gan 2017 3/9 4/7 67.3 % 0.38 [ 0.05, 2.88 ]
Wang 2016 2/8 1/6 19.2 % 1.67 [ 0.11, 24.26 ]
Total (95% CI) 25 15 100.0 % 0.80 [ 0.20, 3.19 ]
Total events: 10 (Intervention A), 6 (Intervention B)
Heterogeneity: Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 4 Presence of intrauterine adhesions at second-look hysteroscopy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 4 Presence of intrauterine adhesions at second-look hysteroscopy
Study or subgroup Intervention A Intervention B Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device vs device
Lin 2015b 25/82 28/80 32.8 % 0.81 [ 0.42, 1.57 ]
Subtotal (95% CI) 82 80 32.8 % 0.81 [ 0.42, 1.57 ]
Total events: 25 (Intervention A), 28 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Device + graft vs device
Gan 2017 11/40 16/40 19.3 % 0.57 [ 0.22, 1.46 ]
Wang 2016 6/29 10/28 13.4 % 0.47 [ 0.14, 1.54 ]
Subtotal (95% CI) 69 68 32.7 % 0.53 [ 0.25, 1.10 ]
Total events: 17 (Intervention A), 26 (Intervention B)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
3 Device + gel vs device
Xiao 2015 34/55 47/56 29.6 % 0.31 [ 0.13, 0.76 ]
Subtotal (95% CI) 55 56 29.6 % 0.31 [ 0.13, 0.76 ]
Total events: 34 (Intervention A), 47 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
4 Gel + HT + antibiotics vs HT + antibiotics
Fuchs 2014 (1) 1/21 3/20 4.9 % 0.28 [ 0.03, 2.98 ]
Subtotal (95% CI) 21 20 4.9 % 0.28 [ 0.03, 2.98 ]
Total events: 1 (Intervention A), 3 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 227 224 100.0 % 0.55 [ 0.36, 0.83 ]
Total events: 77 (Intervention A), 104 (Intervention B)
Heterogeneity: Chi2 = 3.32, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 3.26, df = 3 (P = 0.35), I2 =8%
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Analysis 2.5. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 5 Mean adhesion scores in women treated for intrauterine adhesions.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 5 Mean adhesion scores in women treated for intrauterine adhesions
Study or subgroup Intervention A Intervention B
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Device vs device
Lin 2015b 80 1 (2.3) 82 1 (2.1) 100.0 % 0.0 [ -0.68, 0.68 ]
Subtotal (95% CI) 80 82 100.0 % 0.0 [ -0.68, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Device + graft vs device
Wang 2016 (1) 29 3.2 (1.5) 28 6.3 (2.5) 100.0 % -3.10 [ -4.17, -2.03 ]
Subtotal (95% CI) 29 28 100.0 % -3.10 [ -4.17, -2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.65 (P < 0.00001)
3 Device + gel vs device
Xiao 2015 55 2.1 (1.1) 56 3.7 (2.5) 100.0 % -1.60 [ -2.32, -0.88 ]
Subtotal (95% CI) 55 56 100.0 % -1.60 [ -2.32, -0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
Test for subgroup differences: Chi2 = 25.18, df = 2 (P = 0.00), I2 =92%
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Analysis 2.6. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 6 Mild adhesions at second-look hysteroscopy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 6 Mild adhesions at second-look hysteroscopy
Study or subgroup Intervention A Intervention B Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device + gel vs device
Xiao 2015 27/55 26/56 100.0 % 1.11 [ 0.53, 2.34 ]
Total (95% CI) 55 56 100.0 % 1.11 [ 0.53, 2.34 ]
Total events: 27 (Intervention A), 26 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative
hysteroscopy, Outcome 7 Moderate or severe adhesions at second-look hysteroscopy.
Review: Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility
Comparison: 2 Anti-adhesion therapy A versus anti-adhesion therapy B following operative hysteroscopy
Outcome: 7 Moderate or severe adhesions at second-look hysteroscopy
Study or subgroup Intervention A Intervention B Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Device + gel vs device
Xiao 2015 7/55 21/56 86.1 % 0.24 [ 0.09, 0.63 ]
Subtotal (95% CI) 55 56 86.1 % 0.24 [ 0.09, 0.63 ]
Total events: 7 (Intervention A), 21 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0039)
2 Gel + HT + antibiotics vs HT + antibiotics
Fuchs 2014 (1) 1/21 3/20 13.9 % 0.28 [ 0.03, 2.98 ]
Subtotal (95% CI) 21 20 13.9 % 0.28 [ 0.03, 2.98 ]
Total events: 1 (Intervention A), 3 (Intervention B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 76 76 100.0 % 0.25 [ 0.10, 0.61 ]
Total events: 8 (Intervention A), 24 (Intervention B)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.01 0.1 1 10 100
Favours A Favours B
(1) Poly gel at 5-8 weeks
A D D I T I O N A L T A B L E S
Table 1. Median American Fertility Society (AFS) scores Lin 2015b
Outcome Balloon group
(intervention: n = 82)
IUD group
(control: n = 80)
P value
AFS score before surgery (me-
dian, 95% CI)
8 (5 to 12) 8 (5 to 12) 1.00
Median reduction in AFS score 7 (2 to 12) 7 (0 to 12) 1.00
IUD: intrauterine device; n: number of participants.
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Table 2. Median American Fertility Society (AFS) scores Amer 2010
Statistic Fresh amnion graft (group
2: n = 14)
Dried amnion graft (group
3: n = 15)
No amnion graft (group 1:
n = 14)
P value
Median 1.5 2 2 -
IQR 1 to 2 1 to 2 1 to 2 0.27
IQR: interquartile range; n: number of participants.
Table 3. Median American Fertility Society (AFS) scores Gan 2017
Statistic Amnion graft
(intervention: n = 40)
No graft
(control: n = 40)
P value
Median 2 4 -
IQR 2 to 5 2 to 6 0.03
IQR: interquartile range; n: number of participants.
A P P E N D I C E S
Appendix 1. CGF Specialised Register search strategy
Procite platform
Keywords CONTAINS “hysteroscopy” or “hysteroscopy pain” or “hysteroscopy pain -surgical” or “hysteroscopy, techniques” or “hys-
teroscope ” or “office hysteroscopy” or “operative hysteroscopy” or Title CONTAINS “hysteroscopy” or “hysteroscopy pain” or “hys-
teroscopy pain -surgical” or “hysteroscopy, techniques” or “hysteroscope ” or “office hysteroscopy” or “operative hysteroscopy”
AND
Keywords CONTAINS “adhesiolysis” or “adhesion” or “adhesions” or “adhesions outcome” or “adhesion prevention” or “adhesion
formation” or “pelvic adhesions” or “Sepracoat” or “icodextrin” or “hydrogel” or “hydrotubation” or “Seprafilm” or “intergel” or “Barrier
Membrane” or “hyaluronan” or “hyaluronic acid” or “hyaluronidase” or “Promethazine” or “dextran” or “SprayGel” or “adhesion
barrier” or “adhesion barriers” or “post-operative adhesions” or “gynecologic surgical procedure” or “pelvic adhesions” or “amnion
graft” or “antibiotics” or “*Estrogens” or “Estrogen” or “oestrogen” or “intrauterine device” or “Intrauterine Devices, Medicated”
or “Intrauterine Releasing Devices” or Title CONTAINS “adhesiolysis” or “adhesion” or “adhesions” or “adhesions outcome” or
“adhesion prevention” or “adhesion formation” or “pelvic adhesions” or “Sepracoat” or “icodextrin” or “hydrogel” or “hydrotubation”
or “Seprafilm” or “intergel” or “Barrier Membrane” or “hyaluronan” (
11 records
Database: Search strategy for JB1900 in the Cochrane Gynaecology and Fertility specialised register was rerun and date limited from
01.01.15 (last search) to 07.06.17
Most recent update: 7 June 2017
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Appendix 2. CENTRAL search strategy
#1MeSH descriptor: [Hysteroscopy] explode all trees (403)
#2hysteroscopic surgery (309)
#3operative hysteroscopy (212)
#4synechiolysis (6)
#5#1 or #2 or #3 or #4 (639)
#6barrier agent (816)
#7hyaluronic acid gel (218)
#8intrauterine balloon (116)
#9amnion graft (52)
#10estrogen treatment (6,178)
#11MeSH descriptor: [Intrauterine Devices] explode all trees (616)
#12MeSH descriptor: [Anti-Bacterial Agents] explode all trees (10,749)
#13#6 or #7 or #7 or #8 or #9 or #10 or #11 or #12 (18,605)
#14intrauterine adhesions (119)
#15adhesion score (566)
#16reproductive outcome (4,098)
#17#14 or #15 or #16 (4,665)
#18#5 and #13 and #17 Publication Year from 2015 to 2017 (14)
Cochrane reviews (7)
Other reviews (0)
Trials (7)
14 records
Database: Cochrane Database of Systematic Reviews: Issue 6 of 12, June 2017
Most recent update: 6 June 2017
Appendix 3. MEDLINE search strategy (PubMed)
(((((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR “drug ther-
apy”[Subheading] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (“animals”[MeSH Terms] NOT “humans”[MeSH
Terms]))) AND ((((reproductive outcome) OR adhesion score) OR intrauterine adhesions) OR “Gynatresia”[Majr])) AND
((((((((((“Anti-Bacterial Agents”[Majr]) OR “Intrauterine Devices”[Mesh]) OR estrogen treatment) OR amnion graft) OR intrauterine
balloon) OR gel) OR hyaluronan) OR hyaluronic acid gel) OR barrier agents) OR adhesion prevention)) AND (((((synechiolysis) OR
operative hysteroscopy) OR “Gynecologic Surgical Procedures”[Majr]) OR hysteroscopic surgery) OR “Hysteroscopy”[Majr])
21 records
Database: MEDLINE using PubMed
Most recent update: 6 June 2017
Appendix 4. Embase search strategy (Embase.com)
#1’hysteroscopy’/exp OR ’hysteroscopy’(10,800)
#2hysteroscopic AND ’surgery’ (3,504)
#3gynaecological AND ’surgery’ (15,150)
#4operative AND ’hysteroscopy’(1,775)
#5synechiolysis (82)
#6#1 OR #2 OR #3 OR #4 OR #5 (25,733)
#7’adhesion’/exp AND ’prevention’ (2,460)
#8barrier AND agents (11,435)
#9hyaluronic AND ’acid’/exp AND ’gel’/exp (28)
#10’hyaluronan’/exp (33,533)
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#11’gel’/exp (55,900)
#12’intrauterine’/exp AND ’balloon’/exp (602)
#13’amnion’/exp AND graft (735)
#14’estrogen’/exp AND treatment (79,899)
#15’intrauterine’/exp AND ’device’/exp (22,666)
#16’antibiotics’/exp (1,175,044)
#17#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 (1,365,328)
#18’intrauterine’/exp AND ’adhesions’/exp (465)
#19’adhesion’/exp AND score (937)
#20reproductive AND outcome (44,546)
#21#18 OR #19 OR #20 (45,864)
#22#6 AND #17 AND #21 (342)
#23’clinical trial’/exp (1,201,041)
#24’randomized controlled trial’/exp (447,991)
#25’randomization’/exp (73,693)
#26’single blind procedure’/exp (27,124)
#27’double blind procedure’/exp (137,917)
#28’crossover procedure’/exp (51,040)
#29’placebo’/exp (305,105)
#30randomi?ed AND controlled AND trial* AND [embase]/lim (554,250)
#31rct AND [embase]/lim (23,901)
#32’random allocation’/exp AND [embase]/lim (46,023)
#33’randomly allocated’ AND [embase]/lim (23,118)
#34’allocated randomly’ AND [embase]/lim (1,917)
#35allocated NEAR/2 random AND [embase]/lim (766)
#36’single blind$’ AND [embase]/lim (29,481)
#37’double blind$’ AND [embase]/lim (193,062)
#38(treble OR triple) NEAR/2 blind$ AND [embase]/lim (591)
#39placebo$ AND [embase]/lim (364,742)
#40’prospective study’/exp (372,790)
#41#23 OR #24 OR 25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37
OR #38 OR #39 OR #40 (1,883,550)
#42’case study’/exp (46,539)
#43’case report’/exp AND [embase]/lim (1,627,297)
#44’abstract report’/exp (89,710)
#45’letter’/exp (926,515)
#46#42 OR #43 OR #44 OR #45 (2,538,528)
#47#41 NOT #46 (1,819,026)
#48’animal’/exp (23,131,376)
#49’human’/exp (18,279,043)
#50#48 NOT #49 (4,852,333)
#51#47 NOT #50 (1,756,205)
#52#22 AND #51 (85)
#53#22 AND #51 AND [1-3-2015]/sd NOT [1-6-2017]/sd (32)
32 records
Database: Embase using Embase.com
Most recent update: 6 June 2017
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Appendix 5. Web of Science search strategy
# 1TS = (hysteroscopy) (509)
# 2TS = (hysteroscopic surgery) (156)
# 3TS = (operative hysteroscopy) (122)
# 4TS = (synechiolysis) (8)
# 5#1 OR #2 OR #3 OR #4 (585)
# 6TS = (barrier agent)(3,157)
# 7TS =(hyaluronic acid gel)(482)
# 8TS = (intrauterine balloon)(70)
# 9TS = (amnion graft)(35)
# 10TS = (estrogen treatment) (5,460)
# 11TS = (intrauterine device) (701)
# 12TS = (antibiotics) (39,645)
# 13#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 (49,338)
# 14TS =(intrauterine adhesions) (125)
# 15TS =(adhesion score) (690)
# 16TS = (reproductive outcome)(4,515)
# 17#14 OR #15 OR #16 (5,293)
# 18#5 AND #13 AND #17 (28)
# 19 TS =(randomized controlled trial) (82,310)
# 20 #18 AND #19 (11)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2015-2017
11 records
Database: Web of Science (WoS)
Most recent update: 6 June 2017
Appendix 6. CINAHL search strategy (EBSCOhost)
S1 TX hysteroscopy (466)
S2 TX hysteroscopic surgery (25)
S3 TX operative hysteroscopy (28)
S4 TX synechiolysis (2)
S5 S1 OR S2 OR S3 OR S4 (473)
S6 “”barrier agent“” (24,118)
S7 TX hyaluronic acid gel (26)
S8 TX intrauterine balloon (29)
S9 TX amnion graft (4)
S10 TX estrogen treatment (522)
S11 TX intrauterine device (1,577)
S12 TX antibiotics (35,078)
S13 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 (37,486)
S14 TX intrauterine adhesions (15)
S15 TX adhesion score (29)
S16 TX reproductive outcome (590)
S17 S14 OR S15 OR S16 (632)
S18 S5 AND S13 AND S17 (5)
S19 (MH “Clinical Trials”) (87,486)
S20 PT clinical trial* (52,906)
S21 (MH “Randomized Controlled Trials”) (29,785)
S22 PT randomized controlled trial* (30,863)
S23 (MH “Random Assignment”) (34,135)
S24 TX Randomi*ation (5,181)
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S25 TX single blind* (8,515)
S26 TX double blind* (707,324)
S27 TX triple blind* (137)
S28 “”TX treble blind*“” (38,806)
S29 TX Placebo* (31,331)
S30 TX prospective stud* (204,534)
S31 S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 (975,773)
S32 S18 AND S31 (1)
1 record
Database: CINAHL using EBSCOHOST
Most recent update: 6 June 2017
Appendix 7. Items of the pilot-tested data extraction form
1. Source
• Study ID.
• Report ID.
• Review author ID.
• Citation and contact details.
2. Eligibility
• Confirm eligibility for review.
• Reason for exclusion.
3. Trial characteristics
Study design
• Random sequence generation.
• Participant recruitment.
• Participant inclusion and exclusion criteria.
• Allocation concealment.
• Blinding of participants, personnel and outcome assessors.
• Completeness of outcome data.
• Selective outcome reporting.
• Other potential sources of bias.
Follow-up
• Duration of follow-up.
• Type of follow-up.
Size of study
• Number of women recruited.
• Number of women randomly assigned.
• Number of women excluded.
• Number of women withdrawn and lost to follow-up.
• Number of women analysed.
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Study setting
• Single- or multicentre.
• Location.
• Timing and duration.
Diagnostic criteria
• Screening by transvaginal sonography (TVS).
• Screening by hysterosalpingography (HSG).
• Screening by TVS and HSG.
• Screening by other ultrasound diagnostic procedures, e.g. saline infusion sonography or gel instillation sonography.
• Screening by hysteroscopy.
• Diagnosis confirmed by hysteroscopy and biopsy.
4. Characteristics of study participants
Baseline characteristics
• Age.
• Primary or secondary subfertility.
• Duration of subfertility.
• Diagnostic workup: baseline follicle-stimulating hormone, semen analysis, diagnosis of tubal pathology, confirmatory test of
ovulation.
• Other contributory causes to subfertility than uterine factor.
• Previous treatments, e.g. in vitro fertilisation (IVF), intrauterine insemination (IUI) or other treatments.
Treatment characteristics
• IUI natural cycle.
• IUI controlled ovarian stimulation with anti-oestrogens or gonadotropins.
• IVF protocol and number of embryos transferred.
• Intracytoplasmic sperm injection protocol and number of embryos transferred.
• Detailed description of hysteroscopic procedure.
• Detailed description of anti-adhesion therapy.
5. Interventions
Total number of intervention groups
Absence of other interventions in treatment and control groups
For each intervention and comparison group of interest:
• specific intervention;
• intervention details;
• timing of the intervention.
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6. Outcomes
Outcomes and time points reported
Definition and unit of measurement for each of the following outcomes.
Primary outcome
• Live birth.
• Presence of intrauterine adhesions at second-look hysteroscopy.
Secondary outcomes
• Pregnancy.
• Miscarriage.
• Mean adhesion scores at second-look hysteroscopy.
• Severity of adhesions at second-look hysteroscopy.
For each outcome of interest:
• sample size;
• missing participants;
• summary data for each intervention group in 2 × 2 table;
• estimate of effect with 95% confidence interval;
• subgroup analyses.
7. Miscellaneous
• Funding source.
• Key conclusions of study authors.
• Miscellaneous comments from study authors.
• References to other relevant studies.
• Correspondence required.
• Miscellaneous comments by review authors.
WH A T ’ S N E W
Date Event Description
2 September 2017 New citation required but conclusions have not
changed
The addition of 5 new studies and additional data from
one further study have not led to a change in the con-
clusions of this review
2 September 2017 New search has been performed New searches from 1 March 2015 to 1 June 2017
identified 5 additional studies (Do 2005; Gan 2017;
Vercellini 1989; Wang 2016; Xiao 2015).
We updated the data of Lin 2015b which were partially
presented in the previous review as Lin 2013.
Amer 2010 and Fuchs 2014 were re-classified under
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(Continued)
the comparison “Any therapy versus any other therapy”
in the updated version
C O N T R I B U T I O N S O F A U T H O R S
JB: co-ordinating author.
SW, FB and TD: co-authored protocol, provided comments and criticisms on the methods and content of the review, and were involved
in data extraction and risk of bias assessment.
BWM: responsible for overall supervision of the methods and consulted ’ad hoc’ for assistance in resolving disagreements.
HT: involved in data extraction and risk of bias assessment for the updated version.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• In the protocol, we defined two primary outcomes: live birth (positive outcome) and presence of intrauterine adhesions (IUAs)
at second-look hysteroscopy (adverse outcome). We defined as secondary outcomes the following: clinical pregnancy, miscarriage,
mean adhesion scores and severity of adhesions at second-look hysteroscopy. In the full review, we decided to include only one
primary outcome, namely, live birth or ongoing pregnancy - the primary outcome of interest for women with subfertility. Clinical
pregnancy, miscarriage, presence of IUAs at second-look hysteroscopy, mean adhesion scores and severity of adhesions present at
second-look hysteroscopy were defined as secondary outcomes. We made this change on the basis of advice provided by the peer
review editorial team in the interest of simplification and readability. We similarly avoided use of the outcome ’incidence of de novo
adhesions’; several included studies enrolled participants with existing IUAs, and at second-look hysteroscopy the distinction between
de novo and recurrent adhesions may not be possible and may not be clinically relevant.
• Term delivery and ongoing pregnancy were used in the review as a surrogate outcome for live birth because the number of
studies reporting live birth was very limited. We used sensitivity analyses to study the impact of including only studies reporting live
birth versus all studies reporting live birth or a surrogate outcome.
• The protocol prespecified that data would be extracted simultaneously and independently by two review authors. For practical
reasons, data were extracted by at least one pair of review authors: for the previous review. JB extracted data from all studies, and TD/
FB/JK/SW divided all studies between them, and each extracted data from only a portion of the included studies. In cases of
disagreement, BWM acted as a ’third’ review author for arbitration. For the updated version, we used a similar approach for practical
reasons. See Potential biases in the review process.
• We clarified the inclusion criteria to specify that studies in which at least a proportion of women were undergoing operative
hysteroscopy for subfertility were eligible.
• In the review we reported numbers needed to treat for a beneficial effect (NNTB) when there were statistically significant
differences between both comparison groups. This was not prespecified in the protocol.
• In the 2017 update authors updated the Methods sections to current Cochrane standards, and changed the format of Effects of
the interventions to improve readability of the review.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Amnion [transplantation]; Estrogens [therapeutic use]; Gels [therapeutic use]; Hysteroscopy [∗adverse effects]; Infertility, Female
[∗surgery]; Intrauterine Devices; Live Birth [epidemiology]; Randomized Controlled Trials as Topic; Second-Look Surgery [statistics
& numerical data]; Tissue Adhesions [epidemiology; etiology; therapy]; Uterine Diseases [epidemiology; etiology; ∗therapy]
MeSH check words
Female; Humans; Pregnancy
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